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Despite considerable progress and the emerging use of immunotherapies, chemotherapy remains the 
only routine clinical option for treating triple negative breast cancer (TNBC). However, this is associated 
with severe toxicity, is not effective in all patients and chemo-resistance can develop. NK cells are 
emerging as powerful tools for cancer immunotherapy and we hypothesised that NK cell-based 
therapies could be improved by combining them with other approaches that modify various 
components of the tumour and its environment and renders tumours more sensitive to NK cell 
cytotoxicity.  
In addition to being less toxic and having a lower impact on a patient’s quality of life, evidence suggests 
that low-dose metronomic chemotherapy modulates adaptive and innate anti-tumour immune 
responses.  Accordingly, the aim of this study was to enhance anti-tumour activity of adoptively 
transferred NK-cells using low-dose metronomic chemotherapy.  
Herein, the effect of treatment with low-dose doxorubicin on the phenotype of human breast cancer 
cell lines corresponding to different molecular subtypes of disease [MCF-7 (Luminal A); SK-BR-3 
(Her2+); MDA-MB-468 (Triple Negative); MDA-MB-231/RFP/LUC (Triple Negative)] and their sensitivity 
to NK cell killing was investigated, as was the capacity of combining low-dose doxorubicin and adoptive 
NK cell transfer to control the growth and metastasis of human MDA-MB-231 xenografts in 
immunedeficient mice. 
We demonstrate that low-dose doxorubicin treatment halts the proliferation of breast cancer cells and 
triggers expression of natural killer (NK) cell ligands, enhances sensitivity to NK cell-mediated 
cytotoxicity in vitro and modulates important cancer pathways associated with invasion and metastasis. 
In vivo, the combination of low-dose doxorubicin with adoptive transfer of IL-2 activated human NK 
cells, reduced the growth of MDA-MB-231 cell-derived tumours in a pre-clinical murine xenograft 
model.  
These findings confirmed the capacity of low-dose chemotherapy to sensitise tumours to NK cell 
cytotoxicity and indicated the therapeutic potential of combining low-dose chemotherapy and NK cell 
therapy for the treatment of patients with TNBC, for whom current therapies are largely ineffective.  
9 
 
Chapter 1: Introduction  
1.1 Overview of the Immune system  
The immune system is a collection of organs, cells and proteins that work in coordination within an 
organism to protect its host from threats. These can be external in the form of pathogens, such as 
viruses and bacteria, or internal, such as toxins and tumour cells. At the centre of this protection is the 
immune cells’ ability to recognize and discriminate between non-self/altered-self and self/healthy 
molecules and to mount an adequate immune response. In an immunocompetent setting, an effector 
response will develop based on the type of the threat and will lead to its neutralization and elimination. 
The immune system is broadly divided into the innate and adaptive immune system, although these 
arms have overlapping functions and are closely related. 
1.1.1 The innate and adaptive immune systems 
The innate immune system represents the first line of defence, and is composed of physical and 
chemical barriers, circulating blood proteins and a panoply of cells. The cells of the innate immune 
system include phagocytic leukocytes (neutrophils, macrophages), dendritic cells (DCs), natural killer 
(NK) cells and other innate lymphoid cells. The activation of the innate response is based on the 
recognition of pathogen-associated molecular patterns (PAMPs), which are structures shared by 
various pathogens; or soluble factors, heat shock proteins and abnormal membranes that stressed cells 
typically release, called damage associated molecular patterns (DAMPs) by cognate pattern recognition 
receptors (PRRs) such as toll-like receptors (TLRs) and C type lectin receptors on the surface of innate 
immune cells (Boller, Felix 2009; Mogensen 2009). The innate response is able to quickly eliminate the 
majority of pathogens however, some pathogens can evade innate effectors. Protection against these 
involves the development of specific, more potent responses mediated by the adaptive immune 
system. Adaptive immune responses take longer to develop, are antigen-specific and are characterized 
by the establishment of long-term memory. They are divided into two types: humoral response, 
mediated by B lymphocytes that produce antibodies, and cell-mediated response, mediated by T 
lymphocytes which includes CD4+ T helper (TH) cells and CD8+ cytotoxic T lymphocytes and a panoply 
of other effector and regulatory cell populations and sub-populations. 
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1.1.2 Tumour immunology - Tumours and immunity 
Evidence from animal models and clinical studies in cancer patients demonstrates the ability of the 
immune system to recognise and eradicate tumours. Although the idea that immune cells have the 
ability to control cancer growth was introduced more than 100 years ago by Paul Ehrlich (Ehrlich 1909), 
the actual concept of cancer immunosurveillance was conceived and validated later (Kaplan 1971; 
Stutman 1975; Thomas 1982; Burnet 1957). First, through results demonstrating the role of IFN-γ in 
promoting tumour recognition and control in mice implanted with IFN-γ-insensitive tumour cells versus 
mice implanted with wild-type IFN-γ-sensitive tumour cells (Dighe et al. 1994) and subsequently by  
various studies demonstrating  the role of pre-existing immunity and various components of the 
immune system in protecting mice against different types of malignancies. The main findings from 
these studies which led to the establishment and development of the modern tumour immune-
surveillance concept are reviewed by Vesely et al. (Vesely et al. 2011). The interaction between the 
immune system and tumours is a complex, dynamic process. Understanding the mechanisms governing 
this process, often referred to as the “cancer immune cycle” is essential for the development of 
immune modulatory therapies. The generation of a successful specific anti-tumour immune response 
depends on the dynamics of tumour growth, as tumour cells can escape both the innate and adaptive 
responses by a process called immunoediting. 
1.1.2.1 Immunoediting 
The three sequential phases in the cancer immunoediting theory consists of the elimination, 
equilibrium and escape phases. Elimination occurs when tumour cells are successfully eliminated by 
innate and adaptive immune cells, usually prior to the tumour becoming clinically apparent. However, 
the immune response might not achieve a complete elimination and might create a selection towards 
non-immunogenic cancer cells, which can survive leading to the equilibrium phase. The equilibrium 
phase is thought to be the longest phase of the process. Finally, resistant tumour cell variants with 
cumulative mutations may arise and allow them to escape immunosurveillance. Subsequently, in the 
escape phase, tumour cells form established primary tumours which can go on to metastasize (Dunn 
et al. 2004; Kim et al. 2007). 
1.1.2.2 Immune escape mechanisms  
Immune evasion is one the key hallmarks of cancer (Prosperi, Goss 2010; Hanahan, Weinberg 2011). 
Tumours have the ability to evade immune recognition and destruction via different mechanisms such 
as loss of antigenicity; this could be by downregulation of MHC class I expression, or antigenic 
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modulation where tumours acquire mutations in genes involved in antigen presentation and processing 
(Schreiber et al. 2011). Other mechanisms include, induction of tolerance; where tumour cells decrease 
their immunogenicity by upregulating the expression of immunoinhibitory molecules (such as PD-L1) 
(Blank et al., 2005), producing immunosuppressive molecules such as IL-10, Transforming Growth 
Factor beta (TGF beta) or Vascular Endothelial Growth Factor (VEGF) and through altering the balance 
between effector and regulatory cells, such as myeloid-derived suppressor cells (MDSCs) and regulatory 
T cells (Tregs) which will contribute to the generation of immune tolerance and an immunosuppressive 
microenvironment  (Pawelec et al., 2000 ; Itakura et al., 2011; Yang et al.,2010). 
1.1.3 Anti-tumour immunotherapy  
Cancer therapeutic modalities belong to five main categories; surgery, radiation, chemotherapy, 
targeted therapy, and immunotherapy. Immunotherapy represents a treatment modality based on 
harnessing the power of the patient’s own immune system. The first immunotherapy concepts in the 
context of cancer treatment date back to more than 137 years ago, when it was first noticed by Busch 
(Busch,1868) and Fehleisen (Fehleisen,1882) that accidental infections by erysipelas induced tumour 
regression in cancer patients. This was followed by Coley’s studies on several types of malignancies 
using bacterial toxins (Coley 1910; Wiemann, Starnes 1994). Exciting progress has been made in the 
field of immunotherapy since its conception (Oiseth, Aziz 2017; Eno 2017). This was highlighted by the 
US Food and Drug  Administration (FDA) approval of different therapeutic agents, the emergence of 
new therapeutic concepts, and the  award of 2018 Nobel Prize in Physiology and Medicine from the 
Nobel Committee to Tasuku Honjo and James Allison “for their discovery of cancer medicine by 
inhibition of negative immune regulation” (www.nobelprize.org/prizes/medicine/2018). 
Although the actual concept of immunotherapy date back to the last century (Old 1996), it is only 
recently that it has gained a wide interest mainly due to the advances in the fields of immunology 
research and immune-oncology, but also the lack of success that other therapeutic modalities are 
encountering for some cancer types. In fact, most often for solid tumours, the primary therapeutic 
indication is surgery for operable tumours, which can be curative for local disease. However, advanced 
and metastasized cancers have a poor prognosis and such tumours continue to account for ~90% of 
cancer-related deaths(Chaffer, Weinberg 2011; Seyfried, Huysentruyt 2013).  
Diverse strategies have been investigated to convert the anti-tumour properties of different elements 
of the immune system into therapeutic approaches. They broadly fall into five groups: vaccines, 
antibody-based therapies, immune targeted agents, cytokine-mediated therapies and adoptive cell 
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therapies (Zhang, Chen 2018; Riley et al. 2019; Couzin-Frankel 2013). Adoptive cell transfer therapy 
(ACT) is based on supplying autologous or allogeneic functional immune effector cells in high numbers 
to attack the tumour. The main approaches involve autologous tumour infiltrating lymphocytes (TILs) 
or autologous T cells genetically engineered with T cell receptors (TCRs) having a defined specificity or 




1.2  Natural killer cells 
Natural killer (NK) cells are the predominant innate lymphocyte subsets that contribute to the first line 
of defence against tumours and viruses. They comprise 5–15% of circulating lymphocytes and are 
characterized by a large, granular morphology. Derived from CD34+ progenitor cells in the bone 
marrow, commitment to the NK cell lineages is associated with loss of CD34 and gain of the cytotoxicity 
receptors NKp44 and NKp46 (Freud, Caligiuri 2006). NK cells are found in different lymphoid and non-
lymphoid tissues including the liver, lungs, gut and uterus. They are also one of the first immune cells 
to arrive at target inflamed organs (Carrega, Ferlazzo 2012; Shi et al. 2011). Phenotypically, human NK 
cells are defined by the absence of the T cell receptor CD3 and the expression of the neural cell adhesion 
molecule CD56 (Cooper et al. 2001). The relative expression of CD56 and the Fc gamma receptor 3 
(CD16, FcγRIIIA) which enables antibody dependent cytotoxicity (ADCC) allows two main 
subpopulations of NK cells to be distinguished; CD56dimCD16bright representing ≥90% of total NK cells, 
referred to as the cytotoxic subset, and cytokine producing CD56brightCD16dim cells, although many other 
populations exist and the discrimination between cytotoxic effector functions and cytokine regulatory 
functions is not binary (Cooper et al. 2009; Caligiuri 2008). NK cells were originally defined by their 
natural cytotoxicity functions, but it was later shown that they were also able to mediate cytokine 
production and secretion (Vivier et al. 2008). 
As they have a central role in the research programme described in this thesis, the main aspects of their 
effector functions and use in immunotherapy approaches will be discussed in this section.  
1.2.1 Mechanisms of action of NK cells  
1.2.1.1 Activating and inhibitory receptors  
NK cell activation relies on a fine balance of signals originating from activating and inhibitory receptors 
expressed at their surface. Also, the co-engagement of various activating receptors is required for NK 
cell lysis of target tumour cells, as target lysis does not occur by default when inhibitory receptor/ligand 
interaction is absent  (Bryceson et al. 2009). 
Inhibitory receptors 
Traditional NK cell inhibitory receptors belong either to the Ig superfamily - these are the killer 
immunoglobulin-like receptors (KIRs) that bind to human leukocyte antigen (HLA- A, -B or-C), or to  the 
C-type lectin receptor NKG2A which forms a complex with CD94 (CD94/NKG2A) - these bind to the 
human leucocyte antigen HLA-E. Although they vary in their structure, upon engagement, these 
receptors share a common signalling pathway through the phosphorylation of their shared motif, the 
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immune tyrosine-based inhibitory motifs (ITIM). This leads to the recruitment of tyrosine 
phosphatases, commonly, the Src homology 2 domain-containing phosphatases (SHP1 or 2) that 
prevent Ca2+ influx  and induce an inhibition of various NK cell effector functions (Vivier et al. 2008; 
Lanier 2005; Tomasello, et al. 2000). These receptors are central to the regulation of self-tolerance and 
activation of NK cells. Indeed, in order to avoid killing of self-cells, NK cells express at least one inhibitory 
receptor specific for self-MHC molecules (Tomasello, et al. 2000).  
Other inhibitory receptors include Ig-like transcripts (ILTs) or leukocyte Ig-like receptors (LIRs). They are 
homologous to KIR receptors, as they contain the typical ITIMs motifs. However, they interact mainly 
with non-classical HLA-G molecules, and with a better specificity (Vitale et al., 1999). Additionally, NK 
cells express a killer cell lectin-like receptor G1 (KLRG1) that also contains an ITIM and regulates NK cell 
effector functions (Ito et al. 2006). 
Activating receptors 
NK cells acquire the expression of natural cytotoxicity receptors (NCRs) early during their maturation. 
These receptors belong to the Ig superfamily and are germline encoded transmembrane receptors. 
NCRs can mediate direct non-MHC-restricted killing of target cells and the secretion of cytokines and 
include NKp30, NKp44, NKp46, NKp65 and NKp80. Although NKp30 and NKp46 are constitutively 
expressed on NK cells in the peripheral blood, NKp44 was shown to be expressed on activated NK cells 
only (Lanier 2005).  NCRs can bind to viral ligands, heat-shock associated proteins or tumour antigens 
and associate with immunoreceptor tyrosine-based activation motif (ITAM)-containing subunits. Their 
surface density was found to correlate with the magnitude of NK cell cytotoxicity against target cells 
(Baychelier et al. 2013; Pende et al. 1999; Mandelboim et al. 2001). 
The second type of NK cell activating receptors belong to the lectin-like family.  The NK group 2 member 
D and F (NKG2D and F). The NKG2D receptor associates with DNAX activation protein DAP-10 whereas 
NKG2F binds to DAP12. Of note, NKG2F does not translocate to the cell surface (Kim et al., 2004). When 
associated with the DAP10 adaptor protein, NKG2D can recruit the phosphoinositide 3-kinase (PI3K) 
and signal through its binding motif (Billadeau et al. 2003; Wu et al. 1999). The cellular ligands of NKG2D 
include MHC class I chain-related protein A MICA and MICB and the UL16-binding proteins 1-6 (UBLP1-
6) (Mistry, O’Callaghan 2007; Biassoni n.d.). Additional receptors are important in the activation of NK 
cell cytotoxicity include the DNAX accessory molecule-1 (DNAM-1), CD2 and 2B4 (Bryceson et al. 2009). 
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NKG2D and DNAM-1 ligands are frequently expressed on stressed cells and various studies have 
demonstrated the key role played by these receptors in immune surveillance of tumours (Morisaki et 
al. 2012a; Fionda et al. 2015a). NKG2D has also been shown to contribute to shape tumour 
immunogenicity, as evidenced by a tumour cell’s ability to prevent NKG2D-mediated recognition 
through NKG2D ligand shedding (Pegram et al. 2011). A comprehensive overview of various NK cell 
receptors is displayed in Figure 1.1. 
 
Figure. 1.1. NK cell surface receptors and their ligands. Representation of a human NK cell. Shown on top 
are cytokine receptors. Receptors’ s ligands are shown within parentheses. Other known receptors not 
shown include chemotactic and adhesion receptors (CD2 and β1 and β2 integrins) as well as some co-
receptors (CD96, CS1, and TLR). (Reprinted from Clinical Cancer Research,2014,20/13,3390-3400, Leung, 
Infusions of Allogeneic Natural Killer Cells as Cancer Therapy, with permission from AACR) (Leung 2014). 
1.2.1.2 NK cell cytotoxicity 
Unlike B and T cells, NK cells do not require prior sensitization and have the innate ability to eliminate 
cancer cells in a non-major histocompatibility complex (MHC) and non-tumour antigen restricted 
manner (Chiossone et al. 2018a; Vivier et al. 2011a; Raulet 1996; Moretta et al. 1992). NK cell 
recognition of target cells and cytotoxicity are mainly regulated by the interplay of multiple inhibitory 
and activating receptors that bind cognate ligands on target cells. The cytotoxic response can be divided 
into three main processes; target cell recognition, target cell contact and formation of immunological 
synapse, and induction of target cell death (Mace et al. 2014). Upon target cell recognition, NK cells can 
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respond via two types of actions (Figure 1.2) - the perforin-granzyme serine protease killing and 
caspase-mediated apoptosis. NK cells form an immune synapse at the point of contact with the tumour 
cell (Krzewski, Strominger 2008) and, with sufficient activation signals, the NK cell cytoskeleton 
rearranges leading to the polarization and release of their cytotoxic granules (degranulation) via 
exocytosis. The two main components of these cytotoxic vesicles are perforin and granzymes  (Smyth 
et al. 1999). Once released at the immune synapse, perforin forms pores in the membrane of target 
cells through binding to the lipid bilayer. This allow granzymes, mainly the serine protease  granzyme 
B  to enter the tumour cell and induce apoptosis or programmed cell death (Orange 2008). 
Alternatively, endocytosis has been proposed as a different delivery pathway of granzymes into target 
cells (Bird et al. 2005; Thiery et al. 2011).  Second, NK cells can induce caspase-mediated apoptosis via 
cell surface death receptor ligation mediated by Fas ligand (FasL) and TNF-related apoptosis-inducing 
ligand (TRAIL) (Lavrik et al. 2005). Moreover, NK cells can also exert their functions through antibody-
dependent cellular cytotoxicity (ADCC) which involves ligation of the CD16 receptor by antibodies 
bound to the surface of tumour cells.  
In addition to direct cytotoxic effects, NK cells can exert indirect anti-tumour effects by stimulating 
other immune cells through their release of pro-inflammatory cytokines, most notably interferon 


















Figure 1.2 – NK cell cytotoxicity. (a) Perforin/granzyme mediated apoptosis (b) Caspase-mediated apoptosis 
via death inducing ligands. c-FLIP: Cellular FLICE-like inhibitory protein. Reprinted by permission from 
Springer Nature: on behalf of Cancer Research UK: [Nature Reviews Cancer] [New aspects of natural-killer-
cell surveillance and therapy of cancer, Mark J. Smyth et al, [COPYRIGHT] (2002). (Smyth et al. 2002). 
1.2.1.3 Cytokine secretion  
In addition to their cytolytic activity, NK cells serve a number of regulatory functions via their release 
of various pro-inflammatory cytokines such as IFN-γ, TNF-α and of chemokines such as CCL3 and CCL4 
that contribute to the development and regulation of adaptive immune responses. IFN-γ is known to 
be the signature cytokine of NK cells, it has a wide range of roles in immune responses, including anti-
proliferative and anti-angiogenic effects, and it can also induce sensitivity to apoptosis (Chin et al., 
1996; Beatty & Paterson, 2001; Chawla-Sarkar et al., 2003). In addition to  contributing to the priming 
and presentation of antigens to antigen presenting cells (APCs) through upregulating MHC class I 
molecules on the surface of target cells (Seliger et al., 2008), IFN- γ can directly activate macrophages 

























inflammation site (Hu et al. 2008). TNFα is also produced by NK cells which initiates a cytokine cascade 
during an inflammatory response and can directly induce target cell death (Waters et al., 2013). 
Although cytotoxicity and cytokine secretion were regarded as two distinct functions of NK cells in the 
past,  the combination of IFN-γ and TNF-α  has been shown to synergistically enhance NK cell 
cytotoxicity through upregulation of ICAM-1 expression in target cells (Wang et al. 2012). Interestingly, 
when present simultaneously, TNF- α and IFN-γ have been shown to induce tumour senescence 
(Braumüller et al. 2013a). 
1.2.1.4 Memory function of NK cells 
NK cells are commonly considered as being incapable of mounting memory responses. This is mainly 
due to their use of germline-encoded receptors which are thought to lack antigen-specificity, a 
characteristic believed to be essential for the formation of immunological memory (Kurtz 2005). 
However, emerging evidence has supported the concept of a memory function for NK cells, including 
features of persistence, reactivation, and possibly the ability to respond to specific antigen 
stimulation (Vivier et al. 2011b; Peng, Tian 2017). Additionally, recent studies indicate that cytokine 
stimulation (a combination of IL-12, IL-15, and IL-18) can induce memory-like NK cells that display 
higher functional competence and longevity in vitro and in vivo (Cooper et al. 2009; Romee et al. 2012; 
Capuano et al. 2019a; Romee et al. 2016).  
1.2.2 NK cells in cancer  
The importance and pivotal role of NK cells in the immune surveillance of cancer is supported by several 
lines of in vitro and in vivo evidence. A large number of studies have demonstrated the capacity of NK 
cells to kill different types of tumour cell lines as well as primary tumour cells from patient biopsies in 
vitro. In most cases, this was found to be primarily mediated by engagement of NKG2D or DNAM-1 
(Castriconi et al. 2004; Malmberg et al. 2017a). Antibody-mediated depletion experiments of NK cells 
in mouse models of cancer have demonstrated the contribution of NK cells in controlling the growth 
and metastatic spread of spontaneous, transplanted or carcinogen-induced tumours (Gorelik et al. 
1982; Smyth et al. 2000; Kärre et al. 1986; Cerwenka et al. 2001; Malmberg et al. 2017a). On the other 
hand, in the context of human disease, analysis of NK cell infiltration in tumour samples demonstrated 
the correlation of high intra-tumoural NK cell levels with a good prognosis of patients with multiple 
cancer types. Of note, some of these studies used CD57 as NK cell marker, which is not ideal as the 
CD57 epitope is expressed on about 70% of CD56dim NK cells, but also on T cell subsets (Coca et al. 1997; 
Ishigami et al. 2000; Villegas et al. 2002; Hsia et al. 2005; Zhu et al. 2009). 
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A recent interesting finding, was the ability of NK cells to recognise and lyse cancer stem cell (CSC)-like 
populations, as defined on the basis of their expression of CSC-associated proteins CD44, CD24, CD326 
(EpCAM) or the aldehyde dehydrogenase (ALDH) enzyme, also a cancer stem cell marker, in human 
cancer cell lines and in patient-derived tumour samples (Ames et al. 2015; Murphy Urayama et al. 2019; 
Luna et al. 2017; Pietra et al. 2009; Castriconi et al. 2009; Toledo-Guzmán et al. 2019). Furthermore, 
Bottcher et al have defined a new role for NK cells, demonstrating that they arrive early to the tumour 
microenvironment and recruit type 1 (CD103+) dendritic cells (DCs) to the tumours, and that this 
cooperation results in the recruitment of CD8+ T cells and induction of immune responses (Böttcher et 
al. 2018; Fessenden et al. 2018). 
1.2.2.1 Tumour escape from NK cell surveillance  
As discussed earlier, the ability of tumours to grow and spread is mainly due to the immune escape 
mechanisms they developed, including evasion from NK cell surveillance. Tumour cells establish a 
suppressive tumour microenvironment (TME) by modulating the expression of different factors that 
affect immune signalling and immune infiltration. Indeed, tumours are characterised as ‘hot’, ‘altered’ 
or ‘cold’ according to the presence and infiltration of immune cells (Galon, Bruni 2019). 
Tumour cells have the ability to secrete inhibitory cytokines such as transforming growth factor beta 
(TGF-β), IL-6 and IL-10, other immunomodulatory molecules such as prostaglandin E2 (PGE2), 
indoleamine 2,3-dioxygenase (IDO), and recruit suppressive immune cells such as Treg cells and MDSCs. 
Tumour cells can also subvert NK cell anti-tumour activity by reducing the expression of NK cell 
activating receptor NKG2D and CD16, or shedding NKG2D ligands, namely MICA and B. Tumour cells 
can also express inhibitory receptor specific ligands such as glucocorticoid-induced TNFR-related 
protein (GITR) that can down modulate activating receptors NKG2D on NK cells. All of this translates 
into decreased numbers of NK cells and decreased tumour infiltration. A defective expression of 
activating receptors and overexpression of inhibitory receptors has been observed in various types of 
cancer (Guillerey et al. 2016a). Figure 1.3 summarises the main strategies that tumours employ to 




   Figure 1.3. Mechanisms of tumour escape from NK cell surveillance. (a) NK cell recognition of target cells. 
(b) alterations in DNA modifying enzymes inhibit the expression of MICA/B (c) persistent expression of 
activating ligands resulting in  hypo-responsiveness, decreased NKG2D expression and reduced IFN-γ 
production(d) Tumour-released cytokines such as TGF-β repress MICA/B expression, downregulate NKG2D 
and IFN-γ and promote the conversion of CD4+ T cells into regulatory CD4+CD25+FOXP3+ T cells (e) shedding 
of MICA ligands due to upregulation of the matrix metalloproteinases (MMPs) and  a disintegrin and 
metalloproteinases (ADAMS), leading to degradation of NKG2D and conversion of CD4+ T cells into regulatory 
CD4+CD25+FOXP3+ T cells. (Reprinted from  (Groth et al. 2011). Copyright © 2011 Karger Publishers, Basel, 
Switzerland. 
 
1.2.2.2 Approaches using NK cell for cancer immunotherapy and clinical outcomes 
The important contribution of NK cells to anti-tumour immune responses has been illustrated by 
several pre-clinical and clinical studies which made them a very attractive tool for immunotherapy (Hu 
et al. 2019a). Different strategies have been investigated as NK cell-based treatments, these are aimed 
at either repairing, replacing or enhancing the effector functions of NK cells (Tonn et al. 2013a; Leung 
2014; Hu et al. 2019b; Rezvani, Rouce 2015). Strategies aiming to enhance the activation, proliferation 
and cytotoxicity of patient’s NK cells include the administration of immune stimulants to patients such 
as cytokines and antibodies. A variety of cytokines have been used in an attempt to improve NK cell 
function and activation including IL-2, IL-15, IL-12, IL-18, and IL-21 which have been described to 
regulate NK cell maturation, activation and survival (Zwirner, Domaica 2010a; Nayyar, Chu, Mitchell S 
Cairo 2019). In addition to the adoptive transfer of ex-vivo activated and expanded NK cells, recent pre-
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clinical studies introduced the use of exosomes derived from NK cells as a promising method for 
inducing anti-tumour effects (Zhu, Kalimuthu, et al. 2017; Lugini et al. 2012; Hu et al. 2019a). The 
adoptive transfer of NK cells will be discussed further below, and the contribution of other NK cell-
based approaches will be highlighted in this context.  
1.2.2.2.1. NK cell adoptive transfer 
For adoptive cell therapy, NK cells can be derived from different sources. Usually, they are generated 
from the peripheral blood of the patient or a donor (autologous or allogeneic). NK cells can also be 
derived from hematopoietic stem cells (HSCs) in umbilical cord blood, embryonic or induced 
pluripotent stem cells (iPSCs) (Knorr and Kaufman, 2010). Another source is NK cell lines, and these are 
gaining more attention as a potential “off-the shelf” therapy due to the ease of its application in terms 
of culture, cost-effectiveness and genetic modification (Rezvani, Rouce 2015; Cheng et al. 2013; 
Klingemann et al. 2016).  
Autologous transfer 
In autologous transfer, NK cells are generated from the patient, activated and expanded ex vivo, after 
which they are transferred back into the patient. In some instances, patients then receive cytokines, 
usually IL-2, for sustaining expansion and effector function of the infused cells.  The transfer of 
autologous NK cells is a feasible approach, as it does not need prior immunesuppression, HLA-matching 
and avoids the risk of graft versus host disease (GvHD). However, despite an increase in circulating NK 
cell numbers in peripheral blood, limited therapeutic effects have been demonstrated. This was 
reported to be due to the inhibitory signals from self-HLA molecules (Parkhurst et al. 2011a; Rosenberg 
et al. 2008). Furthermore, the expansion efficiency and activation status of autologous NK cells are not 
optimal as they are obtained from heavily pre-treated patients. These challenges have motivated the 
evaluation of approaches involving allogeneic NK cells. 
Allogeneic transfer 
In allogeneic transfer, it is crucial to isolate NK cells at a high purity and deplete T and B cells in order 
to reduce the potential for GvHD and any risk of immune response to host erythrocytes and 
autoimmunity (Miller et al. 2005). The advantage of NK cells from healthy donors is that they are 
functional and not previously exposed to an immunosuppressive environment. In this context, HLA-
matched or haploidentical (partially-matched) donors can be used. Haploidentical donors that do not 
express inhibitory KIRs able to recognize the patient’s HLA molecules have more potential to generate 
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potent responses, as donor NK cells are not inhibited by a patient’s tumour cells (W. Wang et al. 2017; 
Lupo, Matosevic 2019). 
The first pieces of evidence demonstrating the in vivo efficacy of allogeneic NK cells following both 
donor hematopoietic stem cell transplantation (HSCT) and allogeneic infusions of isolated NK cells, was 
in patients with acute myeloid leukaemia (AML). An increased control of leukaemia was observed along 
with lower rates of relapse without NK cell-related GvHD in the allogeneic HSCT setting (Ruggeri et al. 
2008). Despite these early signs of efficacy with HSCTs, studies carried out by Miller et al demonstrated 
better results in patients with advanced cancers (metastatic melanoma, metastatic renal cell carcinoma 
and acute AML) using haploidentical adoptive transfer of allogeneic IL-2 activated NK cells followed by 
14 days IL-2 administration. Complete remission was observed in 30% of patients with AML having a 
poor prognosis (Miller et al. 2005).  
Other studies have shown KIR ligand mismatching between patient and donor NK cells induces better 
anti-tumour effects. Rubnitz et al, infused KIR‐HLA mismatched NK cells into paediatric patients with 
AML and demonstrated prolonged disease‐free survival (DFS) and overall survival (OS) (Rubnitz et al. 
2010). Infusion of haploidentical NK cells also induced remission in patients with non‐Hodgkin’s 
lymphoma (Bachanova et al. 2018). In a recent study by Cooley et al, infusion of haploidentical NK cells 
with recombinant human IL-15 (rhIL-15) achieved remission in 35% of patients with refractory AML 
(Cooley, He, Bachanova, Gregory M. Vercellotti, et al. 2019). 
 
Induced pluripotent stem cell derived NK cells  
With the aim of generating a more homogenous NK cell population, studies have used NK cells derived 
from induced pluripotent stem cells (iPSCs). Pre-clinical studies of these iPSC‐NK cells have 
demonstrated effectiveness against leukaemia and ovarian cancer  (Woll et al. 2005; Hermanson et al. 
2016). Although these iPSCs show promise as an NK cell immunotherapy, the demonstration of efficacy 
and feasibility in clinical trials is still pending (Hu et al. 2019a). 
 
NK cell lines 
NK cell lines offer various benefits as a source of NK cells for adoptive transfer therapy. In addition to 
the ease of procurement, as they avoid the need for leukapheresis, they can be easily expanded 
enabling clinical scale manufacturing of homogenous cell populations (Tarn et al. 2003). They are also 
free of contaminating T and B cells, avoiding any potential GvHD effects associated with blood-derived 
23 
 
NK cells. Various ongoing clinical trials are demonstrating their safety and efficacy for use in adoptive 
transfer therapy. Among the established NK cell lines are NK-92, NK-YS, YT, YTS, NKG, NKL, KHYG-1, 
SNK-6, IMC-1, NKL and HANK-1.  All of these cell lines have been derived from patients with 
leukemia/lymphoma, as a consequence of which cells have to be irradiated prior to infusion (Cheng et 
al. 2011). Although various studies are investigating the listed cell lines, only the NK-92 cell line has 
progressed to clinical trials and has received approval from the U.S. Food and Drug Administration 
(FDA) (Suck et al. 2016).  
Originally developed by Klingemann’s group and currently licensed by NantKwest 
(https://nantkwest.com), NK-92™ cells differ from  peripheral blood-derived NK cells in a few points. 
They lack the expression of CD16 and so do not induce ADCC (Klingemann et al. 2016), along with some 
typical NK  activating receptors such as NKp44 and NKp46. They are lack the expression of KIR inhibitory 
receptors, the only exception for this is the receptor KIR2DL (Suck et al. 2016), and this was shown to 
result in a more potent cytotoxic activity due to KIR mismatch following adoptive transfer (Maki et al. 
2001).  Multiple trials indicate that NK-92™ cells are safe and appear well-tolerated when used in 
adoptive therapy setting (Arai et al., 2008; Tonn et al., 2013; Tsartsalis et al., 2015; Boyiadzis et al., 
2017; Williams et al., 2017; Tang et al., 2018; Chrobok et al., 2019; Törnroos, Hägerstrand And Lindqvist, 
2019). Among the ongoing trials, many employ NK-92™ that are genetically engineered to induce more 
efficient anti-Tumour responses.  
Genetic modification of NK cells 
Genetic modification is a promising approach for creating more efficient NK cells.  In this context, 
different strategies for enhancing different components of NK cell anti-tumour activity, including 
expression of autocrine cytokines which promote NK cell survival, over-expression of activating 
receptors, CAR arming for targeting tumour associated antigens and more recently expression of high 
affinity CD16 (haNK®) for improving ADCC activity have been investigated (Guillerey et al. 2016a; 
Klingemann 2014; Binyamin et al. 2008; Jochems et al. 2016). The major source of cells used for CAR-
NK cell engineering are NK-92 cell lines, although CAR-NK cells based on primary NK cells have also been 
reported (Chu et al. 2014).  More recently, Kaufman’s group explored the use of iPSCs in this context 
and demonstrated that NK-CAR-iPSC-NK cells containing the transmembrane domain of NKG2D, the 
2B4 co-stimulatory domain, and the CD3z signalling domain, were able to control tumour growth in an 
ovarian cancer xenograft mouse model (Y. Li et al. 2018). In addition to the previously mentioned 
advantages associated with the use of NK-92 cells, another benefit in this framework is the relative 
ease of their transfection, as they show a transfection efficiency of at least 50% with viral or non-viral 
methods, such as electroporation.(Ingegnere et al. 2019; Boissel et al. 2012; Klingemann et al. 2016). 
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Multiple pre-clinical studies have shown promising efficacy of CAR-NK cells targeting various tumour-
associated antigens (TAAs) in haematological malignancies, but also in a few solid tumours (e.g. 
glioblastoma and breast cancer). TAAs tested include CD19, CD20, CD33, HER2, EGFR, EpCAM and 
CD138 (Romanski et al. 2016; Jiang et al. 2014; Mehta, Rezvani 2018; Zhang et al. 2017). Various CAR-
NK cells have also progressed to clinical trials. For instance, transduction of a CD33-specific chimeric 
receptor in NK-92 cells has been shown to be safe in patients with AML (Tang et al. 2018), whereas 
clinical trials of CD19 CAR-NK cells have indicated potential efficacy for lymphoid malignancies 
(Romanski et al. 2016). In solid tumours, the clinical trial (NCT02839954) was the first to prove the 
safety and efficacy of CAR-NK cells. The trial included patients with lung, pancreatic, colon and ovarian 
cancer.  These studies used dual-specific NK92 cells expressing CAR-Mucin1 and CAR-PD-1 with CD27 
and 4-1BB (CD137) as signalling domains.  
Overall, genetic modification provides more options for enhancing NK cell anti-tumour activity, albeit 
with various factors to consider for successful applications. 
1.2.2.3 Methods for advancing NK cell therapies 
Although it is clear that NK cell adoptive transfer is a promising tool for cancer treatment, some limiting 
factors and barriers need to be overcome for clinical practice. These include the expansion and 
activation of cells, their persistence once infused into the patient, their homing to tumour sites, and 
sustaining their activation and overcoming inhibition and suppression from the tumour 
microenvironment (Hu et al. 2019a). Various strategies have been developed in this sense, some of 
these will be discussed in this section.  
1.2.2.3.1. NK cell expansion and activation 
NK cell transfer therapy requires large number of functional cells. Except for NK cell lines, ex vivo 
expansion of NK cells is crucial for clinical application. Thus, several NK cell expansion protocols have 
been developed using either cytokines or feeder cells combined with cytokines. Although IL-2 and IL-
15 were initially used, combining IL-12, IL-15, and IL-18 showed enhanced effector functions with 
increased IFN-γ secretion and cytotoxicity, but also an induction of memory properties (Romee et al. 
2012). Feeder cell-based strategies applied in the clinic include irradiated peripheral blood 
mononuclear cells (PBMCs) and cell lines. Moreover, artificial antigen-presenting cells (aAPCs) have 
been developed as feeder cells for expanding NK cells ex vivo, such as gene-modified K562 feeder cells 
expressing membrane-bound IL-21 (K562-mbIL21, developed by Denman et al.,2012) which have been 
shown to induce intensive proliferation and a significant expansion of NK cells with a yield of 35,000-
fold in 3 weeks (Denman et al. 2012; Somanchi, Lee 2016). Phase I clinical trials using these NK cells in 
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patients with leukaemia after transplantation of allogeneic hematopoietic stem cells have 
demonstrated their safety and efficacy in improving NK cell anti-tumour activity (Ciurea et al. 2017).  
The Lowdell group has proposed that NK cell cytotoxicity is dependent on a ‘priming-triggering’ signal 
(Kottaridis et al. 2015). For this, cell lysates from the leukaemia cell line CTV-1 (CNDO-109) were used 
to prime NK cells. A phase I/II clinical trial using activated  haploidentical NK cells co-incubated with 
CNDO-109 prior to infusion in patients has indicated tolerability and a reduced incidence of disease 
relapse in patients with AML (Fehniger et al. 2018). 
Another approach is to activate autologous NK cells ex vivo using a 14-mer peptide from the sequence 
of the heat shock protein 70 (Hsp70) in combination with low dose IL-2 (ENKASTIM-ev, multimmune 
GmbH, Munich)(Hsp70). This approach results in NK cell activation and the targeting of tumours 
expressing a membrane form of Hsp70 (Shevtsov et al. 2018). A Phase I study in patients with 
metastatic colorectal and non-small cell lung cancer demonstrated the safety of Hsp70-activated 
autologous NK cells (Krause et al. 2004) and a Phase II trial in patients with non small cell lung carcinoma 
is ongoing (Specht et al. 2015). Furthermore, combining this approach with checkpoint inhibition has 
induced long-term survival in a patient with non small cell lung carcinoma ((Kokowski et al. 2019). 
Furthermore, Romee et al. demonstrated that short-term cytokine stimulation (IL-12, IL-15, and IL-18) 
of NK cells generate populations with “memory-like” phenotypes that exhibit increased survival and 
effector functions, thereby proposing that this approach could enhance the efficacy of NK cells in cancer 
immunotherapy (Romee et al. 2012). 
1.2.2.3.2. Reducing the inhibitory effect of the tumour microenvironment (TME) using 
regulatory checkpoint blockade 
Advances in immunotherapy have included impressive clinical outcomes associated with the 
administration of immune cell checkpoint inhibitors in the form of monoclonal antibodies (mAbs) such 
as anti-CTLA-4 and anti-PD-1 (Korman et al. 2006). In addition to their conventional inhibitory 
receptors, NK cell functions are also regulated by non-MHC class I inhibitory receptors which represent 
targets for immune checkpoint blockade and have the potential to enhance the anti-tumour activity of 
NK cells (Kim, Kim 2018; André et al. 2018; Stojanovic, Cerwenka 2018). These emerging targets include 
NK cell and T cell-expressed checkpoints PD-1 (programmed death-1), TIGIT (T cell immunoreceptor 
with Ig and ITIM domains), LAG-3 (lymphocyte activation gene 3 protein) and TIM-3 (T cell 
immunoglobulin domain and mucin domain-3) and NK cell checkpoint receptors KIR, ILT and 
CD94/NKG2A (Kim, Kim 2018; Sanchez-Correa et al. 2019). The administration of immunomodulatory 
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mAbs to block NK cell inhibitory receptors may represent a potential strategy to augment NK cell 
mediated antiTumour responses. 
1.2.2.3.3. Combinatorial therapies 
Results from recent clinical studies indicate that optimal efficacy of anti-tumour therapy will likely be 
achieved through combinations of different therapeutic approaches. In regard to NK cell-based 
immunotherapy, various approaches have been evaluated including the use of cytokines to enhance 
the function and proliferation of NK cells (Cooley, He, Bachanova, Gregory M Vercellotti, et al. 2019; 
Nayyar, Chu, Mitchell S. Cairo 2019), the use of therapeutic antibodies, either tumour-targeted mAbs 
or Bi or Tri-specific Killer Engagers (BiKEs or TriKEs) to redirect NK cytotoxicity and mediate ADCC 
(Gleason et al. 2012; Kellner et al. 2011; Hu et al. 2019b) and also checkpoint blockade aimed at the 
restoration of NK cell functions (Benson et al. 2010; Stojanovic, Cerwenka 2018) . Further efforts to 
augment NK cell anti-tumour responses have included combination with other immunotherapy 
approaches, such as oncolytic viruses. In this regard, one group found that the adoptive transfer of NK 
cells combined with bortezomib and oncolytic HSV-1 significantly prolonged the survival of glioma-
bearing mice (Yoo et al. 2016). Similarly, combining EGFR-CAR-NK-92 cells with oncolytic HSV-1 has 
been reported to enhance anti-tumour effects and survival of breast cancer-bearing mice (X. Chen et 
al. 2016). Some of the recent clinical trials with NK cell immunotherapy are summarized in Table 1.1. 
One of the methods that also has the potential to enhance NK cell function is low-dose chemotherapy, 








Source of NK cells Setting/Disease Therapy Phase status 
NK cell adoptive transfer 
NCT01040026 Allogeneic haploidentical NK 
cells 
Multiple myeloma Ex vivo expanded NK cell 
infusions (30 days) 
I/II ANR 




like (CIML) NK cells 
Pediatric acute myeloid 
leukemia (relapse after 
allogeneic HSCT) 
Fludarabine, Ara-C, and G-
CSF+CIML-NK cells 
I R 
NCT01520558 Allogeneic PBMC-NK cells 
from first- or second-degree 
relative 
Acute myeloid leukemia Preparative chemotherapy 
prior to NK cell infusion 
I/II U 
CAR-NK cells 
NCT03415100  NKG2D-CAR allogeneic NK 
cells (from parent or sibling 
donor) 
Metastatic solid Tumours CAR-pNK cell infusion I R 
NCT02892695 CD19-CAR-NK-92 cells CD19+ leukemia and 
lymphoma 
CAR-NK-92 cell infusion I/II R 
NCT02742727 CD7-CAR- NK-92 cells CD7 positive leukemia and 
lymphoma 
CAR-NK92 cell immunotherapy I/II R 
NCT02839954 MUC1-CAR-pNK cells MUC1 positive advanced 
refractory or relapsed Solid 
Tumours 
CAR-pNK cell immunotherapy I/II R 




Intracranial NK cell injection I R 
NK cells + therapeutic antibodies 
NCT02030561 expanded activated 
autologous NK cells 
HER2+ breast and gastric 
cancer 
NK cells + trastuzumab I/II U 
NCT02843061 NS Recurrent B-cell lymphoma NK cells + rituximab I/II U 
NCT02507154 expanded activated 
autologous NK cells 
Refractory head and neck 
cancer 
NK cells + cetuximab I/II R 
NCT02857920 NS Malignant solid tumours NK cells + bevacizumab I/II U 
NCT02843204 NS Malignant solid tumours NK cells + nivolumab I/II U 
NCT02650648 Allogeneic NK cells Recurrent non-small cell lung 
cancer 
NK cells + cetuximab I/II R 
NK cells + checkpoint blockade using mAbs against NK inhibitory receptors 
NCT03841110 FT500 (iPSC-derived NK 
cell product) 
Advanced solid tumours FT500+Nivolumab, 
Pembrolizumab, Atezolizumab 
I R 
NCT03937895 allogeneic NK cells Advanced biliary tract cancer NK cells+ Pembrolizumab I/II ANR 
NCT02843204 NS Recurrent solid tumours Nivolumab+ NK 
immunotherapy 
I/II U 




1.3  Low-dose metronomic chemotherapy  
1.3.1  The concept of low-dose metronomic chemotherapy 
Conventional chemotherapy has been used for a long time in cancer treatment. Conventional 
chemotherapeutic drugs used in standard clinical protocols are typically administered at the maximum 
tolerated dose (MTD) which targets rapidly growing cells including tumour and normal cells (Hanahan 
et al. 2000). These high doses necessitate prolonged resting periods of generally 2–3 weeks between 
treatment cycles to allow for the recovery from the cytotoxic adverse effects on normal tissues. 
Consequently, these drug-free periods allow the development of therapeutic resistance, as chemo-
resistant cancer cell populations regrow and elicit tumour neovascularization and metastasis (André et 
al. 2014; Kerbel, Kamen 2004). In fact, in addition to the high toxicity and adverse effects on the 
patients’ quality of life, MTD chemotherapy often leads to disease relapse, despite initial tumour 
regression (Munoz et al. 2005; Hanahan et al. 2000).  
The emergence of targeted therapies and recent advances in tumour biology changed the therapeutic 
goals for cancer treatment in clinical practice towards the delivery of prolonged responses rather than 
short-term tumour regression, which does not necessarily mean an increase in long-term survival for 
patients. One interesting alternative to MTD chemotherapy that has gained more attention recently is 
low-dose metronomic chemotherapy (LDMC). The term “metronomic chemotherapy”, first used by 
Hanahan (Hanahan et al. 2000), currently refers to the frequent and regular administration of lower 
doses of chemotherapeutics. Indeed, in contrast to MTD therapy regimens, LDMC is characterized by 
the frequent administration (daily, weekly or several times per week) of chemotherapeutics at a lower, 
less toxic dose without long drug-free periods  (André et al. 2014; Kerbel, Kamen 2004), the aim being 
to keep drug concentrations constant in plasma and maintain a continuous exposure of tumours to the 
chemotherapeutic agent. Initially, the anti-tumour mechanism of LDMC action was thought to be solely 
based on its anti-angiogenic activity (Kerbel, Kamen 2004). However, extensive studies have led to the 
identification of additional mechanisms, leading LDMC to be considered as a multi-targeted/multi-
modal therapy. In addition to direct anti-proliferative effects on tumour cells and induction of tumour 
dormancy (Natale, Bocci 2018; Chen et al. 2017), other mechanisms include actions on stromal tissue, 
targeting of cancer stem cells and activation of the immune system/immunomodulation (Muthusamy 
2016; Nars, Kaneno 2013; Chen et al. 2010a; Loven et al. 2013; Robert S Kerbel, Shaked 2017; Natale, 
Bocci 2018).  
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1.3.2 Immunomodulation by low-dose metronomic chemotherapy 
In the past, chemotherapy was thought to be immunosuppressive, however various studies have 
demonstrated the positive effects on immune modulation of various chemotherapeutic agents, 
especially when administered at low-doses in a metronomic schedule (Sistigu et al. 2011; Damber et al. 
2006a; Nars, Kaneno 2013; Chen et al. 2010a; Wu et al. 2016a). LDMC can activate the immune 
response against cancer by different means, including promoting the maturation and antigen 
presentation functions of DCs (Nars, Kaneno 2013; Tanaka et al. 2009), ablating immunosuppressive T-
reg cells and MDSCs in the tumour bed (Sistigu et al. 2011; Ghiringhelli et al. 2007b) and, most 
importantly, enhancing the activation and function of CD8+ T cells and NK cells (Ma, Waxman 2009; 
Wu, Waxman 2015; Wu, David J. Waxman 2014).  
Various chemotherapy drugs currently used in standard chemotherapy regimens, such as 
cyclophosphamide, paclitaxel, doxorubicin, cisplatin, and temozolomide, have been studied/evaluated 
in the context of LDMC to modulate tumour immunity (Nars, Kaneno 2013; K Lien et al. 2013). Changing 
the dosage of these commonly used drugs was shown to affect APCs, such as DCs. In one study, 
vinblastine, which is highly immunosuppressive at high doses, was found to promote DC maturation 
when used at low concentrations (Tanaka et al. 2009). Another study also reported increased activity 
of CD8+ T cells against melanoma cancer cells following LDM vinblastine (Cruz-Munoz et al. 2009). Low 
dose cyclophosphamide was also shown to convert CD4+ T-helper type 2 to a type 1 phenotype and 
enhance T-cell memory responses via the secretion of IFNα (Chen, Emens 2013). 
Several preclinical studies have demonstrated LDMC to inhibit and reduce immune suppressive 
populations of CD4+CD25+ T-reg cells and MDSCs and alleviate immune suppression and that this was 
typically accompanied by improved anti-tumour responses (Ghiringhelli et al. 2007a; Sistigu et al. 2011; 
Generali et al. 2009; Banissi et al. 2009; Nars, Kaneno 2013). In regard to innate immune responses, the 
treatment of brain tumour xenografts with LDM cyclophosphamide has been shown to induce 
significant regression of tumours and to be associated with recruitment and activation of NK cells, DCs 
and macrophages (Chen et al. 2014; Wu, David J Waxman 2014). Moreover, the stress induced by LDMC 
can also activate NK cells by inducing expression of NK cell activatory ligands, such as NKG2D (Khallouf, 
Märten, Serba, Teichgräber, Markus W. Büchler, et al. 2012; A. Soriani et al. 2009; Gasser et al. 2005a). 
Death receptors such as TRAIL can also be induced on the surface of tumour cells, thereby  enhancing  
the susceptibility of tumour cells to immune cell attack (Fine et al. 2010; A. Soriani et al. 2009). 
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1.3.3 Targeting Cancer Stem Cells (CSCs) 
Studies have reported the ability of LDMC to inhibit the tumour initiating/CSC subpopulation. For 
instance, Chan et al, demonstrated that LDMC inhibited tumour promoting chemokines affecting 
fibroblasts in the stroma and that are otherwise induced by MTD of doxorubicin, cyclophosphamide or 
paclitaxel, thereby improving therapeutic outcome (Chan et al. 2016). It has also previously suggested 
that inhibition of angiogenesis disrupts the CSC niche. Thus LDMC can also directly inhibit CSCs (Loven 
et al. 2013; Chan et al. 2019; Wu et al. 2016a). 
1.3.4 Low dose metronomic chemotherapy in the clinic  
Cyclophosphamide (CP) and methotrexate (MTX) used in metronomic regimens has shown clinical 
benefit in various studies in breast cancer (Colleoni et al. 2006; Orlando et al. 2006). In a study in 
patients with metastatic breast cancer, this combination yielded 5 and 7 months median PFS and OS, 
respectively, with 1 patient out of 48 experiencing a complete response (Hussein et al. 2017).  A 
combination of metronomic CP, vinorelbine and capecitabine has been evaluated in patients with 
metastatic, hormone receptor positive breast cancer showed a significant activity with a median time 
to progression of 25.1 months when used as first-line therapy and 11.2 months as second-line 
treatment (Montagna et al. 2017). In a phase II trial, oral etoposide (60 mg/m2 for 10 days, followed by 
11 days rest) was used in patients with metastatic breast cancer. A clinical benefit rate of 21.3% was 
achieved with median PFS of 4.5 months (Yuan et al. 2015). In ovarian cancer, metronomic 
chemotherapy regimens have also shown encouraging results. One retrospective study using oral 
etoposide in platinum-resistant patients showed it to be effective and well-tolerated with a median PFS 
of 3.9 months and a median OS of 16.4 months (Kucukoner et al. 2012). Topoctecan has also shown 
promise as a single agent or in combination with the anti-angiogenic molecule Bevacizumab. Various 
other chemotherapeutics have been evaluated, either alone or in combination with other agents in 
various cancers. Table 1.2 represent a selection of clinical studies of LDMC.  
31 
 
Table 1.2. Low dose metronomic chemotherapy in the clinic (adapted from Simsek et al.,2019) (Simsek et al. 2019a) 
Author 
 
Setting Therapy/ regimen N SD PR CR ORR TTP CB PFS OS 
Studies evaluating Metronomic chemotherapy in Breast cancer        
Wong, 2010 Metastatic, 
pretreated or 
untreated 
CP 50 mg qd po MTX 2.5 mg bid po two days q1w Prednisone 5 
mg qd 
41 7% 2% 15% 24% 10 
w 




pretreated, HER2 + 








pretreated, HER2 +/- 
CP 50 mg qd MTX 1 mg/kg iv q14d Bevacizumab 10 mg/kg iv 
q14d Trastuzumab (in HER2 +) 
22 32%  
(24 w) 
32%    63.6% 
 
7.5 m 13.6 
m 
Wang, 2012 Metastatic, 
pretreated 
CP 65 mg /m2 iv days 1-14 q3w Capecitabine 1000 mg/m2 bid 
days 1-14 q3w 
68    30.3% 5.2 
m 






Capecitabine 825 mg/m2 bid days 1-21 q 28d 33 24%  
(> 6 m) 






Paclitaxel 80 mg/m2 days 1. 8. 15, 4 cycles Cyclophosphamide 50 
mg qd po 4 cycles Capecitabine 1200 mg/m2 qd 4 cycles 5-FU 500 
mg/m2 q3w, 4 cycles Epirubicin 100 mg/m2 q3w, 4 cycles CP 500 
mg/m2 q3w, 4 cycles 
33  54.5%    31 
(93.9%) 
  
Mutlu, 2015 Metastatic, 
pretreated 








Capecitabine 1000 m2 bid po days 1-14 q21d 86    24.3% 7 m 55.8%  24.0 
m 
Yuan, 2015 Metastatic, 
pretreated 
Etoposide 60 mg/m2 po days 1-10 q 21d 75 39% 9%     4.5 m  
Studies evaluating Metronomic chemotherapy in Ovarian cancer        
Garcia, 2008 Platinum refractory Bev 10 mg/kg q14d CP 50 mg qd po 17  17 
(24%) 
  7.2 
m 






















Table 1.2. Continued. 
Roque, 2015 Uterine/Ovarian- 
fallopian-
peritoneal 
    Ixabepilone 16-20 mg/ m2 days 1, 8, 15, q28d 
Vs 





   41.7%   3.0 m/- 
 
 





Studies evaluating Metronomic chemotherapy in glioblastoma multiforme (GBM)        
Kesari, 2007 GBM and AG Etoposide 35 mg/m2 days 1-21 CP 2 mg/kg days 22-42, 
Talidomide Celecoxib 
48 59% 11% 
 







Kong, 2010 Pretreated GBM TMZ 40 mg/ m2 m2 qd or 50 mg/ m2qd 38       32.5% 56.0% (6 
m) 
Zustovich, 201 Pretreated GBM TMZ 40 mg/ m2qd Sorafenib 400 mq qd 43       26% 7.5 m 
Studies evaluating Metronomic chemotherapy in Prostate cancer 
Author 
 
Setting Therapy/ regimen N PSA DS PR TTP  PFS OS 
Nishimura, 2001 Hormone 
refractory 
CP 100 mg qd UFT 400 mg qd Estramustine 560 mg qd 21 57% 7 m      
Fontana, 2009 Hormone 
refractory 
CP 500 mg/m2 bolus than 50 mg qd po Celecoxib 200 
mg bid Dexamethasone 1 mg/day po 
28 
 
32%     3 m 21 m 
Gebbia, 2011 Castration 
resistant, 
CP 50 mg qd MTX 2.4 mg po two times a week LHRH 
analogue 
58 25% 24% 28%     
Yashi, 2014 Castration 
resistant, 
metastatic 
CP 50 mg qd po Dexamethasone 1 mg qd po 24 33.3
% 
 
    5.0 m 19.0 m 
Petrioli, 2015 Castration 
resistant 
Abiraterone 25 mg qd po Prednisone 5 mg qd po 26 69.2
% 
    6.4 m 14.3 m 
           
SD Stable disease, PR Partial response, CR complete response, OS Overall survival, PFS progression free survival, TTP time to progression, EPS event free survival, 
ORR overall response rate, CB clinical benefit. DS duration of response. 
33 
 
1.3.5 Potential synergy between LDMC and immunotherapy  
The immunomodulatory properties of LDMC make it a good combination candidate to immunotherapy, 
as it has the potential to enhance immunogenicity of tumour cells, the recruitment of immune cells and 
address immunosuppression issues by depleting immunosuppressive cells. Emerging evidence is 
supporting the idea that immunotherapy may be synergistic with LDMC. Indeed, LDMC has been shown 
to increase potency of immunotherapeutic modalities such as vaccines. Doxorubicin (5 mg/kg) was 
shown to enhance anti-tumour responses when given 7 days after vaccination in neu-transgenic FVB/n 
female mice. Responses were associated with polarization of macrophages to an anti-tumour M1 
activation status (Machiels et al. 2001). In a phase II trial, low dose cyclophosphamide and celecoxib 
enhanced responses to a DC-based vaccine in patients with advanced melanoma, doubling the number 
of patients with stable disease and significantly increasing survival compared to trials with the vaccine 
alone (Chen et al. 2010b; Ellebaek et al. 2012). In the context of checkpoint molecule blockade, pre-
clinical studies have demonstrated the impact of combining CTX with anti-CTLA4 in a model of breast 
cancer (Parra et al. 2017b). A large proportion of clinical trials have used LDM cyclophosphamide. In a 
prospective trial, LDM cyclophosphamide (50 mg/day, orally) combined with G-CSF, a sulfhydryl donor, 
a Cox2 inhibitor, and a preparation of autologous tumour antigens resulted in higher anti-tumour 
reponses and improved survival in cancer patients (advanced, unresectable pancreatic 
adenocarcinoma, non-small cell lung cancer, or prostate cancer) compared to standard chemotherapy 
alone (Lasalvia-Prisco et al. 2012). Many other clinical trials evaluating LDMC and immunotherapy 
combination are ongoing (https://clinicaltrials.gov), indicating that LDMC has potential to increase the 
contribution of immunotherapy responses, especially for solid tumours where targeting the tumour 










1.4 Breast cancer 
Breast cancer is a heterogeneous disease, and represents one of the most frequently diagnosed cancers 
and the second leading cause of cancer-related mortality among women worldwide (Siegel et al. 2016; 
Torre et al. 2015). The aetiology behind breast cancer is complex and involves environmental, lifestyle 
and genetic factors that collectively influence the risk of developing the disease (Ripperger et al. 2009; 
Rojas and Stuckey, 2016). Although the prognosis is generally favourable for breast cancer patients due 
to early detection and treatment, around 20%–30% of patients will still develop metastasis leading to 
a poor prognosis and low survival rate for cases with progressive disease (Kennecke et al. 2010; 
Eckhardt et al. 2012). 
1.4.1 Breast cancer metastasis 
Breast cancers can arise from epithelial cells of different parts of the breasts: ducts, lobules and 
connective tissues. Metastasis occur when cells leave the original tumour site and spread to the distant 
organs of the body through circulatory or lymph systems (Benson et al. 2009; Melzer et al. 2017). 
It is believed that breast cancer-related deaths are predominantly due to metastatic progression, and 
despite advances in treatment modalities, it remains largely incurable (Weigelt et al. 2005; Lu et al. 
2009; Torre et al. 2015). This is particularly challenging as tumour spread can both be an early event in 
breast cancer, where tumour cells dissemination can start 5-7 years prior diagnosis of the primary 
tumour (Hüsemann et al. 2008; Hosseini et al. 2016) and a late event, as metastasis can also develop 
decades after the time of diagnosis and primary treatment. In fact, the risk of distant recurrence from 
breast cancer was shown to be persistent for at least 20 years after diagnosis (Engel et al. 2003; Pan et 
al. 2017). Breast cancer cells disseminate to different sites and organs, including brain, lungs and liver, 
with the most common first site being the bones (Redig, Mcallister 2013; Schwartz, Erban 2017). 
A range of factors can indicate progression, invasiveness and metastatic behaviour of different breast 
tumours, among these, a molecular classification is used to predict the prognosis and direct the 
treatment of breast cancer patients (Sorlie et al. 2001; Akrami et al. 2017). This classification is based 
on the expression of three different receptors, including estrogen receptor-alpha (ERα), progesterone 
receptor (PR), and overexpression of HER2. There are 3 distinct molecular subtypes,  Luminal 
(ERα+/PgR+, HER2−/+), HER2 (ERα−/PgR−, HER2+), and triple-negative (ERα−/PgR−, HER2−) (Perou et 
al. 2000; Prat et al. 2010). 
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1.4.2 Triple negative breast cancer  
Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers (Brown et al. 2008; 
Garrido-Castro et al. 2019). Compared with other breast cancer subtypes, TNBC affects a young patient 
population (<40 years) and is more prevalent in women of African and Hispanic descent (Carey et al. 
2006; Dent et al. 2007). There is also an enrichment of TNBC phenotype in the subset of patients with 
BRACA1 germline mutations (80-85% of BRCA1 BCs are triple negative) (Foulkes et al. 2010). TNBC 
represent the most aggressive subtype of breast cancer due to its poor prognosis, high rates of local 
and systemic relapse and the lack of available targeted treatments  (Rakha et al. 2009; Gonzalez-Angulo 
et al. 2011). Histologically, the majority of the TNBCs are high-grade invasive ductal carcinomas (grade 
III) of no special type, with distinctive features such as central necrosis, pushing borders, high mitotic 
rate and prominent tumour lymphocytic infiltrate (Dent et al. 2007).   
Given that TNBC as a group is defined by the absence of the known markers, it is only plausible to 
imagine that there would be different subtypes within TNBC. Sub-classification of TNBC tumours can 
be based on molecular, prognostic signatures and lymphocytic infiltrate. In a seminal study, using gene 
expression microarray, Lehmann and colleagues classified TNBC into 7 subtypes (6 defined subtypes 
and one unstable group) based on gene ontologies and differential gene expression. Known as the 
Vanderbilt classification, the 6 subtypes have been shown to display distinct biology and responded 
differently to various therapies. They included two basal-like subtypes (BL1 and BL2), one 
immunomodulatory (IM), one mesenchymal (M), one mesenchymal stem-like (MSL), and one luminal 
androgen receptor (LAR) class (Lehmann et al. 2011a). Following further studies and observations 
suggesting that the IM phenotype was not an isolated cluster, Lehmann et al., later refined their 
classification to only include four subtypes (BL1, BL2, M, LAR) (Lehmann et al. 2016). Other molecular 
groups were identified based on different approaches. A group from Baylor University proposed 
additional clusters, incorporating immune signatures and labelled as basal-like immune-suppressed 
(BLIS) and basal-like immune-activated (BLIA) associated with poorest and best prognosis, respectively 
(Burstein et al. 2015). Other similar classifications include the PAM50 algorithm  (Liu et al. 2016) and 
the French subtypes (Jézéquel et al. 2015). More recently, the 3 groups of the French subtypes were 
further characterized, C1 as a molecular apocrine cluster, with luminal, PIK3CA-mutated, and HER2E 
features. Although C2 and C3 are associated with basal-like hallmarks, they are substantially different 
in terms of immune responsiveness, with the C3 subtype being associated with a more anti-
Tumourigenic immune response and C2 being more pro-Tumourigenic (Jézéquel et al. 2019). 
The classification of TNBC into subtypes is not only useful to better understand the disease, dissect its 
heterogeneity and aid to direct therapeutic decisions, but also to identify new targets for treatments 
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(Ahn et al. 2016). However, the predictive role of this molecular classification in response to treatment 
remains elusive (Lehmann et al. 2016; Burstein et al. 2015). 
1.4.2.1 Treatment options and challenges in TNBC  
Since TNBC tumours are negative for ER/PR and HER2, TNBC patients cannot benefit from endocrine 
and anti-HER2 agents. In clinical practice, chemotherapy remains the only treatment option available. 
First-line systemic treatment include various chemotherapy regimens (anthracyclines, taxanes, and/or 
platinum compounds) and single-agent response rates range from 20 to 50% (Zeichner et al. 2016). 
Despite aggressive treatment with adjuvant and neoadjuvant chemotherapies, and the prolonged 
survival found to be associated with the pathological complete response (pCR) to neoadjuvant 
chemotherapy (Cortazar, et al. 2014), the mortality rate for patients with advanced stage TNBC who do 
not achieve pCR remains very high, as tumour relapse occurs usually within 2 years (Groheux, et al. 
2015).   
The recent classifications of TNBC and improved understanding of their heterogeneity has been 
changing the treatment landscape toward more targeted alternative approaches such as poly (ADP-
ribose) polymerase (PARP) and tyrosine kinase receptor inhibitors, antibodies targeting Notch or 
PI3K/AKT/mTOR pathways  (Bianchini et al. 2016; Vidula, Bardia 2017; Jhan, Andrechek 2017; Zhang et 
al. 2016). A selection of approaches in clinical trials is listed in Table 1.3. Despite these treatment 
modalities in clinical trials, no significant survival improvements have been proven. To date, there is 














Table 1.3. Selected active clinical trials using targeted therapy for TNBC  
Trial  
 
Setting Therapy  Phase  Status  
Studies evaluating PARP inhibitors 
NCT03167619 Platinum treated 
advanced TNBC 
Olaparib in combination with durvalumab II R 
NCT02484404 mTNBC Olaparib +/- Cediranib + MEDI4736(anti-PD-L1 antibody) I/II R 
NCT03330847 mTNBC Olaparib+ DNA damage/repair targetting agents II R 
Studies evaluating VEGF/VEGFR inhibitors (Tyrosine kinase inhibitors)  
NCT02624700 Reccurent/mTNBC Sorafenib + Pemetrexed  II ANR 
NCT03394287 mTNBC Apatinib (tyrosine kinase inhibitor targeting VEGFR2) + 
SHR-1210(anti-PD-1 antibody) 
II ANR 
NCT03316586 mTNBC Cabozantinib+Nivolumab II ANR 
Studies evaluating EGFR inhibitors 
NCT01097642 TNBC Cetuximab+ Ixabepilone II ANR 
NCT03692689 mTNBC SCT200 (recombinant anti-EGFR mAb) II R 
Studies evaluating multi tyrosine kinase inhibitors  
NCT01639248 mTNBC ENMD2076 II R 
NCT03797326 TNBC lenvatinib (E7080/MK-7902)+Pembrolizumab (MK-3475) II R 
ANR active, not recruiting, R recruiting 
In addition to the vast inter-and intra-tumour heterogeneity, the main obstacles facing the 
development of effective treatment for TNBC are the lack of specific biomarkers and the aggressive 
nature of the disease, making it more difficult to develop treatment strategies. Moreover, conventional 
chemotherapy has been shown to be associated with an enrichment of CSCs (Jia et al. 2017; Zhou et al. 
2018). Hence, a significant challenge is to eliminate CSC populations as they are the main drivers of 
disease relapse. Indeed, CSCs have the ability to initiate new tumours through their self-renewal and 
differentiation properties (Matsuda et al. 2014). The involvement of CSCs in invasion and metastasis 
and their resistance to treatment has been demonstrated and various studies are looking at their 
targeting and elimination such as through targeting Notch pathway. Therefore, to ease the burden of 
TNBC treatment, an optimal therapeutic approach focusing on overcoming these obstacles should be 
found. 
One modality having potential in this area is metronomic chemotherapy (MC). Preclinical studies have 
demonstrated the potential of MC for TNBC treatment, as it has been shown to modulate angiogenesis, 
proliferation and drug resistance (Di Desidero et al. 2015). In the clinical setting, metronomic 
cyclophosphamide with paclitaxel after neoadjuvant epidoxorubicin-cisplatin-fluorouracil (ECF) has 
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been reported to decrease proliferation (41-91% decrease of Ki-67) in patients that had a complete 
pathological response (Cancello et al. 2015). For advanced, pre-treated TNBC, Viale et al. reported that 
the combination of metronomic CP with cisplatin yielded a 23.3% clinical benefit at 6 months after 
treatment (Viale et al. 2017). On the other hand, emerging evidence has highlighted the role of tumour-
infiltrating lymphocytes in predicting the prognosis of TNBC (Loi et al. 2019; Criscitiello et al. 2016; Loi 
et al. 2013). These data, together with the recent encouraging results from the IMpassion130 trial on 
the implementation of immune checkpoint blockade for TNBC which demonstrated an improved OS  
with the addition of anti-PD-L1 to first line nab-paclitaxel in patients with PD-L1 positive TNBC (Schmid 
et al. 2018) provide a rational for the use of immunotherapy for treating TNBC, and various phase II 
and III clinical trials are ongoing in this area (Table 1.4). 
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Table 1.4. Ongoing phase II/III randomized immunotherapy trials in triple negative breast cancer (adapted from Marra et al.,2019) (Marra 
et al. 2019) 
Trial Setting Therapy Phase Status 
NCT03639948 (NeoPACT) Neoadjuvant Carboplatin + docetaxel + pembrolizumab II R 
NCT03289819 Pembrolizumab + Nab-paclitaxel ➔ pembrolizumab + epirubicin and cyclophosphamide II R 
NCT03356860 (B-IMMUNE) Paclitaxel + epirubicin + cyclophosphamide ± durvalumab II R 
NCT03036488 (KEYNOTE-522) Neoadjuvant/Adjuvant Carboplatin + paclitaxel + (anthracycline) + cyclophosphamide ± pembrolizumab➔ 
pembrolizumab 
III ANR 
NCT03281954 Doxorubicin + cyclophosphamide + paclitaxel + carboplatin ± atezolizumab ➔ atezolizumab III R 
NCT03197935 (IMpassion031) Doxorubicin + cyclophosphamide + nab-paclitaxel ± atezolizumab ➔ atezolizumab III ANR 
NCT02954874 Adjuvant only for patients with residual 
disease after neoadjuvant chemotherapy 
Pembrolizumab vs. observation III R 
NCT03756298 Capecitabine ± atezolizumab II R 
NCT03498716 (IMpassion030) Adjuvant Paclitaxel ➔ dose-dense doxorubicin/epirubicin + cyclophosphamide ± atezolizumab III R 
NCT02926196 (A-Brave) Avelumab vs. observation III R 
NCT02768701 Locally advanced or metastatic TNBC Cyclophosphamide + pembrolizumab II ANR 
NCT03121352 Carboplatin, nab-paclitaxel and pembrolizumab II R 
NCT02819518 (KEYNOTE-355) Abraxane or paclitaxel or carboplatin/gemcitabine ± pembrolizumab III ANR 
NCT02555657 (KEYNOTE-119) Capecitabine, eribulin, gemcitabine, or vinorelbine as TPC vs. pembrolizumab III ANR 
NCT03644589 Cisplatin + pembrolizumab II NYR 
NCT02755272 Carboplatin + gemcitabine ± pembrolizumab II R 
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Trial Setting Therapy Phase Status 
NCT02447003 (KEYNOTE-086) Pembrolizumab monotherapy II ANR 
NCT03125902 (IMpassion131) Paclitaxel ± atezolizumab III R 
NCT03164993 (ALICE) Pegylated liposomal doxorubicin + cyclophosphamide ± atezolizumab II R 
NCT03206203 Carboplatin + gemcitabine II R 
NCT03606967 Nab-paclitaxel + durvalumab ± neoantigen vaccine II NYR 
NCT03616886 (SYNERGY) Paclitaxel, carboplatin, durvalumab ± oleclumab II R 
NCT03371017 (IMpassion132)     Carboplatin + gemcitabine or capecitabine ± atezolizumab III R 
NCT03167619 (DORA) Durvalumab + olaparib II R 









1.5 Thesis aims:  
The central objective of the research programme described in this thesis was to determine the 
therapeutic potential of combining low-dose chemotherapy (LDC) with NK cell-based immunotherapy 
and thereby provide novel insights for improving existing NK cell-based immunotherapy strategies.  The 
experimental aims of this programme were: 
1. To establish a LDC treatment protocol for human breast cancer cell lines and characterize the 
phenotype of treated cells in vitro (Chapter 3); 
2. To characterize the influence of LDC on the expression of NK cell ligands on breast cancer cell 
lines and determine the sensitivity of untreated and treated cells to NK cell cytotoxicity in vitro 
(Chapter 4); 
3. To interrogate the biology of treated cells and mechanisms involved in the response to the 
treatment using gene expression analysis (Chapter 5); 
4. To evaluate the influence of LDC and adoptive NK cell transfer on the growth of implanted 









CHAPTER 2 : Materials and Methods  
2.1 Blood donors  
Ethical approval for taking blood samples from healthy volunteers was provided by Nottingham Trent 
University’s Ethical Committee (Humans) under the application Number: 435- 25/01/2016, and 
informed consent obtained. 
2.2 Mouse strains  
The pre-clinical studies have been approved by the Home Office under the Animals (Scientific 
Procedures) Act under the Project Licence (PPL): PB26CF602, granted on the 28th of November 2016 
and valid until the 28th of November 2021. Female nonobese diabetic (NOD)-scid gamma (NSG)  mice 
(NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) have a background of SCID mice and IL-2 receptor gamma chain 
deficiency. These mice are one of the most immunodeficient strains due to the lack of mature B, T, and 
NK cells; they also lack cytokine signalling.  NSG mice were purchased from Charles River Laboratories. 
The other mice strain used in these studies is the NOD,B6.SCID Il2rg-/- KitW41/W41 (NBSGW) mice, which 
was developed by the intercrossing of the NSG mouse strain with mice homozygous for the KitW41 allele 
C57BL/6J-KitW-41J/J (C57BL/6.KitW41). NBSGW mice support engraftment of hematopeoetic cells without 
requiring myeloablative irradiation due to the mutant KitW41 and were purchased from Jackson 
Laboratories (USA). All mice were 6-8 weeks old at the start of the studies.  
2.3 Cell lines  
Cell line  Breast cancer 
subtype 
Culture conditions Supplier 
MCF-7  Luminal A  EMEM, 10% v/v FCS, w/v 1% L-
glutamine  
37°C in 5% v/v CO2  ATCC 
SKBR-3  
 
Her2+ McCoy’s 5, v/v 10% v/v FCS  37°C in 5% v/v CO2  ATCC 
MDA-MB-468  Triple negative  Leibovitz's L-15, v/v 10% FCS, 
1% w/v L-glutamine  
37°C without CO2  ATCC 
MDA-MB-231 Triple negative  Leibovitz's L-15, v/v 10% FCS, 
1% w/v L-glutamine  




Triple negative  Leibovitz's L-15, v/v 10% FCS, 
1% w/v L-glutamine, 1% w/v 
NEAA 
37°C without CO2 AMSBIO 
K562 (erythroleukemia)  RPMI, 10% v/v FCS, 1% w/v 
glutamine  









Source-Characteristics Culture conditions  Supplier 
 
NK92 
Natural Killer Cell line (IL-
2 dependent) derived 
from peripheral blood 
mononuclear cells from a 
50 year old Caucasian 
male with rapidly 
progressive non-Hodgkin's 
lymphoma 
75% alpha-MEM + 12.5% v/v FCS + 
12.5% v/v horse serum + 2mM L-







 IL-2 independent Natural 
Killer Cell line derived 
from the NK-92 cell line 
by transfection. 
75% alpha-MEM + 12.5% v/v FCS + 
12.5% v/v horse serum + 2mM L-
glutamine + 0.2 mM inositol+0.1 mM 

























2.4 Methods  
2.4.1 Cell culture  
2.4.1.1 Cell culture maintenance (thawing, subculture and freezing) 
Cryovials of cells were withdrawn from liquid nitrogen and thawed quickly by transfer into Falcon tube 
with added medium. The cells were centrifuged (300g, 5min, RT). Following removal of the 
supernatant, the cells were resuspended in fresh, pre-warmed medium and transferred into cell culture 
flasks for culture (37°C, with or without 5% v/v CO2). Cells were subcultured once they reached around 
80-90% confluency. 
Adherent cells were passaged using trypsin-EDTA treatment. After the culture medium was decanted 
the cell layer was gently washed with sterile PBS and pre-warmed trypsin-EDTA was added until it 
covered the cell layer, the cells were then incubated at 37°C until the all cells detached from the surface. 
Complete medium was added to neutralise the activity of trypsin-EDTA and the cell suspension was 
then transferred into Falcon tubes and was centrifuged (300g, 5min,RT). The supernatant was removed 
and the cell pellet resuspended in fresh medium and either counted or used for assays or split at 
appropriate ratios for culture (37°C, without or without 5% v/v CO2).Cultures of suspension cells were 
maintained by addition of fresh medium with an appropriate split ratio.  
Suspension of cells to be frozen down were centrifuged (300 or 400g, 5min, RT) and following the 
removal of the supernatant, the cell pellet was resuspended in an appropriate volume of freezing 
medium (90% v/v FCS+ 10% DMSO) and transferred into cryovials (1ml aliquots). The cryovials were 
stored in -80°C freezer and transferred into liquid nitrogen for long-term storage. 
 
2.4.1.2 Counting of cells 
 Cells were checked for viability and counted using either a Haemocytometer or the NucleoCounter®.  
For Haemocytometry counting, the cell suspension was pre-diluted with an appropriate volume, and 
10μl were added to 90μl of trypan blue solution (0.05 % w/v) mixed 1:1 with PBS. Cells were transferred 
into the counting chamber and live cells were counted. The concentration of cells was calculated using 
the following formula: 
                            Cell concentration = Counted cells/counted squares x dilution x104    
For NucleoCounter®cell counting. The cell suspension was pre-diluted with an appropriate volume, 
from which 50μl of cells were mixed with 2.5μl of Solution 18 AO.DAPI which contains Acridine 
Orange and DAPI for living and dead cells staining, and transferred into the counting slide. The slide 
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was inserted into the NucleoCounter® and viability percentages and cell concentration were obtained 
from the software.  
2.4.2 In vitro experiments  
2.4.2.1 Doxorubicin treatment of cells 
Cells were seeded into tissue culture plates and then allowed to adhere for 24h before being treated 
with a range of doxorubicin concentrations (15-500 nM) for 24h-72h or with 1 or 2μM for 2h. 
Concentrations that maintained the viability of cells >90%, as determined using Trypan Blue dye 
exclusion, were selected. Following treatment, cells were washed free of doxorubicin and provided 
with fresh complete medium. The cells were then cultured in drug-free medium for an additional 24h 
to 7 days and used for assays. 
2.4.2.2 Flow cytometry cell surface and intracellular staining 
The expression of senescence, DNA damage markers and NK cell ligands on tumour cells was assessed 
using flow cytometry (See Appendix 8.1.6 for antibodies details). For the analysis of cell surface marker 
expression, cells were harvested, counted and 0.5-1x106 cells for each condition were washed with 2ml 
PBS then incubated with a panel of Fluorochrome-conjugated monoclonal antibodies at recommended 
concentrations for 30min on ice in the dark, after which they were washed once with PBS by 
centrifugation (300g, 5min,4°C) and the supernatant was discarded. The cell pellet was resuspended in 
200-300 μl Isoton™ (cytometer running buffer) and analysed on the flow cytometer.  
For intracellular antigens, cells were fixed and permeabilised using an eBioscience™ Intracellular 
Fixation & Permeabilization Buffer Set, according to the manufacturer’s protocol. After fixation, cells 
were incubated with FcR blocking reagent for 10 min, after which they were incubated with antibodies 
diluted in permeabilisation buffer for 30 min on ice. Cells were finally washed with buffer before data 
acquisition. Antibody panels included LIVE/DEAD™ Fixable Dead Cell Stain to exclude dead cells from 
the analysis. Data was acquired on the Gallios flow cytometer (Beckman Coulter) and Kaluza 1.3 version 
(Beckman Coulter) was used for all flow cytometry data analysis. Figure 2.1 represent the basic gating 




Figure 2.1 Basic gating strategy for flow cytometry analysis.  Following the identification of cells on a forward 
scatter (FS INT) vs side scatter (SS INT) plot, Single cells are selected by exclusion of cell aggregates/doublets using 
cell height and areas. Viable tumour cells are then identified for analysis using LIVE/DEAD Cell Stain.  
1.2.2.3.4. Assessment of SA-B-gal expression  
On day 6-7 post-treatment, culture medium was removed and replaced by pre-warmed fresh culture 
medium. As SA-β-gal is detected at ~pH 6, the internal pH of lysosomes was first neutralized using a 
lysosomal inhibitory drug, Bafilomycin-A1 at 100nM for 1 h at 37°C, 5% v/v CO2. Cells were then 
incubated for 1 h with 30 µM 5-Dodecanoylaminofluorescein Di-β-D-Galactopyranoside (C12FDG) a β-
galactosidase substrate which becomes fluorescent after cleavage by the enzyme. Following 
incubation, cells were washed twice with phosphate buffered saline (PBS), harvested by trypsinization 
and centrifuged at 300g for 5 min at 4°C. Cells (1x105) were resuspended in 250µl Isoton™. SA-β-gal 
positive cells were detected and quantified on the flow cytometer (Gallios-Beckman Coulter). Kaluza 
1.3 version (Beckman Coulter) was used for all flow cytometry data analysis. 
1.2.2.3.5. Cell cycle analysis  
Cells were harvested and washed in PBS, after which they were fixed in 1 mL ice cold 70% v/v ethanol 
for 30 min on ice. Ethanol was added dropwise to the cell pellet whilst vortexing to avoid clumping and 
ensuring an even fixation. Fixed cells were then treated with 50 µL of 100 μg/ml Ribonuclease A to 
ensure that only DNA was stained, after which cells were incubated with propidium iodide (200 µl, 50 
μg/ml, Invitrogen) for 10 min at room temperature. Samples were then analysed by flow cytometry 











Figure 2.2 Gating strategy for cell cycle analysis.  Staining with propidium iodide allows for the identification of 
the percentage of cells in G1, S, G2/M phases of the cell cycle.  
2.4.2.3 Isolation of human PBMCs 
Peripheral blood was collected from human healthy volunteers into 100 U/ml of heparin by a trained 
phelebomist and diluted with PBS at a 1:1 ratio. Peripheral blood mononuclear cells (PBMCs) were 
isolated by layering diluted blood over Ficoll-Paque density gradient medium and centrifuging tubes at 
800xg for 20 min at room temperature with the brake off. PBMCs were harvested from the interface 
layer into 50ml Falcon tubes using Pasteur pipettes. Cells were then washed twice with PBS and 
centrifuged at 400xg for 10 min at room temperature. The resulting cell pellet was resuspended in RPMI 
culture medium cells and counted using the NucleoCounter®. 
2.4.2.4 Isolation of human NK cells 
Human NK cells were isolated from PBMCs by immunomagnetic negative selection using EasySep™ 
Human NK-Cell Isolation Kit. For this, PBMCs were transferred into a 5 ml polystyrene round-bottom 
tube at a concentration of 5x107 cells/mL in 0.25-2 mL, 50 μL of isolation cocktail was added per ml of 
sample, mixed and incubated for 5 min, RapidSpheres beads were vortexed and added to the sample 
at 50 μl/ml after mixing, the sample volume was made up to 2.5 ml with recommended medium (PBS 
with 2% v/v FBS and 1 mM EDTA) and mixed by gentle pipetting. The sample tube was then placed into 
the magnet for 3 min, after which isolated cells were collected by pouring the enriched cell suspension 
into a new tube. Cells were counted using the NucleoCounter® and checked for purity using flow 





                           Figure 2.3. Purity of CD3-CD56+ NK cells after isolation from PBMCs 
2.4.2.5 In-vitro cytokine stimulation of NK cells 
Following isolation, NK cells were either used in their resting state or after stimulation for 24h/48h with 
IL-2 (100 U/ml or 200 U/ml). 
2.4.2.6 Cytotoxicity assays 
NK cell cytotoxicity was determined using a flow cytometry-based technique, the principle of which is 
that target cells are fluorescently labelled and the viability of these is determined by flow cytometry 
following the inclusion of a viability stain. 
1.2.2.3.6. CellVue™ labelling of target cells 
Target cells were washed with serum-free medium and labelled with CellVue™ NIR780 cell labelling kit 
(633-779nm). These are lipophilic dyes that can be used to label the cell membrane for the purpose of 
identifying and tracking labeled cells. For staining, the cell pellet was resuspended in 200 μl of Diluent 
C and pipetted gently to ensure a single cell suspension. The dye solution (2 μl of the 1 mM dye stock 
to 200 μl of Diluent C) was rapidly added to the sample and mixed well by pipetting to ensure uniform 
labelling. Cells were incubated for 3 min and the staining was stopped by the addition of an equal 
volume of foetal calf serum (FCS) for 1 min. Cells were then centrifuged at 300x g for 5 min and the 
supernatant discarded. Cells were then washed twice with complete medium, counted and transferred 
to sterile conical poly-propylene tubes. 
1.2.2.3.7. Cytotoxicity assay 
CellVue™ dye-labelled target cells, at a minimum of 1x105 cells in 100 μl medium were added to 5x105 
primary NK cells or NK-92® cells in 100 μl (effector: target [E:T] cell ratio of 5:1, other E:T of 1:1 and 
10:1 were also tested), and incubated for 3 h at 37°C and 5% v/v CO2. As controls, untreated and 
treated cells alone without NK cells were used to measure spontaneous cell death. After the incubation 
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period, the cells were resuspended in a solution of LIVE/DEAD® Fixable Dead Cell Stain for 20 min and 
then centrifuged for 5 min at 300xg, resuspended in Isoton™ Sheath Fluid and analysed by flow 
cytometry (Figure 2.4). At least three independent experiments were performed unless otherwise 
stated. NK cell cytotoxic activity was calculated using the following equation:  
% 𝐂𝐲𝐭𝐨𝐭𝐨𝐱𝐢𝐜𝐢𝐭𝐲 = (% 𝐬𝐚𝐦𝐩𝐥𝐞 𝐜𝐞𝐥𝐥 𝐝𝐞𝐚𝐭𝐡 − % 𝐬𝐩𝐨𝐧𝐭𝐚𝐧𝐞𝐨𝐮𝐬 𝐜𝐞𝐥𝐥𝐬 𝐝𝐞𝐚𝐝) 𝐱𝟏𝟎𝟎/ 










Figure 2.4. Gating strategy of the cytotoxicity assay. Percentage of cell death was analysed by gating on the 
cellvue+ target cells (target +) first and then the number of positive and negative LIVE/DEAD™ cells. 
 
2.4.2.7 Flow cytometric assessment of intracellular cytokines and CD107a degranulation 
assay 
To determine the expression levels of IFN-γ, perforin, granzyme B and CD107a secretion/expression. 
NK-92® MI cells were incubated alone, with K562 target cells (as a positive control target) or with 
treated / untreated MDA-MB-231 cells at a 1:1 ratio for 4 h at 37°C. After 1 h, Brefeldin A  and monensin 
were added to allow the accumulation of CD107a protein in the Golgi complex, as well as CD107a 
antibody. Cells were washed, stained with CD56 antibody and LIVE/DEAD™ stain, followed by fixation 
and permeabilisation using PerFix-nc assay kit and intracellular staining for the expression of IFNγ, 
perforin  and granzyme B. Cells were washed and analysed on the flow cytometer (Gallios-Beckman 




2.4.2.8  NanoString nCounter™ amplification-free gene expression profiling 
1.2.2.3.8. Fluorescence activated cell sorting (FACS) 
For sorting treated cells by size using the forward and side scatter scale (FShigh and FSlow), at least 2x106 
cells were re-suspended in cell-sorting sorting medium (PBS + 1% v/v FCS + HEPES (25mM) + EDTA 
(2mM)), then sorted into FShigh and FSlow  populations using MoFlo™ cell sorter, onto a plate containing 
collection medium (normal cell medium + 20% v/v FCS). Sorted cells were washed with PBS twice and 
cell pellets were frozen at -80°C until used for RNA extraction.   
1.2.2.3.9.  RNA extraction and Nanostring gene expression profiling  
The transcriptomes of untreated and low-dose doxorubicin-treated breast cancer cells were 
determined using NanoString nCounter™ FLEX platform. The nCounter™ analysis system detects the 
expression of up to 800 genes in a single reaction with high sensitivity across a wide range of expression 
levels and allows for direct multiplexed measurements of gene expression without the need for 
amplification by PCR. For the analysis, total RNA was extracted from cell pellets (5x105 cells) using the 
RNAqueous™-micro total RNA-isolation kit, following the manufacturer’s recommended protocol. RNA 
was assessed for quantity and purity using a NanoDrop spectrophotometer. An OD260/280 ratio 
between 1.8-2.2 was considered for further processing. 
The PanCancer Pathways Panel, which includes 770 genes from 13 cancer-associated canonical 
pathways was used.  Samples were analysed in 3 biological replicates. For each sample 150ng of RNA 
in 5μl (diluted in nuclease-free water) was hybridized to the probes at 65°C for 17 h in 8 μl of a Master 
Mix solution (containing 3 μl of reporter CodeSet and 5 μl of hybridization buffer) and 2 μl of capture 
ProbeSet.  Hybridised samples were then transferred to an automated fluidic handling system 
(nCounter™ prep-station), in which excess of probe was removed using a magnetic beads-based 
purification process. Biotinylated capture probe/target sample complexes were bound, immobilized 
and aligned on a streptavidin-coated cartridge. The cartridge was then transferred for quantification of 
the abundance of specific target molecules using digital image processing within the nCounter™ Digital 
Analyser instrument (555 fields of view (fov) collected for each sample). The reporter probe counts, 
were tabulated for analysis using the nSolver™ package and Advanced Analysis module. The analysis 
software automatically performs quality controls, normalization, data analysis and creates reports with 
the options of performing advanced analyses including pathway applications. Principle component 
analysis (PCA) was used for assessing sample grouping. Genes with a false discovery rate below 0.05 
were considered as being significantly differentially expressed.  Further Gene ontology enrichment 
analysis was carried out using MetaCore software.    
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2.4.3 In vivo assays 
2.4.3.1 Preparation of cells for tumour injections into mice 
Prior to implantation into animals, tumour cells were checked for mycoplasma contamination and for 
luciferase signal.  MDA-MB-231/RFP/LUC cells were harvested while in the exponential phase (no more 
than 70% confluency), washed once with sterile PBS, checked for good viability (≥95) and counted. Cells 
were then resuspended in appropriate volumes of sterile PBS and extracellular matrix (ECM) (1:1 v/v). 
5x106 MDA-MB-231/RFP/LUC cells in a final injection volume of 100μl (PBS+ECM) for each animal were 
implanted subcutaneously into the 4th inguinal mammary fat pad. 
2.4.3.2 Animal treatment  
Implanted cells were allowed to grow until tumours became palpable, at which time animals were 
imaged and randomised into treatment groups based on tumour size (Bioluminescent signal, total Flux 
[p/s]), in order to ensure that there was no statistically significant differences in tumour mass within 
the different groups of mice at the start of treatment.  
Animals received 2 cycles of treatment consisting of; 3 doses of doxorubicin (0.5 mg/kg) per week, 
administered through intraperitoneal injection (IP), followed by 1 intravenous injection (IV) of 
adoptively-transferred donor-derived NK cells or NK-92® MI cells (10x106 cells). Control mice received 
PBS alone. Doxorubicin only group were only treated with doxorubicin, and NK alone group only 
received NK cell infusions (Figure 2.5). Tumour growth was monitored twice a week using calliper 
measurements and at regular intervals using bioluminescence-based in vivo imaging. The development 
of metastasis was also assessed using ex vivo whole body imaging after culling. Tumour implantations, 
monitoring of animals, NK cell infusions as well as most of Doxorubicin injections were undertaken by 
the Manager, Deputy Manager and technicians in the Biological Support Facilities (BSF) unit. 




2.4.3.3 Preparation, cytokine activation and VivoTrack680 labelling of NK cells 
Primary NK cells were isolated from PBMCs from healthy volunteers blood and were activated by 
culturing overnight with IL-2 (PeproTech, 100U/ml, 37°C, 5% v/v CO2) prior to adoptive transfer. In 
order to monitor NK cells migration to the tumour using in vivo imaging, primary NK cells and NK-92® 
MI cells were fluorescently labelled with the VivoTrack 680 NIR fluorescent imaging agent prior to 
adoptive transfer. For this, cells were first washed with sterile PBS and resuspended (up to 250 x 106 
cells/mL) in 2ml PBS. 2ml of VivoTrack680 cell labelling solution (0.2mg of dye in 1g of PEG) was added 
to the cells and mixed by gentle vortexing. Cells were then incubated for 15 min in the dark, at room 
temperature. 20ml PBS with 1% FCS was used to wash the cells 3 times. Cells were then resuspended 
in PBS alone for counting before resuspension in appropriate volumes for injection, 10x106 cells in 100ul 
PBS were injected for each animal.  
2.4.3.4 In vivo imaging  
Mice were imaged using the IVIS® imaging system. D-luciferin at a concentration of 30 mg/ml was 
injected i.p. at 150 mg/kg (typically 120 μl) 10min before the acquisition of the bioluminescent signal 
intensity (BLI).  General anaesthesia was induced with 5% isoflurane in a chamber and then continued 
with 2.5% isoflurane via nose anaesthetic cones during the acquisition. Luminescent images were 
acquired using the IVIS Living Image Software. For analysis, regions of interest (ROI) were drawn around 
the signal to quantify the emitted photons (Figure 2.6). Luminescence was expressed as Total flux 
(Photons/secs) in all respective experiments. Fluorescence images for VivoTrack were taken in the 
same imaging sessions as bioluminescent images.  
 




2.4.3.5 Tumour processing and preparation of single cell suspensions  
Tumours were collected from treated and untreated mice at the time of culling, cut into pieces using 
forceps and scalpels and were dissociated in digestion medium containing collagenase 4 (10u/µl) and 
DNase-I (50ug/ml) in a shaking incubator (37°C,180 rpm) for 45min. Digested tissues were minced 
through a 70 μm strainer, washed with PBS (400g, 10 min, 4°C) and resuspended in complete medium 
prior to counting and use for assays.  
2.4.3.6 Analysis of tumour samples  
The phenotype of isolated tumour cells including proliferation potential (KI67), NK cell ligand MICA/B 
expression, as well as their sensitivity to NK cell killing was determined using flow cytometry as 
described previously. Infiltration of tumours by NK cells was also determined using flow cytometry and 
in vivo fluorescence imaging. 
The proportion of cancer initiating cells (CIC) using CD44 and EPCAM, was determined using flow 
cytometry surface staining as described above. Data was acquired using Gallios flow cytometer 
(Beckman Coulter) and analysed using Kaluza 1.3 version (Beckman Coulter).The gating strategy for CIC 
population is presented in Figure 2.7. 
 
Figure 2.7.  Gating strategy for the identification of Cancer initiating cells population. 
2.4.4 Statistical analysis  
Except for gene expression data, for which statistical analysis was carried out using the Nanostring 
nsolver software. p-values were calculated using either Student’s t-test with two-tailed distribution or 
Two-way/one-way ANOVA as stated, using GraphPad Prism. Values of p < 0.05 were considered to be 
statistically significant.  
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 Chapter 3: Effect of treatment with low-dose doxorubicin on the phenotype   
of human breast cancer cells. 
 
3.1 Introduction  
Cancer cells are characterized by their immortality and their aberrant cell growth. This uncontrolled 
proliferation is due to dysfunctions in a range of checkpoint regulators that control progression through 
the different phases of the cell cycle (Zhou, Elledge 2000). Given that the majority of normal cells are 
in a resting state, traditional chemotherapies were developed with the aim of interfering with the cell 
cycle machinery to selectively prevent proliferation and eradicate rapidly dividing cancer cells.  
Doxorubicin, also known as Adriamycin is a natural anthracycline antibiotic produced by  
Streptomyces peucetius var. caesius (Arcamone et al. 1969). Since it was first extracted in the 1970 ’s  
it became routinely used in the treatment of several cancer types including ovarian, lung, multiple 
myeloma and it is one of the most commonly used chemotherapeutics for breast cancer (Tacar et al. 
2013a; Weiss 1992). Doxorubicin is a DNA-damaging agent as it acts by intercalating DNA along with 
inhibition of topoisomerase II and the formation of free radicals (Gewirtz 1999; Fornari et al. 1994). 
Doxorubicin treatment therefore leads to a range of cytotoxic and anti-proliferative effects (Buchholz 
et al. 2002). Although delivering therapeutic success in some cases, doxorubicin at the maximal 
tolerated dose (MTD) levels causes toxicity to various major organs, most importantly cardiotoxicity 
and bone marrow depression (Carvalho et al. 2009; Thorn et al. 2011). Much work has therefore been 
focused on devising strategies that eliminate these deleterious side-effects on healthy tissue while 
maintaining their effects on tumour cells.  
As discussed in the general introduction, an alternative approach to the delivery of chemotherapeutics 
at their MTDs is the use of metronomic chemotherapy which involves the administration of low doses 
of the drug. In vitro evidence indicates that some chemotherapeutic agents given at a low dose still 
elicit anti-proliferative effects on cancer cells and can induce a state of ”therapy-induced senescence” 
in which they remain viable, but do not proliferate (Collado, Serrano 2010).  
3.2 Experimental Aims 
 A key hypothesis of this study is that the induction of a senescence phenotype in breast cancer cells 
using low-dose chemotherapy (doxorubicin) changes the phenotype of these cells to render them more 
sensitive to the cytotoxic effects of NK cells. The aim of the experiments described in this chapter was 
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to develop and optimise a protocol for low-dose doxorubicin treatment of human breast cancer cell 
lines derived from different subtypes of the disease, namely (MCF7 (Luminal A, ER+), SKBR3 (Her2+), 
MDA-MB-468 and MDA-MB-231 (triple negative, TNBC)) and characterize the response of the different 
cell lines to the treatment. The influence of treatment on the induction of a senescence-like phenotype 
was studied using a panel of senescence and DNA damage response markers, alongside the analysis of 
cell cycle progression and proliferation.  
3.3 Results 
3.3.1 Optimisation of drug concentrations and treatment duration 
The aim of the initial set of experiments was to optimize the concentrations of doxorubicin and the 
duration of treatment required to generate a senescence phenotype based on SA-β-gal expression, one 
of the main markers of cellular senescence (Dimri et al. 1995; Lee et al. 2006). Although SA-β-gal is a 
lysosomal enzyme that catalyzes the hydrolysis of X-gal at an optimal pH 4 in young/immortal cells, it 
is activated at pH 6 in senescent cells. It is a commonly used biomarker of senescent cells in culture as 
well as in vivo (Dimri et al. 1995).  In order to assess SA-ß-Gal activity following doxorubicin treatment, 
cells were incubated with C12FDG, a substrate of SA-ß-Gal which becomes fluorescent when it is 
cleaved by the enzyme. As the initial aim was to induce the expression of SA-ß-Gal without affecting 
cell viability, doxorubicin concentrations and treatment duration were first optimized for the different 
cell lines, based on post-treatment cell viability. Cells were treated with a range of doxorubicin 
concentrations (15-500 nM) for 24h-72h or with 1 or 2µM for 2h. Following 24h of treatment, 
concentrations that retained cell viability > 90% were selected for the 48h and 72h treatment time 
points. As cell viability decreased following 72h with most of the doxorubicin concentrations assayed, 
the 48h treatment time period was selected. After which, SA-β-gal expression was assessed at different 
time points post-treatment (24h, 48h, 72h, 120h (5d) and 168 (7d)), Results showed that SA-ß-Gal 
activity remained low directly following treatment, but increased rapidly following several days, with 
the highest SA-β-gal positivity being observed at 7 days (168h) post-treatment, in line with previous 
protocols for senescence induction (Noren Hooten, Evans 2017) This time point was used for all 
subsequent experiments. Optimal doxorubicin concentrations and treatment duration, based on 
retention of cell viability and high SA-β-gal expression, were found to be 50 nM and 25 nM for 48 h for 




Figure 3.1. Doxorubicin treatment optimization. A. Cells were treated using different concentrations of doxorubicin and their viability was assessed using 
Trypan blue staining. Following 24h of treatment, concentrations resulting in more than 90% cell viability were selected for 48h and 72h treatment time 
points, since the cell viability was decreasing following 72h of doxorubicin treatment, the 48h treatment time point has been selected. B. SA-β-gal expression 
was assessed at different time points post-treatment (24h, 48h, 72h, 120h (5d) and 168 (7d)) using the galactosidase substrate C12FDG. Data are presented 
as mean +SD, from two independent experiments.  
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3.3.2 Influence of low-dose doxorubicin treatment on cell morphology and SA-β-gal expression 
Treatment with low doses of doxorubicin induced a large and flattened morphology (Figure 3.2), a 
feature which is known to be typical of a senescent phenotype (Cristofalo, Pignolo 1993). Treatment 
also increased the activity of senescence-associated β-galactosidase (SA-β-Gal) in these cells, the level 
of which varied between the different cell lines. The highest differential expression of SA-β-Gal was 



















Figure 3.2. Morphological changes of Doxorubicin-treated cells. Breast cancer cells were treated with low-
doses of doxorubicin: 25 nM and 50 nM for 48h for SKBR3 and MCF7, respectively and 1 μM for 2h for MDA-MB-
468 and MDA-MB-231 cells. Photomicrographs of untreated (left panel) and doxorubicin-treated (right panel) 
cells were taken on day 7 post-treatment. Images are representative of at least three independent experiments 




















Figure 3.3. Influence of doxorubicin treatment on the expression of SA-β-gal. Untreated and treated cells 
were assessed for their expression of SA-β-gal by flow cytometry using the galactosidase substrate C12FDG. 
Data are presented as means+SD. of three independent experiments. Statistical analysis and significance 
determined by a two-way Anova (* P ≤ 0.0332, ** P ≤ 0.0021, *** P ≤ 0.0002).  
3.3.3 Influence of low-dose doxorubicin treatment on the expression of senescence-related and 
DNA damage response markers 
3.3.3.1 p53, p21 and p16 expression 
As the tumour suppressor pathways p53/p21 and/or p16INK4a/pRB are known to be involved in 
senescence (Chang et al. 1999), the influence of low-dose doxorubicin treatment on the intensity of 
p53 and CDK-inhibitors p21 and p16 expression was determined by flow cytometry (Figure 3.4). A 
significant increase in the expression of p16 was only observed for the MDA cell lines, and an increase 
in p21 expression for MDA-MB-231 cells. A slight increase in the expression of p53 on MDA-MB-468 
and MDA-MB-231 was also observed.  
 
 
Figure 3.4. Influence of doxorubicin treatment on the expression of common senescence markers. 
The intensity of p53, p16 and p21 expression by untreated and treated cells (7 days after treatment) 
was determined using intracellular flow cytometry staining. The Median Fluorescence Intensity (MFI) 
value was used to compare levels of expression. Data are presented as means+SD. of three 
independent experiments. Statistical analysis and significance determined a Two-way Anova (*** P ≤ 
0.001). 
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3.3.3.2 Influence of low-dose doxorubicin treatment on Notch-3 and γ-H2AX expression  
Notch-3 is a member of Notch family transmembrane receptors which has been shown to have tumour 
suppressor functions and to be a mediator of the senescence response, in that elevated levels of Notch-
3 expression in cells during senescence have been reported (Cui et al. 2013). Low dose-doxorubicin 
treatment had no effect on the proportion of cells expressing Notch-3, apart from MDA-MB-231 cells 
in which it was upregulated following treatment (Figure 3.5).  
H2AX is a histone variant of the H2A protein family and the generation of double-stranded breaks 
(DSBs) as a result of DNA-damaging agents is followed by the phosphorylation of H2AX at Ser139 and 
the generation of γ-H2AX (Redon et al. 2002). We have detected levels of γ-H2AX by flow cytometry 
and found that low-dose doxorubicin treatment significantly increases in the proportion of MDA-MB-
468 and MDA-MB-231 cells expressing γ-H2AX (Figure 3.5).   
 
 
Figure 3.5. Influence of doxorubicin treatment on NOTCH-3 and γ-H2AX expression. Cells were analyzed 
for the expression of NOTCH-3 and γ-H2AX by flow cytometry. Data are presented as mean+S.D from three 
independent experiments. A two-way ANOVA was performed for statistical comparison (** P ≤ 0.01, *** P 
≤ 0.001).  
 
3.3.4 Influence of low-dose doxorubicin treatment on breast cancer cell proliferation 
The influence of low-dose doxorubicin treatment on progression of cells through the cell cycle was 
determined by profiling the DNA content of permeabilized cells stained with the DNA binding dye 
propidium iodide using flow cytometry. Analysing the fluorescent intensity profiles enables different 
phases of the cell cycle to be profiled. Low-dose doxorubicin treatment led to the accumulation of cells 














Figure 3.6. Influence of doxorubicin treatment on cell cycle progression. Untreated (Ctrl) and doxorubicin-
treated (+Dox) were fixed, stained with propidium iodide (PI) and the proportion (%) of cells in each phase 
of the cell cycle determined by flow cytometry. Data are presented as means+SD from two to three 
independent experiments. Statistical comparison between the proportions of untreated and treated cells in 
G2 was performed using a two-way ANOVA (* P ≤ 0.0332, **** P ≤ 0.0001).  
 
Ki-67 is a cell proliferation antigen, that is highly expressed in proliferating mammalian cells and is 
downregulated in resting cells, as a consequence of which it is widely used in grading tumours (Dowsett 
et al. 2011). As shown in Figure 3.7, low dose-doxorubicin treatment reduced the proportion of Ki-67+ 









Figure 3.7. Influence of doxorubicin treatment on Ki67 expression. The proliferation of cells was assessed 
by determining the percentage of Ki67+ cells by flow cytometry. Data are presented as means+SD from three 
independent experiments. A two-way ANOVA was performed for statistical comparison (** P ≤ 0.01).  
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3.3.5 Low-dose doxorubicin treatment does not lead to development of resistance to higher 
doses of doxorubicin  
In order to test if the sub-lethal doses of doxorubicin selected would generate resistance to subsequent 
treatments with toxic doses of doxorubicin (an important factor for clinical deployment of this 
approach), MDA-MB-231 cells were treated with the low-doses of doxorubicin, as per the described 
protocol, 7 days after which they were treated with concentrations of Doxorubicin that were shown to 
induce cell death in the preliminary titration experiments (500nM) – these concentrations would be 
equivalent to the maximum tolerated doses in vivo. As shown in Figure 3.8, cells that were pre-treated 
with low doses of doxorubicin remained sensitive to subsequent treatment with high dose doxorubicin. 
 





















Figure 3.8. Low-dose doxorubicin treatment does not lead to the development of resistance to higher 
doses of doxorubicin in vitro. The viability of MDA-MB-231 cells pre-treated low-dose doxorubicin to 
subsequent treatment with a toxic, high dose (MTD) doxorubicin (500nM) was compared to untreated, low-
dose and MTD treated cells. Data are presented as means+SD from 2 independent experiments. A One-way 
ANOVA was performed for statistical comparison (ns, not significant, **** P ≤ 0.0001).  
 
 Summary 
In this Chapter, we describe a protocol that was developed for low-dose doxorubicin treatment of 
breast cancer cell lines and characterized its effect on the phenotype of the cells. Low-doses of 
doxorubicin were previously shown to induce a state of ”therapy-induced senescence” in which cells 
stop proliferating (Collado, Serrano 2010). This led us to optimize low-dose doxorubicin treatment on 
the basis of SA-β-gal expression, as it represents the most commonly used marker for the identification 
of senescent cells. Optimal drug concentrations and treatment durations were established based on 
achieving the greatest proportion of SA-β-gal positive cells while maintaining high levels of cell viability. 




The first observed effect of the treatment was the increased cell size with a flattened morphology. Cells 
were also found to accumulate in G2 phase of the cell cycle following treatment, which correlated with 
the decrease in the expression of the proliferation marker Ki67. A significant increase in the expression 
of the cell cycle inhibitors p16 was observed in treated MDA-MB-468, MDA-MB-231 cells and p21 in 
treated MDA-MB-231. Similarly, Notch-3 levels were only elevated in treated MDA-MB-231 cells. 
Studies have previously shown that Notch-3 upregulation is required for p21 expression (Cui et al. 
2013), and this is reflected in these data, where we found elevated levels of p21 only in MDA-MB-231 
cells in which Notch-3 was also up-regulated. Another marker of a DNA-damage response and cellular 
senescence is the DNA double-strand break γ-H2AX foci, which we found to be significantly up-
regulated in both MDA-MB-468 and MDA-MB-231 cell lines following treatment. Overall, these findings 
suggest that cells acquire a senescent-like phenotype following treatment with low-dose doxorubicin 













 Chapter 4: Influence of low-dose doxorubicin treatment on the sensitivity of 
breast cancer cells to NK cell-mediated cytotoxicity  
4.1  Introduction  
Natural killer (NK) cell activation and cytotoxicity are primarily regulated by the integration and balance 
of signals from inhibitory and activating NK cell surface receptors that are triggered following 
interactions with their respective ligands that are expressed on stressed/tumour cells. The combination 
of ligands on the surface of tumour cells and the degree of intensity of their expression direct NK cell 
cytotoxic responses and determine the susceptibility of target cells to NK cell killing (Bryceson et al. 
2009).  The HLA Class I human leukemic cell line K562 is the most commonly used NK cell-sensitive cell 
line which provides the combination of ligands which allow for engagement of NK cell activating 
receptors.  This engagement results in the triggering of downstream signaling pathways that leads to 
the secretion of lytic granules and a selection of cytokines such as IFN-γ which not only act as a co-
stimulatory signal for other immune cells, but also enhance NK cytotoxicity by upregulating specific 
receptors on tumour cells (Cooper et al. 2009). 
The potentially weakened killing ability of NK cells to kill cancer is partly due  to the capacity of tumour 
cells to escape NK cell recognition by altering  the balance between NK cell activating and inhibitory 
receptors and proteolytic shedding of ligands; mainly MICA and MICB proteins which are recognized by 
the NK cell activating receptor NKG2D (Salih et al. 2002; Raulet et al. 2013). 
Extensive studies have explored different strategies to improve NK cell function and the capacity of NK 
cells to control tumour growth in an immunotherapeutic setting by manipulating the expression of 
these ligands (Morisaki et al. 2012b; Lupo, Matosevic 2019; Hu et al. 2019b). One potential approach 
to enhance the effect of immunotherapies would be to harness the ability of chemotheraputic agents 
to activate responses to cellular stress and render cells more sensitive to NK cell-mediated cytotoxicity. 
Indeed, responses to cellular stress, such as activation of the DNA damage response and the senescence 
programme have been shown to upregulate ligands for activating receptors in tumour cells and 
consequently increase their elimination by NK cells (Soriani et al. 2014a; Sagiv et al. 2016).   
 
Studies reported in Chapter 3 demonstrated that low-dose doxorubicin treatment generates a 
senescence-like phenotype, induces a DNA-damage response in breast cancer cells and markedly 
decreases their proliferation. In this Chapter, the effect of low-dose doxorubicin on the expression of 
NK cell ligands by breast cancer cells and the sensitivity of treated breast cancer cells to NK cell killing 
is described.     
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4.2 Experimental Aims 
The aim of the experiments described in this Chapter was to determine the effect of low-dose 
doxorubicin treatment on the expression of NK cell ligands by breast cancer cells and the sensitivity of 
treated cells to killing by NK cells derived from healthy donors and the NK-92™ MI cell line. Preliminary 
experiments compared the cytotoxic potential of resting NK cells and NK cells stimulated with IL-2, IL-
15 or IL-2 and IL-15. In addition to cytotoxicity, effector cell function was determined based on 
expression of the degranulation marker CD107a, perforin, granzyme B and IFN-gamma. 
4.3 Results 
4.3.1 Influence of low-dose doxorubicin treatment on the expression of NK cell ligands by breast 
cancer cells  
As part of our investigations into the susceptibility of treated cells towards NK cell mediated lysis we 
first looked at the effect of low-dose doxorubicin on the expression of a panel of the most important 
NK cell ligands that bind and trigger NK cell receptors NKG2D, 2B4, DNAM-1, KLRG1, KIRs (see Table 
4.1). For these experiments, cells were treated with low dose doxorubicin as described previously, after 
which the expression of NK ligands was determined by flow cytometry and compared to that by 
untreated cells. 
The expression of ligands for NKG2D and DNAM-1 activating receptors (MICA/B, CD155) were of 
particular interest, as they play a crucial role in enhancing NK cell-mediated recognition of cancer cells  
(Fionda et al. 2015a; Morisaki et al. 2012a).  Across the four cell lines, treated cells expressed higher 
levels of ligands for activatory NK cell receptors compared to their untreated counterparts in terms of 
percentage of positive cells (Figure 4.1). The most upregulated ligands being MICA/B, ULBP1-3 and 
CD155. The expression of CD112 was significantly higher in treated MCF-7 cells, but not in others. A 
modest upregulation in CD48 expression was only observed on treated MDA-MB-231 and MDA-MB-
468 cells. In terms of intensity of expression (MFI) on the positive cell population, a significant increase 
was only observed for CD112 in MCF-7 and MDA-MB-468 cells, MICA/B for MDA-MB-468 and MDA-
MB-231 and CD155 for MDA-MB-231 cells, presented in Figure 4.2 is the Influence of doxorubicin 
treatment on the MFI of NK cell ligand expression, only the ligands that showed significant or close to 
significant differences are shown. Treatment induced a more ‘activatory’ phenotype on the MDA-MB-
231 and MDA-MB-468 cells, in that ligands for the NKG2D receptor and the CD155 ligand for DNAM-1 





Figure 4.1. Influence of doxorubicin treatment on the expression of NK cell ligands. Cell were treated with previously described concentrations of doxorubicin 
and were then tested for cell surface expression of the ligands by flow cytometry. Data (percentage of positive cells) are presented as mean+SD. from three 
independent experiments. Statistical comparison was performed using a two-way ANOVA (** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001). 
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Figure 4.2.  Influence of doxorubicin treatment on the intensity of NK cell ligand expression. Cell were treated 
with previously described concentrations of doxorubicin and the cell surface expression of ligands determined by 
flow cytometry. Data are presented as mean ( ±S.D) median fluorescence intensity of cells expressing ligands from 
three independent experiments. Statistical comparison was performed using a two-way ANOVA (*P ≤ 0.1, ** P ≤ 
0.01). 
4.3.2 Influence of low-dose doxorubicin treatment on the sensitivity of breast cancer cells to NK 
cell-mediated cytotoxicity  
Having demonstrated that low-dose doxorubicin treatment induces an activatory phenotype, we 
determined if this observed effect induces sensitivity to NK cell cytotoxicity. For this, NK cell cytotoxicity 
was determined by flow cytometry using two sources of NK cells; primary NK cells isolated from healthy 
donors and the NK-92™ cell line (parental and NK-92™ MI cells). The NK cell-sensitive, human 
erythroleukemic cell line K562 was used as positive target cell control for NK cell activation and lysis, 
as it lacks expression of HLA class I (an inhibitory ligand for NK cells) and provides the necessary ligands 
for NK cell engagement and lysis. 
4.3.2.1 Influence of low-dose doxorubicin on the sensitivity of breast cancer cells to killing by 
primary NK cells 
Although allogeneic NK cells have been used in several pre-clinical and clinical studies and their safety 
and efficacy has been demonstrated against different hematological malignancies and solid tumours, 
we initially examined the effect of low-dose doxorubicin treatment on the sensitivity of breast cancer 
cells to killing by freshly-isolated, resting donor-derived NK cells. For this, NK cells were isolated from 
PBMCs prepared from the blood of healthy volunteers using immunomagnetic (negative) selection and 
their purity (>90% CD3-/CD56+) confirmed by flow cytometry, immediately after which their capacity to 
kill treated and untreated cells was determined in a 3-hour cytotoxicity assay.  As shown in Figure 4.2, 
treatment of cells with low-dose doxorubicin increased the sensitivity of MCF7, MDA-MB-468 and 
MDA-MB-231 cells to killing by freshly isolated, resting NK cells. In contrast, low-dose doxorubicin 
treatment had no effect on the sensitivity of SKBR3 cells to killing by freshly isolated, resting NK cells. 
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Figure 4.3 Influence of doxorubicin treatment on the sensitivity of breast cancer cells to killing by freshly 
isolated, resting NK cells. NK cell cytotoxic activity towards doxorubicin-treated (Red) and untreated cells (blue) 
was evaluated at 3 different effector to target (E:T) ratios, 1:1 5:1 10:1, using a flow cytometry-based killing assay. 
Data are presented as mean+SD from 3 independent experiments. A two-way ANOVA was used for statistical 
comparisons (**** P ≤ 0.0001). 
 
In vitro stimulation of primary NK cells (IL-2+IL-15 stimulation)  
The phenotype and function of NK cells are also influenced by the presence of cytokines in the 
microenvironment and one of the approaches/possibilities to improve NK cell cytotoxicity is via 
cytokine stimulation. Preliminary experiments therefore determined the effect of stimulating NK cells 
with IL-2, IL-15 of IL-2 and IL-15 on their capacity to kill target cells. IL-2 and IL-15 both stimulate NK 
proliferation and activation are commonly used to activate NK cells,  with IL-15 also promoting NK cell 
development and survival (Zwirner, Domaica 2010b). For this experiment, NK cells were pre-activated 
by incubating with IL-2 (100 U/ml), IL-15 (10 ng/ml) or a combination of the two cytokines for 24 h prior 
to incubation with target cells. As shown in Figure 4.4, although IL-2 and IL-15 stimulation both 
enhanced NK cell cytotoxicity, the effect was greater following IL-2 stimulation. Stimulation with both 
IL-2 and IL-15 had no greater effect than IL-2 alone. However, it should be noted that these data are 
preliminary and were derived from a single experiment. Given that IL-2 is already approved for clinical 
use, we focused on examining the influence of low-dose chemotherapy on the sensitivity of breast 
cancer cells to IL-2 activated NK cells. 




























Figure 4.4 Influence of doxorubicin treatment on the sensitivity of breast cancer cells to cytotoxicity by 
cytokine-activated NK cells. NK cells were pre-activated using either IL-2 (100 U/ml), IL-15 (10 ng/ml) or a 
combination of both for 24h before being used in a cytotoxicity assay against untreated and doxorubicin-treated 
breast cancer cells (E:T=5:1). Data are derived from a single experiment. 
 
Since IL-2 pre-activation enhanced the cytotoxic potential of NK cells, we optimized the concentration 
of IL-2 and the exposure time. For this, the influence of two concentrations of IL-2 (100 U/ml and 200 
U/ml) and stimulation periods (24h, 48h) on the capacity of NK cells to kill MCF7 and MDA-MB-468 cells 
were compared. IL-2 stimulation greatly enhanced the ability of NK cells to kill doxorubicin-treated 
cells. However, no significant differences were observed when comparing the effects of the two 
concentrations and time points (Figure 4.5). 
We also compared NK cytotoxicity against breast cancer cells following IL-2 stimulation at a range of 
effector to target ratios (1:1, 5:1, 10:1) using untreated MDA-MB-231 cells and MDA-MB-231 cells 
treated with low-dose doxorubicin (Figure 4.6). As with the previous studies, IL-2 stimulation increased 
the cytotoxicity of NK cells toward treated cells. Notably, at a 5:1 E:T ratio, IL-2 stimulated NK cells 
displayed a better killing efficiency than resting NK cells at an E:T ratio of 10:1. Overall, as summarized 
in Figure 4.7, IL-2 stimulation greatly enhanced NK cell killing of breast cancer cells treated with low-
dose doxorubicin. 
 
Figure 4.5  Influence of doxorubicin treatment on the sensitivity of breast cancer cells to killing by cytokine-
activated NK cells: Optimisation of IL-2 stimulation protocol (E:T=5:1). NK cells were stimulated with IL-2 (100 
U/ml, 200 U/ml) for 24h or 48h before being co-incubated with their target cells (untreated and doxorubicin-
treated MCF7, MDA-MB-468 cells, and K562 cells as positive control) (E:T= 5:1). Statistical significance is 
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represented for comparisons between IL-2 concentrations and resting NK cells. Data are means+SD from 3 
independent experiments. A two-way ANOVA was used for statistical comparisons (* P ≤ 0.05, ** P ≤ 0.01, *** P 
≤ 0.001, **** P ≤ 0.0001). 
 
Figure 4.6 Influence of doxorubicin treatment on the sensitivity of MDA-MB-231 cells to killing by cytokine 
activated NK cells: (E:T = 1:1, 5:1, 10:1). The cytotoxicity of resting and IL-2 stimulated NK cells (200 U/ml for 48h) 
against MDA-MB-231 cells was assessed at E:T ratios 1:1, 5:1, 10:1. Data are presented as mean+SD from 3 
independent experiments. A two-way ANOVA was used for statistical comparisons (* P ≤ 0.05, ** P ≤ 0.01, *** P 




Figure 4.7 Sensitivity of breast cancer cells to killing by resting versus IL-2 stimulated donor-derived NK cells. 
Summary of the cytotoxicity of resting and IL-2 activated NK cells against untreated and low-dose doxorubicin 
treated cells. Data are presented as mean+SD from 3 independent experiments. A two-way ANOVA was used for 
statistical comparisons (* P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001,**** P ≤ 0.0001). 
 
4.3.2.2 Influence of low-dose doxorubicin on the sensitivity of breast cancer cells to killing by 
the NK-92™ cell line  
The established human cytotoxic NK-92™ NK cell line is emerging as a potential alternative to primary 
NK cells in immunotherapeutic strategies and is being further developed for clinical trials (Klingemann 
et al. 2016; Tonn et al. 2013c). We therefore determined the influence of low-dose chemotherapy 
treatment on the sensitivity of breast cancer cells to killing by NK-92™ cells (either the parental cell line 
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or the NK-92™ MI cell line, as indicated) using the same approaches described above for primary, 
donor-derived NK cells. 
 
Cytotoxicity 
As indicated in Figure 4.8, low-dose chemotherapy treatment increased the sensitivity of cells to killing 
by NK-92™ cells (mean increase ~22% across the three cell lines MCF-7, MDA-MB-468 and MDA-MB-
231). These findings are in broad concordance with the data obtained using primary, donor-derived NK 
cells. Low-dose doxorubicin had no effect on the sensitivity on the HER-2 positive SKBR3 cells to NK-
92™ cells  (mean difference of 5.5%). 
We also determined whether the treatment of cells isolated from MDA-MB-231/Luc tumours harvested 
from immunodeficient NSG mice with low-dose doxorubicin also increased their sensitivity to killing by 
the NK-92™ MI cell line. For this, tumours generated by implanting MDA-MB-231/LUC cells into NSG 
mice were harvested 4 weeks following tumour implantation, dissociated into single cell suspension 
and the cells derived from each animal were either left untreated or were treated with low-dose 
doxorubicin and then used as targets in a cytotoxicity assay. As shown in Figure 4.9, treatment 
enhanced the sensitivity of cells to killing by NK-92™ MI cells. 
 
 
Figure 4.8 Influence of doxorubicin treatment on the sensitivity of breast cancer cells to killing by NK-92™ MI 
cells. The sensitivity of untreated and doxorubicin-treated cells to NK-92™ MI cell-mediated cytotoxicity was 
determined at an E:T ratio of 5:1. Data are presented as mean+SD from three independent experiments. A two-





Figure 4.9 Influence of doxorubicin treatment on the sensitivity of MDA-MB-231/LUC breast cancer cells 
isolated from MDA-MB-231/LUC cell-derived tumours in NSG mice to killing by NK-92™ MI cells. The sensitivity 
of untreated (blue) and doxorubicin-treated (red) MDA-MB-231/luc cells derived from MDA-MB-231/luc 
xenografts to NK-92™ MI cell-mediated cytotoxicity was determined at an E:T ratio of 5:1 and 10:1. Data are 
presented as mean±S.D, n=12. One-way ANOVA (**** P ≤ 0.0001). 
 
 
Degranulation and cytokine function  
NK cells control and kill target cells by secreting granzyme-containing granules and a range of pro-
inflammatory cytokines. We therefore compared the expression of the degranulation marker CD107a, 
granzyme B, perforin and IFN-γ in NK-92™ MI cells following exposure to untreated MDA-MB-231 cells, 
MDA-MB-231 cells treated with low-dose doxorubicin and K562 cells (as control). As indicated in Figure 
4.10, exposure of NK-92™ MI cells to MDA-MB-231 cells treated with low-dose doxorubicin triggers 
higher levels of IFN-γ, perforin, granzyme B and CD107a (indicative of degranulation) expression than 
that triggered by untreated cells. Of note, exposure to low-dose doxorubicin treated cells triggered 




Figure 4.10 Effect of exposing NK-92™ MI cells to untreated MDA-MB-231 cells, MDA-MB-231 cells treated with 
low-dose doxorubicin and K562 cells on degranulation and cytokine expression. NK-92™ MI cells were co-
incubated with untreated/treated MDA-MB-231 cells or K562 cells (as a positive control) at an E:T ratio of 1:2 for 
5 hours, after which the expression of IFN-γ, perforin, granzyme B and CD107a (indicative of degranulation) was 
determined by intracellular flow cytometry (mean+SE,* P≤ 0.03, ** P ≤ 0.002, *** P ≤ 0.0002). 
 
4.3.3  Low-dose doxorubicin treatment does not affect the viability or phenotype of NK-92™ MI 
cells 
One potential concern related to the administration of low-dose doxorubicin followed by NK cell 
transfer in the clinical setting would be the effect that doxorubicin could have on the viability and 
function of NK cells. To assess this, NK-92® MI cells were treated with the same doses of doxorubicin 
as those used for treating the TNBC cells (1uM) and its effect on viability determined using trypan blue 
dye exclusion and on the expression of the NK cell activation receptors NKG2D and NKp30 using flow 
cytometry. As shown in Figure 4.10, treatment had no effect on the viability of NK-92® MI cells, nor did 
it have any effect on their expression of NKG2D and NKp30.  
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Figure 4.11 Low-dose doxorubicin treatment has no impact on the viability of NK92™ MI cells or on their 
expression of the activation receptors NKG2D and NKp30. NK-92™ MI cells were treated with 1uM doxorubicin 
for 24h, after which their viability was determined using trypan blue exclusion and their expression of NKG2D and 
NKp30 receptors using flow cytometry. Data are representative of 3 experiments. 
 
4.3.4 Sensitivity of SA-β-gal positive cells 
In order to determine if the sensitivity of doxorubicin-treated cells aligns with SA-β-gal positivity, and 
to assess its potential use as a marker for NK cell sensitivity, we determined the killing of SA-β-gal 
positive and negative populations by donor-derived NK cells and the NK-92™ MI cell line. For these 
experiments, cells treated with low-dose doxorubicin were stained for SA-β-gal prior to exposure to NK 
cells and the percentages of killed SA-β-gal positive and negative cells determined at the end of the 
standard cytotoxicity assay. Both primary NK cells and NK-92™ MI cells preferentially killed SA-β-gal+ 
MCF7 cells and MDA-MB-468 cells, whereas there was no preferential killing of SA-β-gal+ SKBR3 and 
MDA-MB-231 cells (Figure 4.11). 
Figure 4.12 Sensitivity of SA-β-gal positive cells to NK cell-mediated cytotoxicity. Breast cancer cells 
treated with low-dose doxorubicin were stained for the expression of SA-β-gal using C12FDG prior to 
their inclusion as targets for primary, donor-derived NK cells or NK92™ MI cells in a flow cytometry-
based cytotoxicity assay. The percentages of dead cells in the SA-β-gal positive and negative 
populations was determined by flow cytometry. Data are presented as mean+SD from 3 independent 
experiments. A two-way ANOVA was used for statistical comparisons (* P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 




4.4 Summary  
The aim of these experiments was to determine the effect of low-dose doxorubicin treatment on the 
sensitization of breast tumour cells to killing by primary, donor-derived NK cells and the NK-92™ MI cell 
line. We first observed that low-dose doxorubicin treatment increased the expression of ligands for 
major NK cell activatory receptors (NKG2D, DNAM-1). It was expected that this upregulation would act 
as a “kill me” signal to NK cells and thereby increase their sensitivity to NK cell-mediated killing. We 
therefore compared the killing of untreated and treated breast cancer cells by primary, donor-derived 
NK cells and confirmed that treated cells were indeed more sensitive to NK cytotoxicity, but with the 
exception of SKBR3 cells. We also demonstrated that IL-2 stimulation greatly enhanced NK cell-
mediated cytotoxicity of treated cells. Low-dose doxorubicin treatment also rendered cells more 
sensitive to killing by the NK92™ MI cell line. 
Further experiments focused mainly on MDA-MB-231 cells, as it represented one of the most 
responsive cell lines to NK cell killing following low-dose doxorubicin treatment. This cell line was also 
selected for tumour model studies (presented is chapter 6) as MDA-MB-231 cell-derived breast cancer 
xenograft models  are one of the most commonly used and easily generated models for studying TNBC 
(Iorns et al. 2012) . MDA-MB-231 cells were shown to be highly aggressive and prone to metastasis 
(Simmons et al. 2015; Minn et al. 2005).  We have also shown that treatment of cells derived from 
MDA-MB-231 xenografts harvested from NSG mice with low-dose doxorubicin increased their 
sensitivity to killing by NK92™ MI cells, and observed that the exposure of NK92™ MI cells to MDA-MB-
231/LUC treated with low-dose doxorubicin increased their expression of CD107a (a degranulation 
marker), granzyme B, perforin and IFN-gamma, as determined with flow cytometry. 
Furthermore, we addressed one potential concern regarding the effects that doxorubicin might have 
on NK cells, in terms of viability and activation receptor expression by demonstrating that exposure of 
NK92™ MI cells to doxorubicin had no effect on their viability or expression of NKG2D and NKp30 
receptors. 
In an attempt to identify markers of response and sensitivity to NK cells, we asked if the SA-β-gal 
positive cells induced by low-dose doxorubicin were more sensitive to NK killing. Although this was the 
case for MCF-7 and MDA-MB-468 cells, it was not for SKBR3 and MDA-MB-231 cells, for reasons that 
are currently unclear. 
Taken together, these findings support the proposition that low-dose doxorubicin treatment 




Chapter 5: Gene expression profiling of low-dose doxorubicin treated breast 
cancer cells using the NanoString nCounter™ platform. 
 
5.1 Introduction  
Tumour development and progression is commonly accompanied and/or dictated by epigenetic 
changes (DNA alterations and histone modifications) which affect gene expression in tumour cells and 
cause perturbations in their associated signalling cascade and pathways (Vogelstein and Kinzler, 2004). 
Pathway deregulation may contribute to the initiation and progression of cancer by silencing tumour 
suppressor genes and activating oncogenic genes (Edelman et al., 2008; Vogelstein et al., 2013). Thus, 
identifying pathways that are deregulated in tumours and/or deregulated in response to treatment is 
crucial for advancing the understanding of tumour biology and progression, and may lead to the 
identification of potential treatment targets and/or insights into mechanisms of therapeutic resistance 
(Edelman et al., 2008; Yauch and Settleman, 2012).  
Many studies have demonstrated that several signalling pathways play important roles in the 
development, progression and metastasis of breast cancer. These include estrogen receptor signalling,  
EGFR (epidermal growth factor receptor) signalling, PI3K/AKT/mTOR, MAPK (mitogen-activated protein 
kinases), nuclear factor-κB (NF-κB), Notch and canonical Wnt pathways (Foley et al., 2010; Haagenson 
and Wu, 2010; Prosperi and Goss, 2010; Rosen, Ashurst and Chap, 2010; Guo, Liu and Gonzalez-Perez, 
2011; Vitale Gobbi et al., 2015; Papa and Pandolfi, 2019; Saha et al., 2019).   
Considering the effect of low-dose doxorubicin on the phenotype of breast cancer cells and their 
susceptibility to NK cell killing, as described in previous chapters, it would be expected that treatment 
has an impact on the breast cancer cell transcriptome (gene expression) and that the interrogation of 
this will provide insight into the mechanism of action and reveal predictive markers of susceptibility to 
NK cell cytotoxicity and thereby as actionable targets for therapy.   
High-throughput gene expression analysis can identify gene transcription which is markedly changed 
from a normal state and can generate insights into the mechanisms and pathways underlying these 
changes. The Nanostring nCounter™ amplification-free gene expression profiling platform (NanoString 
Technologies Inc., Seattle, USA) enables the direct quantification of target RNA transcripts using unique 
digital colour-coded barcodes that hybridize to specific targets and can be detected using single-
molecule imaging. This technology gives direct multiplex measurement of mRNA expression levels 
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without the need for amplification and been shown to be highly precise, sensitive and reproducible 
(Geiss et al., 2008). 
5.2 Experimental Aims 
 The aim of the experiments described in this chapter was to investigate the effect of low-dose 
doxorubicin treatment on the gene expression patterns in breast cancer cells and thereby determine 
its influence on relevant cancer-related pathways using the NanoString PanCancer pathways panel. This 
panel encompasses 770 genes representing major cancer pathways. The overall gene expression 
signatures for the different pathways were compared and further analysed in enrichment studies. The 
most significantly differentiated genes, as well as their respective pathways, were defined. 
5.3 Results 
In order to gain a better understanding of the biology and the effect of low-dose doxorubicin treatment 
on breast cancer cells, we have performed a NanoString nSolver™ gene expression analysis using the 
PanCancer Pathways gene code set (Geiss et al., 2008). This panel simultaneously analyses 770 genes 
representing the activity of 13 key cancer pathways (606 critical genes from 13 canonical cancer 
pathways, 124 cancer driver genes, and 40 reference genes). The pathways covered by this panel are 
provided in Table 5.1, with the number of genes included in the panel in relation to the total number 
of known genes identified by KEGG (Kyoto Encyclopedia of Genes and Genomes) for each pathway. It 
should be noted that some genes belong to multiple pathways. 
Three cell lines were selected for the study, the two triple negative cell lines, MDA-MB-231 and MDA-
MB-468 as well as the Luminal A cell line MCF7, in order to compare the transcriptional impact of 
treatment on cells derived from different subtypes of breast cancer. 
As described previously, one common feature of low-dose doxorubicin treated cells was an increase in 
cell size. Thus, in addition to comparing the gene expression profiles of untreated and doxorubicin-
treated cells, treated cell populations were sorted into ‘low’ and ‘high’ forward light scatter (FSlow, FShigh) 
populations using a Beckman Coulter MoFlo™ cell sorter (Figure 5.1). Three replicate samples for each 








Table 5.1. Pathways of the PanCancer Pathways Panel 
Pathway #genes Pathway #genes 
Chromatin modification 22/46 RAS 142/226 
Hedgehog 28/51 Pi3K 201/345 
Wnt 78/139 STAT 86/156 
Notch 24/48 MAPK 157/258 
Apoptosis 66/86 TGF-β 51/80 
Cell cycle 73/124 DNA Damage Control 50/106 






Figure 5.1. Representative Scatter Plot illustrating the regions used to define and sort FSlow and FShigh 
populations in MDA-MB-231 cells. The same sorting strategy was used for MDA-MB-468 and MCF-7 cells. 
Left: Untreated cells used to set the gates according to the baseline. Right: Treated cells with doxorubicin (1 









5.3.1 Influence of low-dose doxorubicin treatment on pathways gene signatures and scores 
First, we compared the overall gene expression signatures for control, treated and FS high and FSlow 
categories. As shown in Figure 5.2, low-dose doxorubicin treatment resulted in a differential gene 
expression for the three cell lines tested in most pathways. However, cells in the FShigh gate did not 
exhibit the most differentially expressed gene profile in terms of pathway signatures in every case. For 
MDA-MB-468 cells, for example, FSlow cells appear to have a more distinct gene expression profile than 
FShigh populations, as most pathways appears to be upregulated, when compared to baseline untreated 
cells. Cell size might therefore not be the best indicator of a response to the treatment. For this reason, 
further analysis only compared the transcriptome covered by the PanCancer Pathways gene code set 
of the entire low-dose doxorubicin treated cells with that of their untreated counterparts at baseline. 














Figure 5.2. Comparison of overall gene expression signatures. Trend Plots of pathways signatures of the 3 









Figure 5.3. Comparison of overall gene expression signatures between untreated and treated samples. 
Trend Plots of pathways signatures of the 3 cell lines tested provide an overview of the influence of 






 In order to gain an initial insight into the impact of low-dose doxorubicin at the pathway, rather than 
individual gene level, pathway score analysis was performed first. This approach condenses the data 
from the different genes in a pathway into a single score, allowing changes of pathway scores across 
experimental samples to be visualized. Presented in Figure 5.4-A is a heatmap of pathway scores 
for MDA-MB-231 cells presenting the pathways that were most influenced by low-dose doxorubicin 
treatment. This can be divided into two sets, a set of pathways that had a lower score in treated cells 
(TGF-beta, Wnt, Chromatin modification and Hedghog pathways and driver genes) and a set that has a 
higher score in treated cells (DNA-Damage-Repair, Notch, JAK-STAT, Ras, PI3K, Transcriptional 
Misregulation, Cell Cycle-Apoptosis and MAPK).  
Gene ontology enrichment analysis using MetaCore provides a more detailed overview of the signalling 
pathways influenced by low-dose doxorubicin. MetaCore is software that offers different tools, such as 
Pathway and Process Network Enrichment Analysis, to reveal which pathways are affected by 
differences in gene expression. The input genes from the NanoString nSolver™ analysis were filtered 
using p<0.05 as the cut-off for differential expression. Enrichment analysis was mainly in line with 
pathway score data. As depicted in Figure 5.4-B, which shows the biological processes and pathways 
influenced by low-dose doxorubicin treatment in MDA-MB-231 cells. Pathway analysis indicated that 
the differential gene expression induced by low-dose doxorubicin treatment significantly correlated 
with multiple signal pathways, the top 10 of which are presented for both Networks and Pathway Maps. 
The  top three networks that were most significantly influenced were the Cell Cycle G1-S growth factor 
regulation, Notch signalling, and Cell Cycle G1-S Interleukin Regulation. For Pathway maps, the top 
three enriched pathways also included Cell Cycle Regulation and EGFR Signalling Pathway. 
For treated MDA-MB-468 cells, fewer pathways were of a higher score than treated MDA-MB-231 cells, 
these were Cell Cycle-Apoptosis, DNA-Damage-Repair, JAK-STAT, Transcriptional Misregulation 
pathways and driver genes. The remainder of the pathways were of a lower score in treated cells (Figure 
5.5-A). Like MDA-MB-231, the 3 top networks in MDA-MB-468 cells which were most significantly 
influenced by low-dose doxorubicin treatment were also the Cell Cycle G1-S Growth Factor Regulation, 
Notch Signalling, and Cell Cycle G1-S Interleukin Regulation. Pathway maps analysis indicated that 
differentially expressed genes were primarily enriched in EGFR, Canonical Leptin Pathways and 
Androgen Receptor (Figure 5.5-B). 
Interestingly, opposite results were observed for MCF7 cells. Most of the previous pathways that were 
of a lower score in TNBC cells were higher in MCF7 treated cells and vice-versa. Scores for Cell Cycle-
Apoptosis, Chromatin Modification, Wnt, DNA Damage-Repair, Transcriptional Misregulation pathways 
and driver genes were of a higher score in untreated controls (Figure 5.6.A). In terms of Network 
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Process Enrichment Analysis, among the top 10 most significant processes, 6 out of 10  were associated 
with cell cycle and 2 of 10 were associated with the DNA damage response. The two others, NOTCH 
and EMT (epithelial to mesenchymal transition), were common to the three cell lines (Figure 5.6-B). 
 
 
Figure 5.4. Influence of low-dose doxorubicin treatment on pathways gene signatures in MDA-MB-231 cells. A. 
Heatmap of Pathway scores of MDA-MB-231 cells treated with low-dose doxorubicin versus untreated controls. 
Overview of pathway scores changes. Orange indicates high scores; blue indicates low scores. Scores are 
displayed on the same scale via a Z-transformation. The Morpheus online tool (Broad Institute, USA) was used to 
visualise pathway score data. B. Enrichment analysis of for Network processes and Pathway Maps. MetaCore 
pathway analysis of gene expression differences between treated and untreated cells. Orange bars represent the 






Figure 5.5. Influence of low-dose doxorubicin treatment on pathways gene signatures in MDA-MB-468 cells. A. 
Heatmap of Pathway scores of MDA-MB-468 cells treated with low-dose doxorubicin versus untreated controls. 
Overview of pathway scores changes. Orange indicates high scores; blue indicates low scores. Scores are 
displayed on the same scale via a Z-transformation. The Morpheus online tool (Broad Institute, USA) was used to 
visualise pathway score data.  B. Enrichment analysis of for Network processes and Pathway Maps. MetaCore 
pathway analysis of gene expression differences between treated and untreated cells. Orange bars represent the 






Figure 5.6. Influence of low-dose doxorubicin treatment on pathways gene signatures of MCF7 cells. A. 
Heatmap of Pathway scores of MCF7 treated with low-dose doxorubicin versus untreated controls. Overview of 
pathway scores changes. Orange indicates high scores; blue indicates low scores. Scores are displayed on the 
same scale via a Z-transformation. The Morpheus online tool (Broad Institute, USA) was used to visualise pathway 
score data. B. Enrichment analysis of for Network processes and Pathway Maps. MetaCore pathway analysis of 
gene expression differences between treated and untreated cells. Orange bars represent the significance of 





5.3.2 Influence of low-dose doxorubicin treatment on differential gene expression 
Differential expression analysis was carried out to identify the changes in the expression levels of the 
genes belonging to the previously reported pathways. For MDA-MB-231 cells, amongst the 770 genes 
tested, there was evidence of differential expression at p<0.05 in treated cells relative to normal 
untreated cells for 257 genes. A volcano plot was generated (Figure 5.7-A) in which gene expression in 
treated cells was compared to that in untreated cells assigned as reference. The Benjamini-Yekutieli 
False Discovery Rate (FDR) approach was employed to generate an adjusted p-value. The top 10 most 
significantly differentiated genes with an adjusted p-value of <0.16 are presented in Figure 5.7-B. From 
these, the highly differentially expressed genes with a fold change value of >2 or <-2 were mainly 
downregulated (HIST1H3H, NPM1, E2F5, PRKCA and HMGA1), with the exception of PTPRR which was 
upregulated in treated cells. Interestingly, these most significantly downregulated genes are mainly 
associated with invasiveness and metastasis of tumours. NPM1 (nucleophosmin 1) which encodes for 
one of the most abundant proteins of the nucleoli and plays a role in different central cellular functions 
such as DNA replication, transcription and repair (Lindström 2011) is overexpressed in many solid 
tumours including liver, colorectal and cervical cancer, and its expression has been reported to 
correlate with cancer development and metastasis (Zhu et al. 2015). Furthermore, siRNA-reduction of 
NPM1 expression has been shown to inhibit the migration and invasiveness of colon cancer cell lines 
(Liu et al. 2012). In a study by Zeng et al, expression level of NMP1 was significantly higher in TNBC 
tissues versus other breast cancer subtypes. And the knockdown of NPM1 impaired the proliferation 
of TNBC cells via activation of the CDH1/Skp2/p27kip1 pathway (Zeng et al. 2019). Moreover, it was 
shown that NMP1 expression conferred resistance to TNBC cells to  platinum chemotherapeutics 
cytotoxicity (Malfatti et al. 2019). E2F5 is an important transcription factor which has been shown to 
be overexpressed in tumours of patients with breast cancer compared to normal tissues and was 
associated with tumour development and metastasis  (Liu et al. 2018). High E2F5 expression levels have 
been reported to be significantly associated with a TNBC phenotype and poor clinical outcome 
(Umemura et al. 2009). Xu et al,  demonstrated that targeting of E2F5 with miR-154 inhibited breast 
cancer cells growth and invasion  (Xu et al. 2016). Also shown to be involved in breast cancer invasion 
is PRKCA. PRKCA, encodes for a Protein kinase C alpha (PKCα), which is a serine-threonine protein 
kinase also implicated in cancer metastasis. PKCα expression was shown to be elevated in TNBC and to 
be responsible for chemotherapy resistance and metastasis (Tonetti et al. 2012; Tam et al. 2013). In a 
study by Pham et al., PKCα was shown to enhance migration of breast cancer cells through 
PKCα/FOXC2-dependent repression of p120-catenin (Pham et al. 2017).  
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Similarly, HMGA1, the high mobility group A1 gene is also involved in cell proliferation and motility of 
breast cancer cells and has been shown to drive metastatic and aggressiveness of triple negative breast 
tumours (Shah et al. 2013; Huang et al. 2015). Zanin et al, showed that through interaction with FOXM1, 
HMGA1 promoted breast cancer angiogenesis by increasing VEGFA transcription levels (Zanin et al. 
2019). The most downregulated gene in treated MDA-MB-231 cells was HIST1H3H (histone cluster 1 
H3 family member H), a member of the histone family genes. Various studies demonstrated the 
prognostic value of these genes as higher expression of histone gene sets was associated with poor 
survival and distant metastasis-free survival of breast cancer patients  (Xie et al. 2019). 
 In contrast, PTPRR was upregulated in treated cells. PTPRR encodes protein tyrosine phosphatase 
receptor type R (PTPRs) which represent a subgroup of protein tyrosine phosphatases (PTPs). They play 
a central role in regulating signal transduction of physiological processes such as cell proliferation, 
apoptosis, migration, and invasion (Du, Grandis 2014; Guan et al. 1990). They are reported to be 
involved in several cancer types (Julien et al. 2011). Interestingly, downregulation of PTPRR is 
associated with tumour progression across multiple cancer types (Menigatti et al. 2009). In ovarian 
cancer, PTPRR was found to act as a tumour suppressor by inactivating the Wnt/β-catenin pathway (Y. 











Figure 5.7. Differentially expressed genes in low-dose doxorubicin treated MDA-MB-231 cells. A. Volcano plot 
displaying -log10 (p-value) and log2 fold change for each gene. Highly statistically significant genes fall at the top 
of the plot above the horizontal lines, and highly differentially expressed genes fall to either side. Horizontal lines 
indicate various False Discovery Rate (FDR) thresholds. The 40 most statistically significant genes are labelled in 
the plot. B. Graph of the top 10 most differentially expressed genes with their fold change (adjusted p-value≤0.16, 





For MDA-MB-468 cells, amongst the 770 genes tested, there was evidence of differential expression at 
p<0.05, in low-dose doxorubicin treated cells relative to normal untreated cells for 228 genes. The top 
10 most significantly differentiated genes with the Benjamini-Yekutieli adjusted p-value of ≤0.16 and a 
log2 fold change of >1 or <-1 are presented in figure 5.8-B. These 10 top differentially expressed genes 
were all downregulated in treated samples. Most of these genes belong to the Cell Cycle-Apoptosis and 
DNA Damage pathways. The top highly downregulated gene was TGFB3 (transforming growth factor, 
beta 3) (Log2 fold change -2.91), TGFβ signaling is at the center of tissue homeostasis maintenance and 
many physiological processes, which makes it frequently exploited by cancer cells to promote survival 
and tumour progression (Massagué 2008). TGFB3 encodes for TGFβ3, one of the three isoforms of 
TGFβ. In cancer, TGFβ3 was shown to have a role in the EMT (epithelial to mesenchymal transition) 
process (Kaartinen et al. 1995; Massagué 2012; Zu et al. 2012; Hao et al. 2019). In a study by Chen et 
al, TGFB3 expression was found to be greatly upregulated in premalignant tumour cells, as 
TGFB3 mRNA levels were increased by 84 % in breast tumours compared with adjacent normal tissues 
(Chen et al. 2015). TGFβ3 was also found to be expressed at higher levels in invasive breast cancer 
compared to normal tissues, highlighting its role in the promotion of breast cancer invasion and 
metastasis (Hachim et al. 2018). Interestingly, treatment of triple negative breast tumours with MTD 
paclitaxel has been reported to increase TGFB3 gene expression (Bhola et al. 2013) highlighting the 
low-dose chemotherapy as a potential alternative free of these adverse effects. Here as well, many of 
the downregulated genes are associated with proliferation and invasiveness across different cancers. 
CREB3L4, member of the CREB/ATF transcription factor family, regulate various cellular processes 
including cell proliferation, differentiation and apoptosis (Velpula et al. 2012) and has been reported 
to be expressed at high levels in invasive breast cancers and to be associated with reduced RFS and 
disease-specific survival (DSP) (Jing et al. 2019). PBX1 (Pre-B-cell leukemia homeobox 1), a member of 
three amino acid loop extension (TALE) family of homeodomain proteins, is involved in various 
developmental processes and at the center of ERα signaling (Delval et al. 2011). It was also shown to 
be highly expressed in breast cancer (J. Wang et al. 2017; Magnani et al. 2011) and has been reported 
to be a driver of metastasis in ER positive breast cancers (Magnani et al. 2015).  
 IL20RA (Interleukin 20 receptor, alpha subunit), encodes for a subunit for the IL-20 receptor composed 
of IL20RA/IL20RB dimer, it’s also a receptor for IL-19 and IL-24 (Rutz et al. 2014). IL-20 is a 
proinflammatory cytokine and its expression was associated with advanced tumour stage, metastasis 
and poor survival in breast cancer patients (Hsu et al. 2012). A few histone deacetylase genes were also 
found downregulated in treated cells, such as the gene encoding histone deacetylase 6 (HDAC6).  
HDAC6 is a cytoplasmic enzyme deacetylase involved in various biologic processes such as cell survival 
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and migration (T. Li et al. 2018). In MDA-MB-231 breast cancer cells, HDAC6 was shown to play a critical 
role in the invasive apparatus of tumour cells (Rey et al. 2011). 
 
Figure 5.8. Differentially expressed genes in low-dose doxorubicin treated MDA-MB-468 cells. A. Volcano plot 
displaying each gene's -log10(p-value) and log2 fold change. Highly statistically significant genes fall at the top of 
the plot above the horizontal lines, and highly differentially expressed genes fall to either side. Horizontal lines 
indicate various False Discovery Rate (FDR) thresholds. The 40 most statistically significant genes are labelled in 
the plot. B. Graph of the top 10 most differentially expressed genes with their fold change (adjusted p-value≤0.16, 





With respect to MCF7 cells, amongst the 770 genes tested, there was evidence of differential 
expression at p<0.05 in low-dose doxorubicin treated cells relative to normal untreated cells for 118 
genes. For this analysis, there were only three highly significantly expressed genes (TNFRS10C, EGFR, 
CDKN1A) based on the stringent corrected p-value≤0.16 and so we increased the FDR threshold to a p-
value ≤0.3. Presented in Figure 5.9-B are the top 10 most differentially expressed genes having a log2 
fold change of >1 or <-1. Contrary to the TNBC cell lines, these were all upregulated in treated cells 
compared to untreated controls. However, similar to the other cell lines, most of these genes belong 
to the cell cycle-apoptosis pathways. The genes that were significantly upregulated and having the 
highest fold change were CDKN1A and TNFRS10C (Log2FC= 3.43, 3.24 respectively). As with the other 
cell lines, CDKN1A, the cyclin-dependent kinase inhibitor 1 which encodes the cell cycle regulator p21 
was upregulated in response to DNA damaged caused by doxorubicin, although no upregulation of p21 
protein levels for MCF-7 cells were observed by flow cytometry (Chapter 3). TNFRSF10C (tumour 
necrosis factor receptor superfamily, member 10c), one of many TRAIL (TNF-related apoptosis inducing 
ligand-like) decoy receptors, which encodes for TRAIL receptor 3, is a p53-regulated DNA damage-
inducible gene and functions as an antagonistic receptor, protecting cells from TRAIL-induced apoptosis 
(Ruiz de Almodóvar et al. 2004). A significantly reduced expression of TNFRSF10C is associated with 
multiple tumour types (Macartney-Coxson et al. 2008; Tanenbaum et al. 2016). Also involved in 
apoptosis are GADD45A and RASGRP1. GADD45A encodes for the Growth arrest and DNA-damage-
inducible protein GADD45 alpha, a member of the GADD45 family of genes which are described as 
stress sensors that modulate cellular responses to various stress stimuli (Cretu et al. 2009; Li et al. 
2017). GADD45A is a downstream target gene of p53 and BRCA1 (breast cancer susceptibility gene 1), 
playing a central role in genomic stability and tumorigenesis in various cancers (Cretu et al. 2009; Reis 
et al. 2015; Cui et al. 2017; Wingert, Rieger 2016). It has been reported to act as a tumour suppressor 
in Ras-driven breast tumorigenesis via increasing JNK-mediated apoptosis and p38-mediated 
senescence (Tront et al. 2010). Also, within the Ras pathway, RASGRP1 encoding for the RAS guanyl-
releasing protein 1, is involved in proliferation, differentiation and apoptosis of tumours (Chang, Karin 
2001). Interestingly, a higher expression of RASGRP1 has been associated with better overall survival 
in TNBC in various studies (Wang et al. 2018; J. J. Wang et al. 2019; Gupta et al. 2019). SHC2 (Src 
homology 2 domain) encode for the adaptor protein Shc 2 which is implicated in mediating several 
intracellular signalling cascades; involved in cell proliferation, survival and migration (Ravichandran 
2001; Ahmed, Prigent 2017).TGFBR2 encoding for TGFβ2, one of TGFβ isoforms, was also upregulated. 
mRNA and protein levels of TGFBR2 were previously shown to be significantly decreased in breast 
cancer tissues compared with adjacent non-tumorous breast tissues, this downregulation in tumour 
91 
 
tissue was correlated with larger tumour size, lymph node metastasis and poor prognosis in breast 
cancer (Wei et al. 2015).  
 
 
Figure 5.9. Differentially expressed genes in low-dose doxorubicin treated MCF7 cells. A. Volcano plot displaying 
each gene's -log10(p-value) and log2 fold change. Highly statistically significant genes fall at the top of the plot 
above the horizontal lines, and highly differentially expressed genes fall to either side. Horizontal lines indicate 
various False Discovery Rate (FDR) thresholds. The 40 most statistically significant genes are labelled in the plot. 
B. Graph of the top 10 most differentially expressed genes with their fold change (adjusted p-value≤0.3, log2 fold 






5.4 Summary   
Pathway and gene expression profile analysis provides essential information for identifying subtle 
changes in the biology of cancers and distinguishing cancer subtypes (Sorlie et al., 2001; Gatza et al., 
2010). With the purpose of understanding the impact of low-dose doxorubicin treatment on cancer-
related gene changes and identifying which cell properties and processes are modified by this 
treatment, we used NanoString nSolver™  amplification-free gene expression profiling using the Cancer 
Pathways code set which includes critical genes from 13 key cancer pathways. In this analysis, mRNA 
expression profiles of breast cancer cell lines treated with low-dose doxorubicin treatment were 
analysed and compared to control untreated cells, we identified the genes and their associated 
pathways that were deregulated for each of the three cell lines tested MDA-MB-231, MDA-MB-468 and 
MCF-7.   
Pathway analysis identified the top consistently upregulated pathways in the two TNBC cell lines; DNA 
Damage-Repair, Cell Cycle-Apoptosis, Transcriptional Misregulation and JAKK-STAT, with PI3K, Notch, 
MAPK and Ras signaling pathways being upregulated in low-dose doxorubicin treated MDA-MB-231 
and MCF7 cells. In terms of downregulated pathways, Chromatin Modification and Wnt were both 
downregulated in all cell lines following treatment, Hedgehog and TGFβ pathways were downregulated 
in both TNBC cells. Although upregulated in TNBC cell lines, DNA Damage-Repair and Cell Cycle-
Apoptosis were downregulated in MCF7 cells. 
In order to supplement the NanoString nSolver™ Analysis and further evaluate the functional pathways 
of deregulated genes, we analysed Pathway Maps, and Networks using MetaCore software. The three 
top networks with the most significant changes were common to both MDA-MB-231 and MDA-MB-468 
cells and were associated to Cell Cycle and Notch signalling. Among these, the cell cycle pathway 
wasalso on the top three deregulated networks of MCF7 cells, in addition to DNA damage checkpoint. 
Other processes that were significantly altered in the three cell lines were Notch and EMT 
signalling. Pathway analysis using the breast neoplasms folder (MetaCore) was also concordant with 
NanoString nSolver™ analysis results. The three top pathways displaying significant alterations in MDA-
MB-231 were associated with Cell Cycle Regulation and the EGFR Signalling Pathway. The EGFR 
Signalling Pathway was also the top deregulated pathway in MDA-MB-468 cells, followed by the 
Canonical Leptin Pathway and Androgen Receptor. For MCF7 cells, genes for Cell Cycle G1/S Transition 
and DNA Damage ATM/ATR Regulation of G2/M Checkpoint Signalling Pathways were highly enriched 
following low-dose doxorubicin treatment. 
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Differential expression analysis identified the highly altered gene levels in treated cells compared to 
untreated controls. A notable observation was that many of these alterations belong to signalling 
pathways that govern cell proliferation and cell differentiation. Interestingly, many of the 
downregulated genes were associated with cancer proliferation and invasiveness, and were shown to 
affect tumour metastasis. Overall, MCF7 cells showed a much weaker response to low-dose 
doxorubicin treatment in terms of significantly differentially expressed genes; as only 3 genes were 
found to be significantly altered following Benjamini-Yekutieli correction for multiple comparison - 
these genes were involved in cell cycle regulation and NDA-damage response. This weaker response 
could be due to the fact that MCF7 cells were treated with a lower concentration of doxorubicin than 
MDA-MB-231 and MDA-MB-468 cells. The concentration was based on the levels of SA-B-gal expression 
as previously explained. This is particularly interesting as it sheds light on the importance of drug 
dosing, as different doses of doxorubicin differently influence gene regulation.  This might explain the 
differences found between the TNBC and MCF7 cells. 
Considering results from previous chapters, showing the effect of low-dose doxorubicin on breast 
cancer cells. It was expected that doxorubicin treatment would have an impact on the transcriptome 
of the cells and induce changes in gene expression that would highlight the decrease in proliferation 
potential and the enhanced susceptibility to NK cell killing. Overall, Pathway and gene expression 
profile analysis gave insight into the altered pathways and molecular changes induced by low-dose 
doxorubicin treatment. Treatment with low-dose doxorubicin downregulated many genes involved in 
tumour progression and invasiveness. These findings are particularly interesting, as they provide insight 
into the mechanisms of action of low-dose doxorubicin and reveal potential predictive markers of 
sensitivity to NK cell cytotoxicity and potential targets/candidates for combination treatment. This 
effect on downregulating invasion and metastasis-related genes is further interrogated in tumour 





Chapter 6: Effect of the combination of low-dose doxorubicin and adoptive NK 
cell transfer on the growth of MDA-MB-231 cell-derived tumours in a murine 
xenograft model 
 
6.1 Introduction  
 
The efficacy of Immunotherapy for cancer treatment has been proven by different studies, especially 
the blockade of immune checkpoint molecules such as cytotoxic T-lymphocyte-associated protein 4 
(CTLA4), programmed cell death protein 1 (PD1), and programmed cell death 1 ligand (PD-L1) (Chen, 
Han 2015; Topalian et al. 2015; Hoos 2016). However these studies also showed that only a subset of 
patients can benefit from this treatment in a sustainable manner, with some patients failing to respond 
completely to such treatment (Braun et al. 2016). Furthermore, the effectiveness of checkpoint 
inhibitor-based monotherapies is dependent on the nature of the cancer entity and its inherent 
immunogenicity (i.e. ‘hot’ versus ‘cold’). Broadening the spectrum of patients that can benefit from 
immunotherapy treatment and achieving higher rates of tumour control will require the use of 
combined approaches.  In TNBC, only a minority of patients benefit from these treatment options. This 
is mainly due to failure in overcoming the well-evolved mechanisms of immune escape in these 
advanced tumours, such as decreased expression of MHC class I which result in reduced 
immunogenicity and recognition (Borcherding et al. 2018) . Until the recent Impassion130 phase-3 trial 
which tested nab-paclitaxel combined to atezolizumab (Schmid et al. 2018), very few studies addressed 
immunotherapeutic approaches for TNBC treatment. Also, despite the encouraging results yielded in 
the Impassion130 trial, the median PFS was only improved in a subset of patients (PD-L1 positive for 
tumour –infiltrating immune cells) (Schmid et al. 2018). Therefore, further studies focusing on 
enhancing immunotherapy response are urgently needed (Chrétien et al. 2019; Sylvia Adams et al. 
2019). 
Identifying and exploiting potential synergies between treatment modalities is critical to increase the 
anti-tumour efficacy of existing cancer treatment approaches and reduce resistance and disease 
relapse. A potentially effective option is to combine immunotherapy with low-dose metronomic 
chemotherapy. As reviewed in the introduction chapter, some chemotherapeutic agents given in a 
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metronomic schedule have been shown to positively modulate anti-tumour immune responses by 
rendering tumour cells more immunogenic and more sensitive to NK cell-mediated cytotoxicity (Pol et 
al. 2015; Heinhuis et al. 2019; Ghiringhelli et al. 2007b). Given that immunotherapies that are based on 
triggering/restoring NK cell function have been shown to generate robust immune responses against a  
number of tumour entities ( Souza-Fonseca-Guimaraes, 2016; Fang and Xiao, 2017; Hu et al., 2019; 
Lupo and Matosevic, 2019), combining low-dose metronomic chemotherapy and NK cell-based 
immunotherapy is likely to improve therapeutic outcomes (Cifaldi et al. 2017). 
The basis of such an approach is to sensitize tumours to NK cell-mediated cytotoxicity by administering 
low doses of the chemotherapeutic prior to the infusion of autologous or allogeneic NK cells, thereby 
enhancing tumour control. Until now, few studies have reported on the clinical efficacy of this 
approach. Pre-clinical studies have reported synergistic activity between low-dose chemotherapy and 
checkpoint inhibition. For example, Parra et al, demonstrated the efficacy of combining anti-CTLA4 and 
metronomic chemotherapy in a breast cancer model (Parra et al. 2017a).  
Murine preclinical models are a crucial step in the development of cancer therapeutics. Different 
mouse models can be used for modelling cancer therapies, from cancer cell line and patient-derived 
xenografts to sophisticated humanized mice,  each with its own advantages and disadvantages (Perrin 
2014). The goal with animal models is to mimic human tumour biology, interactions of the tumour with 
the microenvironment and response to therapeutic concepts (Landis et al. 2013). Xenograft models are 
one of the main models used in cancer research and are based on the implantation of human cells or 
tissues into immunodeficient mice. The development of immunodeficient mouse strains bearing a 
mutation in the IL2 receptor common gamma chain gene (IL2rγnull) (Ohbo et al. 1996) combined with 
the scid, Rag1null, or Rag2null mutations, generate a mouse which is completely deficient in adaptive 
immunity and severely deficient in innate immunity and is highly receptive to engraftment of human 
cells, tissues, and primary tumours (Shultz et al. 2014). 
In the previous chapter, the capacity of low dose doxorubicin to sensitize human breast cancer cells to 
NK cell killing was demonstrated, in this chapter, the experiments to examine the capacity of combining 
low-dose chemotherapy and adoptive NK cell transfer to control the growth of MDA-MB-231 cell-
derived tumours in a murine xenograft model are described. 
6.2 Experimental Aims 
The aim of the experiments described in this chapter was to evaluate the capacity of low-dose 
doxorubicin (LD-Dox) combined with adoptive NK cell transfer to control the growth of MDA-MB-231 
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cell-derived tumours in a murine xenograft model. The effect of treatment on tumour growth and 
metastasis were assessed against controls receiving no treatment. Furthermore, to examine the in vivo 
immunological consequences of treatment, its influence on the expression of ligand for the main 
activatory NK cell receptor NKG2D (MICA/B) and proliferation marker Ki67, as well as the proportion of 
cancer initiating cells (CICs) and sensitivity of isolated tumour cells to ex-vivo killing by NK cells were 
assessed and compared between tumours that received either LD-Dox alone, NK cells alone or the 
combination treatment. The effect of treatment on NK cell infiltration into tumours was also studied 
using in vivo fluorescence imaging.  
6.3 Results 
6.3.1 Establishing murine xenograft model of human triple negative breast cancer (TNBC) 
In order to investigate the influence of combining LD-Dox with adoptive NK cell transfer on the growth 
of TNBC in vivo, we established a murine orthotopic xenograft model using the human MDA-MB-
231/LUC/RFP cells (obtained from AMSbio), which are transfected to stably express the firefly luciferase 
(Luc 3) reporter to enable optical bioluminescence imaging of the tumours following the administration 
of luciferin. Of note is that these cells also stably express red fluorescent protein (RFP), thereby enabling 
fluorescence-based imaging. MDA-MB-231 is a highly aggressive human breast cancer cell line and one 
of the most commonly used models for studying TNBC and its metastasis, as these cells metastasize to 
distant organs from primary tumours implanted in the mammary fat pad (Simmons et al. 2015; Minn 
et al. 2005). MDA-MB-231 cells also express features associated with Cancer Stem Cells (CSC) such as 
the CD44+CD24-/low phenotype (Minn et al. 2005; Sheridan et al. 2006). The orthotopic model used in 
this study involved the direct subcutaneous injection of the cells into the fourth abdominal mammary 
fat pad.  
The NSG (NOD-scid IL2rγnull) mice strain was selected for this study, as it represents one of the most 
immunodeficient mice available and allows for the engraftment of human cells (Shultz et al. 2005; 
Shultz et al. 2007). They are void of mature T and B cells and, most importantly, lack functional NK cells 
(King et al. 2008).  
The luciferase activity of MDA-MB-231/LUC/RFP cells and the relationship of the bioluminescence 
signal with cell number was first determined in vitro using with bioluminescent intensity (BLI)  
technique, as shown in Figure 6.1 (A). Cells titrated in the absence of luciferin (the substrate for 
luciferase) and PBS alone (no cells) acted as controls. As expected, the intensity of bioluminescence 












Figure 6.1. Relationship between MDA-MB-231/LUC/RFP cell number and bioluminescent intensity in 
vitro. A. In vitro bioluminescence of MDA-MB-231/LUC/RFP cells. B. linear correlation between cell number 
and BLI (R2=0.95). (BLI: bioluminescent imaging). The figure is representative of one experiment, however 
the luminescent properties of cells was evaluated and confirmed prior to the start of each study. 
 
To test the Tumourigenicity, as well as the capacity to image tumours using in vivo bioluminescent 
intensity (BLI) imaging, we performed a tumour growth kinetics study using 3 different cell doses 
(0.5/2.5/5x106) in order to determine the optimal cell number to use for tumour implantation. We also 
assessed the capacity of administering cells in the basement membrane extracellular (ECM) gel matrix 
(Matrigel™, 1:1 (v:v)) to improve tumour engraftment and growth using the 2.5x106 cell dose.  
Tumour growth was monitored using caliper measurements as well as BLI. As described in the methods 
chapter, the specific BLI signal was calculated in the region of interest. IVIS™ Spectrum images were 
used at the start of all studies to verify that the tumours were present in the correct location.  Figure 
6.2-A, shows tumour growth over time of the 4 cell doses assayed (tumour volume assessed by caliper 
measurements on the right and BLI on the left). The three cell doses generated a detectable 
luminescence signals in vivo which rose with increased tumour dosage. The quantification of the BLI 
correlated with the tumour load in vivo (R2=0.99) (Figure 6.2-B).  
Administering MDA-MB-231/LUC/RFP cells in Matrigel™ (2.5x106) increased tumour growth both in 
terms of tumour volume and luminescence signal. Figure 6.2- C shows a representative time course of 
the BLI, detected at different time points of the group of animals that received 2.5x106 cells in 
Matrigel™. Based on these findings, and that a dose of 5x106 MDA-MB-231/LUC/RFP cells generated 
robust tumour growth rates in the absence of Matrigel™, all subsequent in vivo studies implanted 5x106 

































































































Figure 6.2 Establishment of xenograft mouse model of triple negative breast cancer (TNBC) using MDA-
MB-231/LUC/RFP cells. (A) NSG mice (n=3/group) received s.c injections of the indicated doses of MDA-
MB-231/LUC/RFP cells. Left: Tumour growth/volume measured by calipers; Right: Tumour growth/volume 
measured using BLI quantification. Data are mean ± SEM (n = 3) (B) correlation between BLI quantification 
and the tumour load in vivo at day 18 after MDA-MB-231/LUC/RFP cell implantation (R2=0.99). Data are 
mean ± SEM (n = 3). (C) Respective time course of IVIS™ Spectrum images for animals implanted with 2.5x105 
MDA-MB-231/LUC/RFP cells in Matrigel™ (1:1 v/v). (BLI= Bioluminescence intensity. Tumour volume = π/6 
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6.3.2 Influence of low-dose doxorubicin (LD-Dox) and/or adoptive NK cell transfer on the growth 
of MDA-MB-231/LUC/RFP cell-derived xenografts in immunedeficient NSG mice 
6.3.2.1 Treatment schedule  
Following the establishment of the tumour model and the validation of its suitability for BLI 
quantification in vivo, the Influence of low-dose doxorubicin (LD-Dox) and/or adoptive NK cell transfer 
on the growth of MDA-MB-231/LUC/RFP cell-derived xenografts in immunedeficient NSG mice was 
evaluated. 
Although metronomic LD-Dox is currently used in the clinic, until now, very few studies have reported 
its use in combination with immunotherapy in preclinical models. The reported LD-50 of doxorubicin in 
the literature is 10.7 mg/kg body weight and the common single maximum tolerated dose (MTD) 
reported in murine models is 10mg/kg (Aston et al., 2017; Johansen, 1981). Our LD-Dox (LDM) mimetic 
regimen was based on a 20 times lower dose than the MTD for single doses, with a dosing regimen of 
doxorubicin at 0.5mg/kg three times a week. This represents a cumulative dose for 1 cycle of 1.5mg/kg 
and a whole treatment cumulative dose of 3mg/kg. This LDM mimetic regimen was previously 
evaluated by Mainetti et al (Mainetti et al. 2013) in combination with cyclophosphamide in a murine 
breast cancer model (0.5 mg/kg i.p. three times/week). 
 
Figure 6.3. Treatment schedule for MDA-MB-231/LUC/RFP cell-based xenograft model. Animals received 
two cycles of the combination treatment, one cycle containing three doxorubicin injections (i.p) followed by 
one dose of 10x106 NK cells (i.v. infusion). NK cells were purified from peripheral blood mononuclear cells 
(PBMCs) isolated from healthy volunteers, stimulated overnight with IL-2 (200U/ml) and then injected i.v 
via the tail vein into tumour-bearing animals. For some studies, NK cells were fluorescently labelled labeled 
with Vivotrack 680 near-infrared (NIR) fluorescent agent to enable tracking of NK cell infiltration using in 
vivo fluorescence imaging. 
 
6.3.2.2 Tumour growth inhibition  
LD-Dox treatment started 11 days after tumour implantation when tumours were palpable. In Study 1 
shown in Figure 6.4-A (left panel) tumour growth was monitored using in vivo imaging during the 
treatment period and tumour volume (right panel) was assessed using caliper measurements at the 
indicated time points following the end of the treatment. The combination treatment group showed 
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smaller tumours than control groups starting from around day 25 following tumour cells injection as 
detected by the BLI signal. LD-Dox combined with adoptive transfer of donor-derived NK cells 
significantly slowed the growth of tumours compared to LD-dox alone and untreated controls (PBS 
only). In terms of tumour volume, a marked reduction in tumour growth rate was also observed in the 
combination treatment group, however a smaller difference (non-statistically significant) could be 
observed between LD-Dox   alone and LD-Dox+NK cells. Treatment also had a significant impact on the 
weight of tumours obtained at the end of the study, thereby confirming an inhibition of tumour growth 
by LD-Dox+NK cells compared to LD-Dox alone and control groups. These differences are illustrated by 
representative images of harvested tumours (Figure 6.4-C.). For all experiments, animals were culled 
when evidence of metastasis was apparent from the IVIS™ Spectrum images. 
 
Figure 6.4. Low-dose doxorubicin combined with adoptive transfer of donor-derived NK cells inhibits the 
growth of MDA-MB-231/LUC/RFP cell-derived xenografts. A. Left: Tumour growth determined by 
bioluminescence intensity using in vivo imaging. Right: Tumour volume assessed by caliper measurements. 
Data are mean+SEM (n=4-5 per group) Statistical significance was calculated by two-way ANOVA (* 
p≤0.0332, **p≤0.0021, ***p≤0.0002, **** p≤0.0001). B. Tumour weights, data are mean±SD (two-way 




Studies also evaluated the therapeutic potential of combining LD-Dox treatment with the adoptive 
transfer of the NK-92™ MI cell line and compared this to that using donor-derived NK cells. This study 
(study 2) was carried out using NOD,B6.SCID Il2rg-/- KitW41/W41 (NBSGW) mice, which support 
engraftment of hematopeoetic cells without requiring myeloablative irradiation due to a mutant KitW41 
allele. The use of this mouse strain was necessary as it was not possible to irradiate mice at Nottingham 
Trent University. Previous studies have reported similar levels of engraftment in irradiated NSG and 
NBSGW mice (McIntosh et al. 2015). For the studies reported in Figure 6.5, the frequency of in vivo 
imaging was reduced due to the reported effect of anesthetics such as isoflurane used in this case on 
NK cell viability and function (Stollings et al. 2016; Tazawa et al. 2017). One BLI measurement was taken 
in order to randomize animals before the start of the treatment (day 8) and BLI measurements were 
taken at the indicated time points following the end of the two cycles of treatment (Figure 6.5-A right). 
In addition, tumour volume was measured by calipers twice weekly (Figure 6.5-A left).   
 
Although LD-Dox treatment alone delayed tumour growth relative to untreated controls, combining 
this with adoptive transfer of NK cells enhanced the anti-tumour effect, this was true for both primary 
NK cells and the NK92™-MI cell line. For the group that received the combination of LD-Dox with 
primary NK cells, two of five animals (40%) remained free of measurable tumours at the end of the 
study (day 47). Animals that received the combination treatment had significantly smaller tumours 
compared to both untreated animals and animals treated with LD-Dox alone, as shown by tumour 
weights (Figure 6.5-B) and representative images of harvested tumours (Figure 6.5-C). 
However, GvHD-like clinical signs became apparent following the second administration of NK-92™ MI 
cells to mice treated with LD-Dox, requiring these animals to be culled before the end of the study (day 
36). Post-mortem examination revealed an apparent accumulation of cells (presumably NK-92™ MI 
cells as detected by fluorescence imaging) in the liver. The same symptoms were also apparent in 







Figure 6.5. Low-dose doxorubicin combined with adoptive transfer of NK-92™ MI cells inhibits the growth 
of MDA-MB-231/LUC/RFP cell-derived xenografts. A. Left: Tumour volume assessed by caliper 
measurements. Right: Bioluminescence intensity of tumours determined by in vivo imaging. Data are 
mean+SEM (n=4-5 per group). Statistical significance was calculated by two-way ANOVA (* p≤0.0332, 
**p≤0.0021, ***p≤0.0002, **** p≤0.0001). B. Tumour weights, data are mean±SD (One-way ANOVA,* 
p≤0.0332, ***p≤0.0002). C. Representative images of tumours.  
 
Does irradiation of NK-92™ MI cells prevent the development of GvHD-like side-effects? 
In order to counteract the GvHD-like side-effects that we observed when using the NK-92™ MI cell line, 
we assessed whether irradiating NK92™ MI cells with sub-lethal doses of gamma irradiation prior to 
administration would lower their proliferation rate and thereby avoid these GvHD-like symptoms. For 
this, NK-92™ MI cells were irradiated at 10Gy, a dose which has been reported to decrease 
proliferation, but not the cytotoxicity of NK-92™ cells (Cheng et al. 2011). The viability of irradiated NK-
92™ MI cells was determined  4,24 and 48 hours following irradiation and their cytotoxicity 24 hours 
after irradiation and compared to control (non-irradiated NK-92™ MI cells) and transport control cells 
(NK-92™ MI cells that were transported to the irradiation facility at City Hospital, Nottingham, but not 
irradiated). Although the viability of irradiated NK-92™ MI cells progressively decreased over 48 hours, 
their cytotoxic potential 24 hours after irradiation was comparable to that of non-irradiated and 
transport control NK-92™ MI cells (Figure 6.6). However, adoptive transfer of irradiated cells did not 




Figure 6.6. Effect of irradiation on the viability and cytotoxicity of NK-92™ MI cells. A. Viability of irradiated, 
non-irradiated and transport control NK-92™ MI cells over 4,24 and 48 hours. B. Cytotoxicity of irradiated, 
non-irradiated and transport control NK-92™ MI cells against K562 cells at different effector to target ratios. 
Irradiated cells were used 24h post irradiation.  
 
Does a lower dose of doxorubicin further potentiate anti-tumour effects? 
To assess whether a lower dose of doxorubicin would potentiate the anti-tumour effects of adoptive 
NK cell transfer, experiments in NSG mice were repeated using 0.25mg/kg doxorubicin (study 3). 
Although 0.25mg/kg doxorubicin alone inhibited tumour growth, as detected by luminescence, but not 
so clearly using caliper measurement, this effect was smaller than that seen when using 0.5 mg/kg 
doxorubicin.  The adoptive transfer of donor-derived NK cells into animals treated with 0.25 mg/kg 








Figure 6.7. Effect of 0.25 mg/kg doxorubicin alone and in combination with the adoptive transfer of donor-
derived NK cells on the growth of MDA-MB-231/LUC/RFP cell-derived xenografts. A. Bioluminescence 
intensity as determined by in vivo imaging. Data are mean+SEM (n=4-5 per group). Statistical significance 
was calculated by two-way ANOVA (**p≤0.0021, **** p≤0.0001). B. Tumour volume growth determined by 
caliper measurements mean+SEM (n=4-5 per group). C. Tumour volume of individual mice. 
 
 
Can the adoptive transfer of donor-derived, primary NK cells alone influence the growth of 
MDA-MB-231/LUC/RFP cell-derived xenografts? 
 
We next determined whether the adoptive transfer of donor-derived primary NK cells alone could 
influence the growth of MDA-MB-231/LUC/RFP cell-derived xenografts in NSG mice (study 4). Here, the 
treatment started at day 7 following tumour implantation (when tumours were palpable) (Figure 6.8.A). 
Although the findings were not of statistical significance, caliper measurements indicated that tumour 
growth was slower in animals that received LD-Dox in combination with NK cells, than that in animals 
treated with LD-Dox or adoptively transferred NK cells alone (Figure 6.8 left). However, no difference 
was observed using BLI imaging (Figure 6.8-B right).Tumour weight on the other hand was consistent 
with previous finding, as tumours derived from animals treated with LD-Dox and primary NK cells 
combination were of a lower weight compared to controls.  
 
 
























Figure 6.8. Influence of adoptive transfer of donor-derived, primary NK cells alone on the growth of MDA-
MB-231/LUC/RFP cell-derived xenografts.  A. Treatment schedule. B. Tumour volume growth determined 
by caliper measurements (Left). Bioluminescence intensity as determined by in vivo imaging (Right). Data 




6.3.3 Influence of low-dose doxorubicin (LD-Dox) and/or adoptive NK cell transfer on the 
metastasis of MDA-MB-231/LUC/RFP cell-derived xenografts in immunedeficient NSG mice 
As in vivo imaging allows for the monitoring of the growth of the primary tumours, it also allows for the 
detection of metastasis if/when tumour cells travel to distant organs. As depicted in Figure 6.10-A, in 
Study 1, metastasis was delayed by 7 days in animals treated with LD-Dox) alone compared to 
untreated animals, and no evidence of metastasis was apparent in animals that received LD-Dox and 
adoptively transferred donor-derived primary NK cells at the termination of the study on day 50.  
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The first evidence of metastasis was observed in control group between day 35 and day 42 after the 
implantation of MB-231/LUC/RFP cells and between day 46 and 56 for animals treated with LD-dox 
alone. Animals in receiving the combination therapy were excluded from the study/terminated at day 
50 because of GvHD-like symptoms described above. Figure 6.10-B shows representative in vivo images 
at day 49 post tumour implantation. Metastasis was primarily apparent in the right axillary region and 
the liver and lungs, with some distant metastases also being observed in the spleens and left inguinal 
area for some animals,  as shown by ex vivo whole body images that were generated following the 




Figure 6.9. Influence of low-dose doxorubicin (LD-Dox) and/or adoptive NK cell transfer on the 
metastasis of MDA-MB-231/LUC/RFP cell-derived xenografts in immunedeficient NSG mice. A. Onset 
of metastasis presented as a Kaplan-Meier curve showing changes in percentage of metastasis-free 
animals by elapsed time after tumour cell implantation (n=4-5 animals/group). B. Representative in 
vivo images of animals at day 49 post tumour cell implantation. C. Ex vivo whole body images of 
metastases following removal of the primary tumour. 
 
 
A delay in the onset of metastasis in animals receiving 0.25 mg/kg and 0.5 mg/kg doxorubicin in 
combination with adoptively transferred donor-derived, primary NK cells was also observed, with a 
longer delay being observed in animals treated with 0.25mg/kg (Figure 6.11). Because of the latter, 





Figure 6.10. Influence of low-dose doxorubicin (LD-Dox) at 0.25 mg/kg and 0.5 mg/kg and/or adoptive NK 
cell transfer on the metastasis of MDA-MB-231/LUC/RFP cell-derived xenografts in immunedeficient NSG 
mice. A. Onset of metastasis presented as a Kaplan-Meier curve showing changes in percentage of 
metastasis-free animals by elapsed time after tumour cell implantation (n=4 animals/group). Statistical 
comparison: Log-rank (Mantel-Cox) test (control vs LD-dox(0.5mg/kg) * p=0.0285, LD-Dox (0.25mg/kg) vs 
LD-Dox(0.25mg/kg)+ pNK * p= 0.0180, **p= 0.0091).B. Representative in vivo images of metastasis. 
 
 
In regards to the effect of adoptive transfer of NK cells alone, although there was no  significant delay 
in metastasis onset between the groups, at the end of the study (day 45),4 out of 5 and 4 out of 4 
animals had  in vivo detectable metastatic signal in control and LD-dox alone groups respectively. in the 
group of animals that received NK cell adoptive transfer alone 5/5 animals had a detectable metastatic 
signal by day 45. While in the combination groups 2 out of 5 animals had metastasis signals detectable 
by in vivo imaging. Whole body ex-vivo IVIS images and BLI quantification, indicate a difference in terms 
of metastasis spread, with the combination group presenting lower metastatic spread compared to 





Figure 6.11. Influence of adoptive transfer of donor-derived, primary NK cells alone on the metastasis of 
MDA-MB-231/LUC/RFP cell-derived xenografts in immunedeficient NSG mice. A. Onset of metastasis 
presented as a Kaplan-Meier curve showing changes in percentage of metastasis-free animals by elapsed 
time after tumour cell implantation (n=4-5 animals/group B. Representative ex vivo images of metastasis at 
the end of the study, following removal of the primary tumours. 
 
6.3.4 In vivo infiltration of injected NK cells to subcutaneous Tumours 
One of the major limiting factors of NK cell-based therapies is the effective infiltration and homing of 
these cells in/to solid tumours, as the tissue presents a barrier preventing NK cells from reaching the 
core of the tumour (Gajewski et al. 2013). Recent studies have shown a positive association between 
NK cell infiltration and the prognosis of colorectal, gastric and lung cancer (Krasnova et al. 2017; Souza-
Fonseca-Guimaraes 2016).  Tracking NK cell trafficking is therefore important for 
assessing the potential efficacy of their transfer. We have used direct fluorescence cell labeling to track 
NK cells using in vivo imaging and to evaluate the effect of LD-Dox treatment on their recruitment and 
infiltration into tumours. 
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NK cells were labeled with VivoTrack 680 near infrared (NIR) fluorescent imaging agent prior to 
adoptive transfer. At the end of the study, NK cell infiltration in tumours was also assessed using flow 
cytometric analysis of isolated cell populations and infiltration patterns between animals that received 
NK cells alone and animals that received the combination treatment comparted. Figure 6.12-B shows 
NK cell infiltration as measured by epi-fluorescence in vivo. At day 25 post tumour cell implantation, 
corresponding to 10 days following the first NK cell infusion, NK cell infiltration in tumours was 
significantly higher in animals that were pre-treated with LD-Dox. The same was observed for day 32 
which represent 3 days following the second NK cell infusion. Although the difference was not of 
statistically significant for the other time-point, it was slightly higher in LD-Dox+pNK combination 
group. In line with these results, flow cytometric analysis of NK cell infiltration at the end of the study 
(Figure 6.12-C) also showed higher percentages of NK cells in tumours from animals that had received 
the combination treatment.  
 
Figure 6.12. In vivo infiltration of intravenously injected NK cells to subcutaneous Tumours. A. Treatment 
Schedule. B. Epi-fluorescence measurements of NK cell infiltration in tumours at different time points 
following NK infusions (n=5, Two-way ANOVA *p<0.0332  **p<0.0021). C. Flow cytometry measurement of 
NK cell infiltration in tumours (n=5.  Unpaired T-test * p=0.0317).  
6.3.5 Influence of low-dose doxorubicin (LD-Dox) and/or adoptive NK cell transfer on tumour cell 
proliferation, expression of MICA/B ligand and sensitivity to NK-92™ MI cell cytotoxicity  
To further evaluate the effects of treatment, we assessed the expression of the proliferation marker 
Ki-67 and the ligand MICA/B on tumours following their dissociation into single cell suspensions. As 
shown in Figure 6.8-A, Ki-67 expression was lower in the tumours from animals that had received LD-
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Dox (0.5 mg/kg) in combination with adoptively transferred donor-derived primary NK cells. Expression 
of MICA/B ligands on cells isolated from the tumours of mice treated with the combination treatment 
was also higher than that on cells isolated from the tumours of control animals (Figure 6.9-B). 
Furthermore, cells isolated from the tumours of mice treated with the combination therapy were more 
sensitive to NK-92™ MI cytotoxicity, as assessed using an in vitro cytotoxicity assay (E:T 1:5, Figure 6.8-
C). 
 
Figure 6.13. Influence of low-dose doxorubicin (LD-Dox) and/or adoptive NK cell transfer on tumour cell 
proliferation, expression of MICA/B ligand and sensitivity to NK-92™ MI cell cytotoxicity A. Expression of 
the proliferation marker Ki-67 by tumour-derived cells: data are mean + S.D from 4-5 animals (One-way 
ANOVA,*P≤0.05, **P≤0.01, ****P≤0.0001). B. Surface expression of MICA/B by tumour-derived cells: data 
are mean + S.D from 4-5 animals (One-way ANOVA,*P≤0.05, ***P≤0.001). C. Killing of tumour-derived cells 
by NK-92™ MI cells (E:T 1:5):  data are mean + S.D from 4-5 animals (Two-way ANOVA,**P≤0.01).(1:study 2, 
2: study 4/. Top Panel: study 2. Bottom Panel: study 4). 
6.3.6 Influence of low-dose doxorubicin (LD-Dox) and/or adoptive NK cell transfer on cancer 
initiating cells (CICs) in tumours   
Gene expression profiling studies have revealed that most primary tumours contain a subset of cells 
with a cancer stem cell (CSC) or cancer initiating cell (CIC) phenotype (Reya et al. 2001). In breast cancer, 
such cells are defined on the basis of their expression of CD44, CD24 and EpCAM (CD326) (Al-Hajj et al. 
2003; Fillmore, Kuperwasser 2008). Many studies have shown that higher proportions of CICs in 
tumours are associated with therapeutic resistance and development of metastasis (Lawson et al. 
2009). We therefore determined the proportion of EpCAM+/CD44high CICs in MDA-MB-231/LUC/RFP 
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cell-derived xenografts following low-dose doxorubicin (LD-Dox) and/or adoptive NK cell transfer. 
MDA-MB-231 cells are negative for CD24, thus this marker has not been used. Lower proportions of 
EpCAM+/CD44high CICs were found in tumours from animals that received LD-dox and LD-dox combined 
with primary NK cells, as compared to controls (Figure 6.13).  




















































Figure 6.14. Proportion of EpCAM+CD44high cancer initiating cells (CICs) in tumours from control tumour-
bearing animals and tumour-bearing animals treated with low-dose doxorubicin (LD-Dox) and/or 
adoptive NK cell transfer. Following dissociation of tumours, single cell suspensions were assessed for 
EpCAM/CD44 surface expression using flow cytometry. Data are as mean+SD (Two-way ANOVA, **P≤0.01).  
 
6.3.7 Immune Checkpoint inhibitors  
Tumours can evade and avoid immune recognition and surveillance by expressing inhibitory receptors 
and so called ‘immune checkpoint’ molecules. Immune checkpoint inhibitors have been shown to 
increase the effectiveness of cytotoxic lymphocytes and to increase patient survival in a number of 
studies and tumour entities (Seidel et al. 2018). Pairing immune checkpoints inhibitors with 
immunotherapy approaches therefore has the potential to enhance anti-tumour responses and 
therapeutic outcomes. In line with this, the expression of three main checkpoints molecules, PD1, TIGIT 
and TIM3, on the surface of tumour infiltrating NK cells was assessed using flow cytometry in order to 
evaluate the potential usefulness of including checkpoint inhibition in the therapeutic protocol. 
However, no significant differences in the expression of these molecules between animals that received 












Figure 6.15. Expression of immune checkpoint inhibitors by tumour infiltrating NK cells in untreated 
tumour-bearing animals and tumour-bearing animals treated with LD-Dox. Flow cytometry analysis of 
surface expression of TIM3, PD1 and TIGIT in tumour infiltrating NK cells (n=5). 
 
6.4 Summary   
Following proof from the in vitro studies showing that LD-Dox induce higher expression of ligands for 
activatory NK cell receptors, and enhance the sensitivity to NK lysis, the next step was to test this 
combination in vivo. We have established an orthotropic TNBC model, using the human cell line MDA-
MB-231/LUC/RFP. TNBC is an aggressive metastatic disease, it was then important to select a cell line 
that would spontaneously mimic these critical features of the disease. Multiple studies demonstrated 
the suitability of MDA-MB-231 cells  for application in preclinical models (Simmons et al. 2015; Minn et 
al. 2005; Arroyo‐Crespo et al. 2019). Moreover, luciferase activity in the cells, allow for in vivo 
monitoring and tracking of tumour progression and metastasis by bioluminescence imaging using the 
IVIS® system.  
Cells were allowed to grow until tumours were palpable, from that point animals received a two-cycle 
treatment, with LD-Dox three times a week and a single NK cell infusion the following week. Initial 
studies showed that LD-Dox combined with adoptive transfer of donor-derived NK cells significantly 
slowed the growth of tumours compared control animals that received either LD-dox alone or were left 
untreated. A significant impact on tumour weight was also observed for all studies, in animals receiving 
the combination treatment. The adoptive transfer of donor-derived NK cells into animals treated with 
an even lower dose of doxorubicin, 0.25 mg/kg also resulted in a significant delay in tumour growth. 
We next sought to determine the effect of adoptive transfer of donor-derived primary NK cells alone. 
Although the findings were not consistent with previous results, in regard to the overall tumour growth 
profile, there was an indication that tumour growth was slower in animals that received LD-Dox in 
combination with NK cells, than that in animals treated LD-Dox monotherapy or adoptively transferred 
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NK cells alone. Overall, with the exception of the last study presented, results indicated a synergistic 
effect of LD-Dox with NK cells in inhibiting tumour growth. 
 
In order to evaluate the therapeutic potential of combining LD-Dox with the adoptive transfer of the 
NK-92™ MI cell line and compare this to that using donor-derived NK cells. We used the NOD,B6.SCID 
Il2rg. А/А KitW41/W41 (NBSGW) mice, as it support engraftment of hematopeoetic cells without 
requiring myeloablative irradiation. However, some problems were encountered with this model as 
GvHD-like clinical symptoms were observed following the last NK-92™MI infusion, a possible indication 
of the high proliferation rate of the cells. Sub-lethal Irradiation of NK-92™MI cells was tested as a way 
to counteract the GvHD-like side-effects observed, by lowering their proliferation rate. NK-92™MI 
viability and cytotoxicity was tested after irradiation. The viability of irradiated NK-92™MI cells 
progressively decreased over 48 hours, on the other hand, their lysis potential 24 hours after irradiation 
was not affected. However, adoptive transfer of irradiated cells did not prevent the appearance of 
GvHD-like symptoms, but did delay their onset by 12 days (data not shown). One potential reason for 
this could be due to expansion of other cells from the PBMC, although NK cells injected were always 
>94% pure (CD3-/CD56+). There are some alternative models to prevent the appearance of the 
symptoms,  such as the NSG B2m, which has an MHC class I molecule (beta-2-microglobulin) deficiency. 
However these could still require pre-conditioning irradiation (King et al. 2009).  
 
As mentioned earlier, MDA-MB-231 tumours have the ability to spontaneously metastasize to distant 
organs. In Study 1, metastasis was delayed by 7 days in animals treated with LD-Dox alone compared 
to untreated animals, and no evidence of metastasis was apparent in animals that received LD-Dox and 
adoptively transferred donor-derived primary NK cells at the termination of the study on day 50.  
A delay in the onset of metastasis in animals receiving 0.25 mg/kg and 0.5 mg/kg doxorubicin in 
combination with adoptively transferred donor-derived, primary NK cells was also observed, with a 
longer delay being observed in animals treated with 0.25mg/kg doxorubicin. In regards to the effect of 
adoptive transfer of NK cells alone, although there was no significant delay in metastasis onset between 
the groups, ex vivo IVIS images and BLI quantification, indicate a difference in terms of the extent of 
metastasis spread, with the combination group presenting lower metastatic spread compared to 
control groups, even though here again it was not statistically significant. The difference was also more 




Labelling NK cells with VivoTrack 680 near infrared (NIR) fluorescent imaging agent prior to adoptive 
transfer allowed their tracking and comparison of their tumour infiltration with and without LD-Dox 
pre-treatment. Analysis of NK tumour infiltration using IVIS and flow cytometry showed that NK cell 
infiltration in tumours was higher in animals that were pre-treated with LD-Dox.  
 
Tumours were used for further mechanistic studies. First, the proliferation of tumour cells was assessed 
using the proliferation marker Ki67, tumours derived from the combination treatment group were 
found to express lower levels of Ki67 compared to control and LD-Dox alone groups. Expression of 
MICA/B ligands on tumour cells was also significantly higher than that on cells isolated from the 
tumours of control and LD-Dox alone animals. Furthermore, these cells were more sensitive to NK-92™ 
MI cell-mediated cytotoxicity in vitro.  LD-Dox alone and the combination treatment also reduced the 
number of EpCAM+/CD44High Cancer Initiating Cells (CICs) in tumours derived from treated mice.  
 
With the aim of evaluating the potential addition of checkpoint inhibitors to the combination 
treatment, the expression of PD1, TIGIT and TIM3, on the surface of tumour infiltrating NK cells was 
assessed using flow. However, there was no significant difference in the expression of these molecules 
















Chapter 7: Discussion  
 
Triple negative breast cancer (TNBC) is the most fatal form of breast cancer, due to its aggressive 
clinical features, very poor prognosis and the lack of targeted therapies (Palma et al. 2015). 
Although immunotherapy has shown great promise recently for various cancer types, breast cancer 
has been considered as being difficult to treat with immunotherapy due to its perceived poor 
immunogenicity and immunologically “cold” features. However, emerging evidence suggests that 
TNBC is the most immunogenic subtype of all breast cancers, because of chromosomal instability 
and increased mutational burden (Disis, Stanton 2015; Chokr, Chokr 2018). This enhanced 
immunogenicity means that patients with TNBC could benefit substantially from immunotherapy 
strategies and recent clinical studies with checkpoint inhibitors showed encouraging results for 
patients with TNBC. However, response rates remain very modest (Adams et al. 2017; S Adams et 
al. 2019; Schmid et al. 2018). 
Until recently, most immunotherapeutic approaches focused on adaptive immune cells, mainly T 
cells, leaving the potential of the innate arm of the immune system not fully addressed. NK cells are 
major effectors in tumour immunosurveillance. Their role and contribution in tumour control has 
been demonstrated in multiple studies. Indeed, in various cancers, the presence of tumour-
infiltrating NK cells is recognised as being a good prognostic marker (Souza-Fonseca-Guimaraes 
2016; Krasnova et al. 2017; Pasero et al. 2015; Hu et al. 2019b). To date, NK cell-based therapeutic 
approaches as monotherapies have delivered limited clinical success, particularly in the case of solid 
tumours, partly due to the profound immunosuppressive nature of the tumour microenvironment 
(TME) (Wagner et al. 2017; Kim et al. 2019; Chiossone et al. 2018b). On the other hand, it is now 
widely accepted that the most promising and effective cancer treatments are combinatorial 
strategies that integrate different treatment modalities and the aim of which is the induction of  a 
synergistic tumour response by targeting distinct elements of the tumour (Bayat Mokhtari et al., 
2017; Esteva et al., 2019; Schmidt, 2019). Therefore, it is crucial to identify and develop strategies 
that would improve NK cell-based therapy. 
Furthermore, there is a growing evidence that low-dose chemotherapy can activate the immune 
response, and chemo-immunotherapy treatment strategies aimed at targeting multiple aspects of 
tumour development and progression are under development (Muthusamy, 2016; Chen, Chang and 
Cheng, 2017; Kerbel and Shaked, 2017; Simsek, Esin and Yalcin, 2019). 
In this thesis, the effect of low-dose doxorubicin on the phenotype of breast cancer cells is 
described and the contribution of this treatment regime to the modulation of the sensitivity to NK 
cell lysis in vitro and in vivo is detailed. The results presented herein demonstrate that low-dose 
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doxorubicin impairs the proliferation of breast cancer cells and induces a more permissive 
phenotype to NK cell lysis. This supports the rationale for combining low-dose chemotherapy with 
NK cell based immunotherapy for TNBC.  
7.1 Low-dose doxorubicin as an approach to enhance the susceptibility of 
TNBC cells to NK cell lysis 
The activity of different chemotherapeutics at lower doses that the standard MTD used in the clinic 
has been investigated for cancer treatment, with the aim of reducing toxicities and 
immunosuppressive effects (Muthusamy 2016; Cazzaniga et al. 2017). Along with their well 
reported anti-angiogenic activity, multiple studies suggest that the administration of some 
chemotherapeutics at sub-lethal doses could trigger anti-tumour immunity by enhancing tumour 
cells immunogenicity and eliminating immunosuppressive cell populations (Zitvogel et al. 2008; 
Lake, Robinson 2005; Apetoh et al. 2008). These studies provide a rationale for using low-dose 
chemotherapy as a standalone or pre-conditioning treatment, as well as in combination with other 
agents. However, few studies have investigated the effects of combining low-dose metronomic 
doxorubicin with an adoptive NK cell-based approach. As mentioned previously,  one of the main 
studies reporting the effect of low-dose doxorubicin on enhancing the sensitivity of cancer cells NK 
cell killing was carried out by Wennerberg et al (Wennerberg et al. 2013). However, this study did 
not investigate this in the context of TNBC. 
7.1.1 Low-dose doxorubicin impairs the proliferation of breast cancer cells 
Clinical doses of doxorubicin lead to DNA damage as a consequence of its intercalation into DNA, 
which causes double-strand breaks and apoptosis in various tumour cells (Tacar et al. 2013b). 
However, these molecular mechanisms may vary depending on multiple factors such as tumour 
type and drug dose. Anti-tumour mechanisms of low-dose doxorubicin have been shown to include 
inhibition of tumour growth and spread through anti-angiogenic activity rather than apoptosis 
(Damber et al. 2006b). These inhibitory effects have also been shown to be associated with a state 
of senescence in some tumours (Rebbaa et al. 2003). Notably, as tumour progression is usually 
accompanied by resistance to apoptosis-based therapies due to accumulation of different defects 
in the apoptotic signaling pathways (Mori et al. 2004), approaches looking at alternatives to 
apoptosis-induction, such as anti-proliferative/senescence-targeted, could be more beneficial.   
The data presented in this thesis showed that low-dose doxorubicin treatment impaired the 
proliferation of breast cancer cells, as indicated by cell cycle arrest and lower Ki67 expression, in 
association with other features of senescence. Senescence is a state of terminal growth arrest 
which is thought to be a process of response to stress that could be triggered by different stimuli, 
including DNA damage, oxidative stress and chemotherapeutic drugs. Multiple anti-cancer 
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therapeutic strategies have been shown to induce cancer cell senescence, such as targeted 
strategies based on cyclin dependent kinases 4/6 inhibitors (Rader et al. 2013), but also 
immunotherapy (Braumüller et al. 2013b). Features of senescence observed here included the 
distinct, large and flattened morphology which has previously been described following treatment 
with low-dose doxorubicin, and which was reported to be associated to focal adhesion kinase 
activity (Cho et al. 2004) and upregulation of cell cycle regulators p16, p21, p53 along with SA-β-gal 
expression which have also been used as indicators of senescence (Wang, Dreesen 2018). 
Senescent cells also accumulate DNA damage markers. In this study, the DNA double-strand breaks 
biomarker γ-H2AX was used to detect DNA damage, and was only found to be upregulated in LD-
Dox treated TNBC cells (Kuo and Yang, 2008).  
Overall, these findings are in line with previous studies that reported that low-doses of doxorubicin 
induce cell cycle arrest and features of senescence (Kim et al. 2009; Bar-On et al. 2007; Lüpertz et 
al. 2010). However, it is important to note that the expression of these markers following LD-Dox 
treatment varied across the different cell lines tested, thereby indicating that response to low-dose 
doxorubicin could be cell line/subtype dependent. In this regard, multiple studies have revealed 
that different subtypes of breast cancer have very distinct gene expression profiles, different 
survival prognosis (Sotiriou et al. 2003; Sorlie et al. 2001) and respond differently to therapy. 
Rouzier et al, as well as Kim et al, reported that the basal-like TNBC and HER+ subtypes were more 
sensitive to neoadjuvant chemotherapy, including doxorubicin (Rouzier et al. 2005; Kim et al. 2010). 
Therefore, these observed differential effects of low-dose doxorubicin across the different cell 
lines, and the higher extent of response in TNBC cells, could be explained by mechanistic differences 
in sensitivity to chemotherapy across the subtypes. 
 
It was crucial to verify that the growth inhibitory effects of low-dose doxorubicin do not induce 
resistance to the MTD of doxorubicin. Results showed that cells remained sensitive to killing by 
higher doses of doxorubicin following low-dose doxorubicin treatment. 
7.1.2 Low-dose doxorubicin treatment enhances NK cell ligand expression by TNBC cells and 
their sensitivity to NK cell-mediated cytotoxicity  
NK cells play an important role in tumour surveillance and control. However, as reviewed in the 
introduction chapter, their potential is hindered by multiple immune escape mechanisms 
developed by tumour cells and features of NK cell dysfunction have been observed in multiple 
studies of cancer patients (Waldhauer and Steinle, 2008; Krneta et al., 2015; Vitale Gobbi et al., 
2015). Therefore, developing strategies that would circumvent NK immunosuppression could be 
game-changing for the development of effective NK cell-based therapeutics.  
118 
 
The first important/key aspect of NK cell cytotoxicity is the recognition of tumour cells, which is 
mediated by activatory receptors on NK cells that stimulate NK cell effector function upon 
interaction with cognate ligands on target cells. Results from the research programme described in 
this thesis show that low-dose doxorubicin treatment increased the expression of ligands for major 
NK cell activatory receptors (NKG2D, DNAM-1) in breast cancer cells, namely MICA/B, ULBP1/2/3 
and CD155. These findings were consistent with previous research showing that responses to 
cellular stress, such as that caused by metronomic-/low-dose chemotherapy, modulate the 
expression of NK cell ligands (Alessandra Soriani et al. 2009; Zingoni et al. 2017; Khallouf, Märten, 
Serba, Teichgräber, Markus W Büchler, et al. 2012). Sagiv et al have shown that the NKG2D ligands, 
MICA/B and ULBP2, mediated immunosurveillance of fibroblasts following the induction of 
senescence using low-dose doxorubicin (Sagiv et al. 2016). It has also been shown that metronomic 
chemotherapy upregulates the expression of NKG2D ligands on melanoma cells (Hervieu et al., 
2013). Although the exact mechanisms which lead to this upregulation remain largely unknown, 
much evidence points toward the central role of the DNA damage response pathway (Gasser et al. 
2005b; Zingoni et al. 2017). 
The NKG2D receptor-ligand interaction is a key activating pathway for NK cell function (Morisaki et 
al. 2012a). Thus, MICA and MICB are at the center of treatment approaches designed to enhance 
NK cell targeting towards tumour cells (Cheng et al. 2011; Morisaki et al. 2012b; Fionda et al. 2015b; 
Lupo, Matosevic 2019). These ligands are normally of low abundance and their shedding represents 
one of the main escape mechanisms to NK cell immunosurveillance (Bryceson et al. 2009; 
Malmberg et al. 2017b). Studies have sought approaches to prevent tumours from shedding these 
ligands and fix them onto the surface of tumour cells, thereby enabling NK cells to identify target 
cells for elimination. In this regard, in contrast to enhancing their expression at the transcriptional 
level, a recent creative approach to tackle this was presented by Ferrari de Andrade et al, using an 
engineered monoclonal antibody (mAb) directed against the specific region of their extracellular 
domain subject to proteolytic shedding by MMPs and ADAMs cleavage, without disturbing NKG2D 
receptor binding. The application of this mAb greatly reduced tumour burden in a mouse model of 
metastatic  melanoma after the administration of human NK cells (Ferrari de Andrade et al. 2018). 
The upregulation of activatory ligands expression demonstrated in this thesis resulted in an 
increased sensitivity to NK cell-mediated killing. Indeed, low-dose doxorubicin treatment rendered 
cells significantly more sensitive to killing by primary donor-derived NK cells as well as NK-92™ MI 
cell line when compared to untreated cells. This was true for all cell lines tested, with the exception 
of SKBR3 cells for which, although ligands for activatory NK cells were upregulated, killing efficiency 
was not significantly enhanced. These results pointed again to the differential response across 
breast cancer subtypes. SKBR3 represent the HER2 subtype of breast cancer, as it overexpresses 
the Her2 gene product. Our findings were particularly surprising as previous research has suggested 
119 
 
the permissive behaviour of HER+ breast cancer to NK cell lysis (Finak et al. 2008). However, it is 
likely that for these cells the upregulation of this ligand combination was not sufficient for inducing 
NK cell adhesion and subsequent activation. Indeed, adhesion and synapse formation are central 
to NK cell lysis. This level of NK cell regulation that precedes lysis of target cells was not explored 
here, but deserves further investigation. Expression levels and signalling by LFA1 and ICAM-1 could 
help further characterise the effect of low dose doxorubicin treatment on NK-target cell contact 
and synapse formation (Bryceson et al. 2009; Long et al. 2013). Of note, in their study, Wennerberg 
et al, pointed towards a TRAIL-dependent mechanism for the enhanced NK cell lysis, as opposed to 
an NKG2D or DNAM-1 pathway. However, as mentioned earlier this has not been tested on the 
same cell lines used for this study (Wennerberg et al. 2013). 
Additionally, NK cell activation and proliferation are influenced by the local cytokine milieu. When 
NK cells are pre-activated with cytokines, such as IL-2, IL-12, IL-15, IL-18, and IL-21 which are 
commonly used in immunotherapeutic approaches, they show enhanced cytolytic activity and 
cytokine production (Guillerey et al. 2016b; Morvan, Lanier 2016). In line with that, IL-2 stimulation 
greatly enhanced NK cell-mediated cytotoxicity against cells treated with low-dose doxorubicin. 
Further functional analysis can be achieved by measuring degranulation and cytokine production. 
Upon contact with target cells, cytolytic granules, containing perforin and granzyme are secreted 
onto the surface through the cytolytic synapse, this process is highly focused and tightly regulated 
towards target cells. In degranulation and intracellular cytokine experiments, the exposure of NK-
92™ MI cells to MDA-MB-231/LUC treated with low-dose doxorubicin increased their expression of 
the degranulation marker CD107a, granzyme B, perforin and IFN-γ. Another commonly reported 
characteristic of dysfunctional NK cells in cancer is the reduced secretion of effector cytokines and 
degranulation (Fang et al. 2018). Thus, these results further support the proposition that low-dose 
doxorubicin positively modulates NK cells toward an enhanced targeting of tumour cells.  
From a therapeutic perspective, one of the questions that needed answering was the impact that 
doxorubicin might have on NK cells. In this context, we demonstrated that exposure of NK-92™ MI 
cells to the low-doses of doxorubicin had no effect on their viability or expression of activation 
receptors (NKG2D and NKp30). This was also shown by Soriani et al., in the case of multiple 
myeloma (Soriani et al. 2014b). 
7.2 Low-dose doxorubicin modulates important cancer-relevant pathways 
in TNBC cells 
The tumourigenesis of breast cancer is a complex, multi-step process. Understanding factors of 
tumour cell proliferation, tumourigenesis and aggressiveness is crucial in designing therapeutic 
strategies. In order to gain a better understanding of the effect of the signaling molecules and 
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pathways that are affected by low-dose doxorubicin treatment, and define the mechanisms 
underlying the acquired susceptibility of breast cancer cells to NK cell killing as a result of low-dose 
doxorubicin treatment, we have performed gene expression analysis comparing low-dose 
doxorubicin treated and untreated cells. As the focus of this study is TNBC, the two cell lines MDA-
MB-231 and MDA-MB-468 were used, added to which was the luminal A cell line MCF7 in order to 
compare any differential effect of the treatment between the two different cancer subtypes. This 
is important given that the immunogenicity of breast cancer is subtype dependent, as previously 
mentioned, with TNBC being the most immunogenic and luminal A the least immunogenic (Bates 
et al. 2018; Hammerl et al. 2018).  
An initial interrogation of gene expression signatures defined the deregulated pathways in response 
to treatment. Relatively similar results were found for the two TNBC cell lines, for which the most 
affected pathways were DNA-damage repair and cell cycle apoptosis. This was expected because 
of the previously described mode of action of doxorubicin. Indeed, regulation of the cell cycle is 
one of the main mechanisms behind anti-proliferation effects of many chemotherapeutic drugs in 
cancer cells (Vermeulen et al. 2003a). In response to DNA damage, the cell cycle is delayed or 
arrested by DNA damage checkpoints (Knudsen et al. 2019a; Cai, Liu 2017; Vermeulen et al. 2003b). 
These mechanisms involve the activation of the p16-Rb (retinoblastoma) and/or p53-p21 pathways. 
Although ATM and ATR were both downregulated, an upregulation of p53 transcriptional target 
p21 was observed, as was observed using flow cytometry. p21 inhibits cyclin-dependent kinase 2 
(CDK2) and activates Rb to prevent entry into cell cycle (El-Deiry 2016; Knudsen et al. 2019b). 
Recently early p21 expression was  reported to control the proliferation versus senescence decision 
of cells following chemotherapy (Hsu et al. 2019) .On the other hand, p16 was also found 
upregulated in TNBC cells, which is reflected in these data by the downregulation of CDK4 (Sherr et 
al. 2016). Cyclins are an important inhibitory factor at the G2/M phase; (Pyo et al., 2013). Our 
data show that low dose doxorubicin treatment downregulated the expression of different Cyclins, 
along with upregulation of p21 consequently inducing cell cycle arrest. This was in line with the cell 
cycle analysis (Chapter 3) results indicating a G2/M cell cycle arrest.  This also concords with the 
data demonstrating NKG2D ligand upregulation (Chapter 4), as previous studies reported that the 
DNA damage pathway played a central, direct role in the process of NKG2D ligand upregulation 
(Gasser et al. 2005b; Alessandra Soriani et al. 2009).  
The lack of targeted therapies for TNBC motivated multiple genomic studies to identify the central 
signaling pathways to TNBC progression, and thus potential targeted therapies. The main pathways 
investigated for TNBC therapies include VEGF, EGFR, NOTCH, CDK, mTOR and PI3K (Mayer et al. 
2014; Bayraktar, Glück 2013). However, it is worth noting that the exact mechanisms by which 
breast cancer arises, as well as the related clinical responses, remain poorly defined/largely unclear. 
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Interestingly, NOTCH and EGFR pathways were among the highly deregulated pathways, as 
indicated by the advanced analysis carried out using Metcore software. An overview of the 
enrichment analysis for the NOTCH pathway is presented in Figure 6.1.   
There is ample evidence that Notch signalling plays a critical role in breast cancer growth, Epithelial 
to Mesenchymal Transition (EMT), invasion and metastasis. In TNBC, Notch signalling is hyper-
activated as a result of combination of elevated levels NOTCH1 receptor protein, NOTCH1 precursor 
mRNA and NOTCH2 protein along with their ligands Jagged1 and Jagged2 (Giuli et al. 2019; Sethi et 
al. 2011; L. Li et al. 2014). This high Notch activity has been reported to be associated with 
chemoresistance, aggressive disease and decreased overall survival rate of patients with TNBC 
(Leontovich et al. 2018). Therefore, inhibition of Notch signalling has been considered for TNBC 
treatment and multiple pan-Notch inhibitors are currently under clinical trials (Bellavia et al. 2018; 
McGowan et al. 2011; Giuli et al. 2019). 
An overall downregulation of these effectors can be observed in treated cells. Although Notch3 was 
found upregulated in MDA-MB-231 cells (Chapter 3), this was associated with cell cycle arrest in 
these cells, and is linked with its role as a tumour suppressor, as a significant decreased of Notch3 
was reported in breast tumour tissues compared to normal tissues (Cui et al. 2013; C.-F. Chen et al. 
2016). Indeed, previous research also pointed toward the individuality of Notch receptors function, 
as they can have opposite roles in the context of TNBC (Giuli et al. 2019).It is mainly for this reason 
that experimental studies looking at Notch-based therapies are challenging (Giuli et al. 2019). 
These results also support the data generated from the most differentially expressed genes 
following low-dose doxorubicin treatment (Chapter 5) which shows that several genes involved in 
tumour survival, progression and metastasis were downregulated in treated TNBC cells. Of note, 
VEGF is also downregulated in both TNBC treated cells (Figure 7.1) along with beta-catenin, thereby 
further confirming the capacity of low dose doxorubicin treatment to inhibit EMT and invasion. 
Some differences between the two TNBC cell lines were observed. However, this was not 
unexpected as even within the same subtype, the response of TNBC to chemotherapy may vary 
(Gautam et al. 2016). It is also crucial to keep in mind here the seminal work of Lehmann et al., 
which showed that TNBC can be clustered into six types based on gene expression, as previously 
described in the introduction chapter (Lehmann et al. 2011b). As previously mentioned, MCF7 cells 
showed contrasting results compared to TNBC cells, thereby endorsing the differential responses 
between breast cancer subtypes. Future studies should also analyse pathway deregulation and 
gene expression changes in low dose doxorubicin treated SKBR3 cells, as these were found to be 






Figure 7.1. Enrichment analysis of mRNA for NOTCH Signaling Pathway. Enrichment analysis of 
NOTCH pathway, as analysed using MetaCore software. Upward thermometers indicate up-
regulated signals (red) and downward (blue) indicate down-regulated expression levels of genes. 1: 







7.3 Therapeutic potential of combining low dose doxorubicin and adoptive 
transfer NK cells for TNBC 
The data presented in Chapter 4 demonstrated the immunomodulating effects of a single low-dose 
of doxorubicin in vitro in terms of upregulating NK cell ligands and sensitising breast cancer cells to 
NK cell-mediated cytotoxicity. Next, it was crucial to investigate the anti-tumour effect of 
metronomic doxorubicin in combination with NK cell adoptive transfer in vivo. 
 
Establishing the tumour model and effects on tumour growth 
Preclinical studies are important and essential for translation of therapeutic approaches into the 
clinic, and experimental mouse models represent a key tool to test and validate anticancer 
therapeutics. In order to perform in vivo experiments that would be relevant to the treatment 
strategy proposed herein, we established a TNBC xenograft model that would enable the analysis 
of adoptively transferred NK cells.  As mentioned previously, in this study, NSG mice represented a 
suitable strain to carry out these experiments. However, we reported issues encountered when 
using the NK-92™ MI cells with both the NSG and NBSGW mice models. Also, sub-lethal irradiation 
of the cells only delayed the onset of the reported GvHD-like symptoms, this highlights the necessity 
for preconditioning irradiation of the animals prior to NK cell infusion. Along with inhibition of 
GvHD-like symptoms, a better engraftment has been reported when mice are given a low dose total 
body preconditioning irradiation (250cGy) prior to NK cell infusion (Jeffrey S. Miller et al. 2014).  
Overall, studies provided evidence of the synergistic effect in vivo of NK cells with low-dose 
doxorubicin treatment in terms of tumour growth inhibition (with the exception of Study 4). Of 
note, variations in NK cell cytotoxicity across individual donors which have been previously 
observed and reported (Nagel et al. 1981; Pasero et al. 2015) could partly explain the variability 
between studies. However. one of the limitations of this model is the lack of the adaptive immunity 
component and future studies would benefit from investigating the effects on a model including 
both, especially given that low-dose doxorubicin treatment has been shown to influence the 
susceptibility of tumour cells to T cells (Wennerberg et al. 2013). The use of an immunocompetent 
model would also deliver useful information to evaluate the efficacy of the proposed combination 
therapy. The use of patient-derived xenografts would also enhance this model, as although cell line 
derived tumour models provide a useful tool for testing immunotherapies for cancer, patient-
derived xenograft model are superior since they more closely mimic the clinical setting (Murayama, 
Gotoh 2019). 
 
One challenge of NK cell therapy is how to optimize the effector-to-target ratio dose that is critical 
for cytotoxicity and ultimately clinical efficacy. One of the limitations encountered in this study was 
the availability of healthy blood donors. It is technically challenging to gather a sufficient amount 
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of NK cells from the blood of healthy donors, as they only make up to 10% of lymphocytes.  The 
dose of 10x106 NK cells was given twice in total for the whole duration of treatment. Further studies 
would benefit from optimizing the cell dose of NK cells, but also from the use of blood cones from 
NHS Blood and Transplant or in vivo expansion strategies to increase NK cell numbers and/or 
infusion frequency.  
Indeed, preclinical studies have suggested that the prolonged treatment with NK cells was 
important, moreover, IL-2 activation has also been reported to be essential for optimizing cytotoxic 
effects (Jeffrey S. Miller et al. 2014; Miller, Lanier 2019; Lehmann et al. 2001). Although the idea is 
to provide competent, activated NK cells to the patient through NK adoptive transfer therapy, it is 
important to consider the immunosuppression that these NK cells will be subjected to in the tumour 
microenvironment (TME). To encounter this, NK cells may require further activation with cytokines 
following infusion. In this regard, the use of the NK-92™ MI cell line is very attractive. NK-92™ MI 
cells constitutively secrete low levels of IL-2, which allows for better activation of the cells without 
the toxicity that may be associated with a systemic administration of IL-2 (Tam et al. 1999; Zhu, Li, 
et al. 2017). Furthermore, the suitability and safety of the adoptive transfer of these cells with 
regard to viral safety aspects is not an issue, as their transfection was based on a non-viral gene 
transfer (i.e. particle-mediated gene gun) (Tam et al. 1999; Zhu, Li, et al. 2017). 
It is worth noting, that the timing of NK cell infusion is also important, as in pre-clinical studies using 
the aggressive melanoma cell line (WM1341) it has been reported that infusion of NK cells was only 
efficient when they were administered shortly before, simultaneously with or shortly after tumour 
cells (~24h) (Hölsken et al. 2015). In the present study, it was important to us to treat established 
tumours, rather than start the treatment right after injection of tumour cells, however, as reported 
in previous studies, the doses and timings of treatments might not have been optimal to generate 
the maximum NK cell response and thus clear tumour regression in such a complex experimental 
setting. 
 
Effect on metastasis 
The ability to prevent and/or treat metastasis is crucial as it is the leading cause of death in TNBC. 
Our results suggested that treatment delayed metastasis on the basis of whole body imaging. 
Another indicator of metastatic potential is the presence of circulating tumour cells (CTCs) in the 
blood, and for one of the studies, blood from mice that received the combination treatment 
contained lower proportions of circulating tumour cells (hCD45-/HLA+) (Data not shown). 
Murine models for cancer therapies have been dominated by treating established primary tumours 
or early stage, low volume microscopic disease. Although this is clearly important for the 
development of therapeutics, models for treating advanced metastatic disease also have immense 
125 
 
value, especially gibven that ~90% of cancer-related deaths are a consequence of advanced, 
aggressive and metastatic forms of disease (Francia et al. 2011). In this study, we tried to more 
closely mimic the clinical setting by resecting the primary tumours, however we encountered 
technical difficulties in doing so. Notwithstanding this, future studies should optimise this approach, 
as demonstrating the effect of the combination treatments on metastatic disease would be of 
immense value for their clinical translation.  
 
Effect on tumour Infiltration  
Another important indication of the potential of this combination is the infiltration of NK cells in 
tumours, as mentioned earlier, NK cell trafficking and infiltration into solid tumours is one of the 
main challenges of NK cell cancer immunosurveillance and NK adoptive cell transfer (Nayyar, Chu, 
Mitchell S Cairo 2019; Gras Navarro et al. 2015). Results showed that low-dose doxorubicin 
treatment increased NK cell infiltration into tumours, and is consistent with previous studies which 
have shown metronomic chemotherapy to enhance immune cell infiltration (Moschella et al. 2011; 
Sistigu et al. 2011; Nars, Kaneno n.d.; Wu, Waxman 2018; Simsek et al. 2019a).  
In this study, NK cell infiltration was assessed by IVIS imaging and flow cytometry, staining of 
tumour sections would have also been useful to have a detailed information about the localisation 
and density of NK cell infiltrates. However, although there was evidence of enhanced NK infiltration 
in animals pre-treated with low-dose doxorubicin, along with higher expression of MICA/B ligands 
on the surface of tumours, in this particular study (Study 4) it did not translate into significant 
tumour control. This suggests that NK cells infiltrating tumours are not fully activated or functional. 
Of note is that although NK cells were pre-activated with IL-2 prior to their infusion, they did not 
receive any cytokines while they were in vivo, this could have translated into enhanced activation 
and function of NK cells, as reported by multiple studies (Lim et al. 2015; Zwirner, Domaica 2010b; 
Rezvani, Rouce 2015). Furthermore, it has previously been reported that although infusion of ex 
vivo activated NK cells by IL-2 generated high numbers of circulating NK cells, no effect was 
observed, as the transferred cells rapidly lost their activation in vivo, however, re-activation of the 
cells with IL-2 led to clinical benefit in a cohort of patients with metastatic melanoma or renal cell 
carcinoma (Parkhurst et al. 2011b). 
   
Impaired proliferation of tumours  
One of the most reliable, and clinically used indicators of the proliferative status of tumours is the 
expression of the proliferation marker Ki67. Various studies have reported its close association with 




Tumours from mice that received low-dose doxorubicin alone or the combination treatment 
showed significantly lower expression levels of Ki67. This was in line with our in vitro data, but also 
with previous preclinical studies using low-dose metronomic chemotherapy. In a study by Di 
Desidero et al., the number of Ki67 positive cells in tumours obtained from LDM topotecan plus 
pazopanib-treated mice was 48% lower than that found in the control group (Di Desidero et al. 
2015). Similarly for clinical studies, the expression of Ki67 after treatment was decreased by 41%, 
and 91% of the patients had complete pathological response (Cancello et al. 2015). 
 
Effect on Cancer Initiating Cells (CICs) 
One interesting aspect of both metronomic therapy and NK cell therapy is their potential to target 
Cancer Initiating Cells/Cancer Stem Cells (CICs/CSCs) (Murphy Urayama et al. 2019; Chan et al. 
2016). Indeed, a recent study demonstrated the capacity of adoptively transferred NK cells to 
reduce intra-tumoural CSCs and tumour burden in a pancreatic carcinoma xenograft model 
(Murphy Urayama et al. 2019). This led us to investigate the effect on the proportion of CSC/CICs 
in tumours following treatment. Results showed that both LD-Dox and LD-Dox+pNK cell 
combination treatment reduced the proportions of CICs in tumours. Of note, in vitro studies also 
confirmed the effect of low-dose doxorubicin treatment on MDA-MB-231/LUC sphere formation 
ability (data not shown), this is particularly interesting in the context of TNBC, as TNBC tumours are 
known to be enriched for CICs (O’Conor et al. 2018), and a strategy able of eliminating this 
population would have immense potential in inhibiting tumour progression and metastasis.  
7.4 Aspects and considerations for clinical translation  
The clinical translation of anti-cancer therapeutics is a complex and challenging process, particularly 
when it comes to combination strategies that involve and affect different aspects of the tumour 
and its microenvironment. In this section, the main aspects and considerations related to the 
potential implementation of the therapeutic strategy proposed in this thesis, namely the 
combination of LD-Dox metronomic chemotherapy and adoptive transfer of NK cells will be 
discussed.   
7.4.1 The choice of the chemotherapeutic agent, route of administration and schedule 
With regards to the first arm of this combination (LD-Dox), essential design criteria need to be taken 
into consideration, such as the choice of the chemotherapeutic agent, route of administration and 
schedule. Although multiple chemotherapeutics have been investigated for their 
immunomodulatory potential, until now no ‘ideal’ chemotherapeutic partner for immunotherapy 
has been identified (Shurin et al. 2012; Wu, Waxman 2018; Sheng Sow, Mattarollo 2013). With this 
in mind, and although the use of doxorubicin has many advantages in this setting, as previously 
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described, better agents may be available and their use in this context should be taken into 
consideration. One of the main challenges with clinical translation is the length of time that it might 
take to get from preclinical testing to the clinic, and this is in part affected by the choice of the drug. 
For example, using chemotherapeutics that have been FDA-approved already would much likely 
have a faster timeline to get to the clinic compared to novel, complex drugs that are yet to gain 
regulatory approval. In this regard and as previously discussed, the advantage of doxorubicin is that 
is already has a broad spectrum of applications in the clinic. As metronomic chemotherapy is based 
on the frequent administration of the drug, generally daily or weekly, the most convenient route of 
delivery would be oral administration. Although in the present study, we have used doxorubicin as 
an injectable solution (i.p injections) it does exist in an oral form, and different nanocarriers have 
been used to improve its absorption and efficacy. Among these, liposomes have shown encouraging 
results for doxorubicin delivery, such as the Pegylated liposomal doxorubicin (Doxil® or European 
trademark Caelyx®) which prolongs circulation time and has a very low toxicity profile (Gabizon 
2001). Multiple liposomal doxorubicin formulations, including given in a metronomic fashion have 
shown encouraging results in terms of safety and efficacy (Munzone et al. 2010; Manso et al. 2013; 
Masci et al. 2013). Thus, future studies in the context of this combination treatment, should 
consider the use of liposomal doxorubicin.  
 
Very few data regarding the right dose and schedule of the different drugs to be used in the 
metronomic administration are available. This is mainly due to the lack of predictive biomarkers for 
response to metronomic chemotherapy. However, several preclinical studies have highlighted the 
dose and schedule dependency of the immune modulatory effects associated with metronomic 
chemotherapy. For instance, Cyclophosphamide, one of the most commonly used 
chemotherapeutics in metronomic clinical trials (K. Lien et al. 2013; Simsek et al. 2019a), has been 
shown to induce transient innate immune responses in a model of glioma when given on an MTD 
schedule, whereas sustained immune responses and regression of tumours were observed when 
using a metronomic schedule (Chen et al. 2014; Wu, David J Waxman 2014). In their seminal paper, 
Shaked et al, looked at the determination of the optimal biologic dose (OBD), which was defined as 
the dose able to cause maximum reduction in tumour volume with no or minimal toxicity, as 
determined for 4 chemotherapeutics, and this OBD was associated with an enhanced anti-
angiogenic activity (Shaked et al. 2005). Some studies rely on mathematical models to determine 
the optimal dose and schedule for administering the drug (Ledzewicz, Schättler 2017). Overall, for 
a combination of low-dose chemotherapy and immunotherapy to be effective, the dose of the 
chemotherapeutic agent needs to be high enough for inducing the immunomodulation effects and 
lower than the threshold dose that induces toxicity. As mentioned previously, the dose and 
schedule of doxorubicin used in this study was based on encouraging results reporting its use as 
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monotherapy or combination with other chemotherapeutics. Interestingly, a lower dose of 
doxorubicin assayed was also able to inhibit tumour growth.  However, as it is in the context of 
combination with immunotherapy, pre-clinical studies looking at the optimisation of the dose and 
schedule of doxorubicin should be carried out, and these should be based on responsiveness to NK 
cell anti-tumour immunity.  
7.4.2 NK cell-adoptive transfer  
The second element of the proposed combination treatment is the adoptive transfer of NK cells. 
Essential considerations relating to the adoptive transfer of NK cells in patients with TNBC include 
source, manufacture and activation/enhancement of NK cells. 
 
Source and manufacture of NK cells 
As reviewed in the introduction chapter, there are different source options for NK cells. Along with 
autologous or allogeneic PBMC-derived NK cells, which are usually used for adoptive transfer of NK 
cells, induced pluripotent stem cells (iPSCs), cord blood (UCB) and NK cell lines are also important 
cell sources for NK immunotherapy. Infusion of the human NK-92 cell line shows remarkable anti-
tumour effects in preclinical studies and clinical studies have demonstrated its safety in cancer 
patients (Klingemann et al. 2016; Tonn et al. 2013c). Although multiple studies have reported a 
superior cytotoxicity of NK-92™ cells towards various tumour targets compared to primary NK cells 
(Tonn et al. 2001; Suck et al. 2016), our in vitro and in vivo data did not necessarily reflect that, and 
because of the issues encountered with the use of NK-92™ MI cells, we focused on the use of 
primary NK cells. However, we still think that NK-92™ cells offer a viable option for use in this 
combination treatment and should be further investigated in appropriate pre-clinical models.  
As discussed earlier, the variable efficacy/cytotoxicity of NK cells across individual donors need to 
be taken into account. For this, some studies proposed the use of predicted donor selection models, 
considering KIR-MHC class I mismatches (W. Wang et al. 2017). However, further characterisation 
of response biomarkers are needed. Moreover, expansion methods should be evaluated to provide 
sufficient numbers of NK cells. 
 
Improving target recognition, NK cell homing and tumour infiltration 
In addition to enhancing tumour target recognition, one of the main desired outcomes of this 
combination treatment was to better target NK cells to tumours. In fact, the migration and homing 
of NK cells to the tumour site is critical and essential to its success in inducing tumour control upon 
adoptive transfer. Tumour infiltration of NK cells in cancer patients is associated with good 
prognosis in multiple tumours (Coca et al. 1997; Ishigami et al. 2000; Jeffrey S. Miller et al. 2014). It 
also represents one of the main challenges NK adoptive transfer therapy has been encountering in 
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its clinical application to solid tumours (Jeffrey S Miller et al. 2014; Fang et al. 2018).  Over the years, 
different approaches have been used to enhance tumour targeting by NK cells and overcome 
immunosuppression, such as administration of cytokines or antibodies, enhancement of tumour-
specific chemokine receptor expression on NK cells or genetic engineering (Zhang et al. 2019; 
Wennerberg et al. 2015; Nayyar, Chu, Mitchell S Cairo 2019). In this context, CAR NK-92™ MI cells 
could further enhance tumour targeting. Indeed, pre-clinical studies have already shown the 
efficacy of CAR NK-92™ cells (Romanski et al. 2016), and multiple clinical studies are ongoing (Zhang 
et al. 2019; Zhang et al. 2017). 
 
The overall efficacy of this combination could also be enhanced by introducing an immune 
checkpoint blockade. There was no differential expression in PD1, TIM3 and TIGIT expression on NK 
cells from tumours treated with the combination, however the expression of other immune 
checkpoint molecules could be investigated. Additional combination strategies could involve the 
blockade of inhibitory pathways, such as KIR receptors or NKG2A. Indeed, blocking of NKG2A has 
previously been shown to enhance both NK cell and CD8+ T cell effector functions (André et al. 
2018). Interestingly, low-dose chemotherapy has also been shown to overcome tumour resistance 
to immune checkpoint inhibitors (Dosset et al. 2018; Pfirschke et al. 2016; Rivera Vargas, Apetoh 
2019). 
7.4.3 Effects and interaction with other components of the immune system and the tumour 
microenvironment 
Low-dose metronomic chemotherapy is a multi-targeted therapy, and although the focus of the 
research programme described in thesis and treatment combination proposed is on NK cell-based 
immunotherapy, one important aspect to consider is the effect of low-dose doxorubicin on the 
adaptive immune response and the tumour microenvironment. Some chemotherapeutic drugs, 
including doxorubicin and cyclophosphamide, can contribute to the induction of T cell-dependent 
anti-tumour responses and modulation of the tumour microenvironment. (Nars and Kaneno, 2011; 
Sistigu et al., 2011; Lien et al., 2013; Hao et al., 2014; Wu, Jordan and Waxman, 2016; Wu and 
Waxman, 2018; Simsek, Esin and Yalcin, 2019b). For instance, a combination of doxorubicin and 
lapatinib has been shown to enhance the infiltration of IFN‐γ secreting CD4+ and CD8+ T cells into 
the mammary tumours of mice bearing HER2+ breast cancer and this to result in improved anti-
tumour responses (Hannesdóttir et al. 2013). On the other hand, as reviewed in the Introduction 
chapter, although NK cells are a part of innate immunity, they contribute to adaptive immune 
responses either indirectly by influencing adaptive cells or directly by the release of cytokines. In 
addition, they can adopt a memory phenotype which allows a stronger response to a previously 




One possible hurdle that could be encountered is the possibility of tumours to develop resistant 
clones to low-dose doxorubicin. Although in vitro studies showed that low-dose doxorubicin did not 
induce resistance to MTD, this should also be tested in vivo. With this in mind, the different 
strategies proposed earlier to enhance the anti-tumour effects should be taken into consideration 
in order to minimise the risk of resistance. Additionally, another aspect that needs to be considered 
is the effect on the host microbiota, as chemotherapy was shown to impact gut microbiota and with 
the ever-growing body of evidence linking the microbiome to the efficacy of cancer therapies 
(Zitvogel et al. 2015; Viaud et al. 2013; Pouncey et al. 2018). 
7.5 Therapeutic implications and concluding remarks  
Despite its general sensitivity to standard chemotherapy, TNBC is considered as the most 
“aggressive” form of breast cancer. Unresponsiveness to current treatment makes the 
development of novel therapeutic strategies an urgent priority.  In recent years, the encouraging 
outcome of immunotherapy and the emergence of synergistic combination strategies generated 
high expectations. Although identifying clinically successful combinations of immunotherapy with 
low-dose metronomic chemotherapy is a challenging task, it has tremendous potential for cancer 
treatment. The ultimate aim is the development of a strategy capable of increasing tumour 
immunogenicity and NK cell homing in the tumour bed, while reducing tumour burden and 
minimising toxicities and side effects. 
In this study, we report for the first time to our knowledge, the potential for combining low-dose 
doxorubicin with the adoptive transfer NK cell as a treatment for TNBC treatment. In vitro studies 
demonstrated that low-dose doxorubicin impairs the proliferation of TNBC cells, enhances their 
sensitivity to NK cells and modulates important cancer-relevant pathways. In vivo studies 
demonstrated the capacity of the combined treatment to control tumour growth, enhance NK cell 
infiltration into tumours as well as delay/inhibit metastasis and reduce the prevalence of cancer 
initiating cells. The optimal timing and dosing, along with potential combinations with other agents 
to achieve therapeutic efficacy must be carefully considered in future studies. 
These findings expand upon the potential of NK cell-based immunotherapeutic approaches 
currently in clinical trials and offer a rationale for a new clinically translatable approach based on a 




8. Appendix  
 
8.1 Cell culture media, reagents and products 
 
                             Product Source 
Media 
alpha-MEM  ThermoFicher scientific 
EMEM SLS (Lonza) 
 Leibovitz media (L-15)                 SLS (Lonza)  
McCoy’s 5 SLS (Lonza) 
RPMI 1640  SLS (Lonza)  
RPMI1640                             SLS (Lonza) 
Supplements and reagents 
2-mercaptoethanol  Sigma  Aldrich 
Acetic acid  Fisher Scientific  
Anhydrous ethanol  Sigma Aldrich 
Dimethyl sulfoxide (DMSO)  Insight Biotechnology  
Dulbecco’s phosphate buffered saline (DPBS)  SLS (Lonza)  
EDTA 0.5M  Ambion  
Foetal calf serum (FCS)  Fisher (GE Healthcare)  
Folic acid Sigma Aldrich 
Human IL-2 Peprotech 
Inositol  Sigma Aldrich 
L-Glutamine  SLS (Lonza)  
Matrigel ECM Sigma Aldrich 
Pen/strep antibiotic solution  SLS (Lonza)  
Phosphate buffer saline (PBS)  BioWhittaker Europe  
Trypan Blue solution 0.4%  Sigma  Aldrich 
Trypsin/Versene  SLS (Lonza)  
Products 
0.22 μm syringe filter  Sartorius  
0.45 μm syringe filter  Sartorius  
24-well flat-bottom with lid – Standard TC  Sarstedt 
5 ml round-bottom polypropylene test tubes  Tyco healthcare group  
6-well flat-bottom with lid – Standard TC Sarstedt 
70 μm nylon strainer  Greiner  
96-well flat-bottom with lid – Standard TC  Sarstedt 
Cell culture flasks (T25,T75,T175)  Sarstedt 
Coverslips  SLS  
Cryovial, 2 ml sterile  Sarstedt 
Cryovials  TPP  
Eppendorf tubes (0.5 ml, 1.5 ml, 2 ml)  Sarstedt 
Falcon tubes  (15 ml,50 ml)  Sarstedt 
Filter tips (10, 20, 100,200, 1000 μl)   Greiner bio-one    
Leucosep® tubes Greiner Bio-One 
Micro tips (0.5-10 μL, 20-200 μL, 200-1000 μL)  Sarstedt 
Multichannel pipette  Sartorius  
Pasteur pipettes  Sarstedt 
Petri dishes  Sarstedt 
Pipettes (5mL, 10mL, 25mL)  Sarstedt 
Serological pipettes  Sarstedt  
Syringes (10ml,20ml)  Becton Dickenson  




8.2 Kits  
8.3 Antibodies  
                     Product         Source 
EasySep™ Human NK-Cell Isolation Kit StemCell technologies 
RNAqueous™-micro total RNA-isolation kit         Ambion™, Life    Technologies 
Nanostring  PanCancer Pathways Panel kit Nanostring Technologies 
FcR Blocking Reagent  Miltenyi Biotec  
LIVE/DEAD™ Fixable Violet Dead Cell Reagent  (1μ in 1ml) ThermoFisher Scientific  
LIVE/DEAD™ Fixable Yellow Dead Cell Reagent (1μ in 1ml) ThermoFisher Scientific 
OneComp eBeads Compensation Beads  ThermoFisher Scientific  
Intracellular Fixation & Permeabilization Buffer Set eBioscience™ 
PerFix-nc assay kit  Beckman Coulter 
Vivotrack680 Perkinelmer 
CellVue™ NIR780 cell labelling kit Affymetrix-eBioscience 
Antibody Fluorochrome  Volume μL/tube  
 
    Clone Manufacturer 
Senescence DNA-Damage markers  
p21 Alexa Fluor 700 5 μl WA-1 (HJ21) Novus Biological 
p16 Alexa Fluor 647 5 μl EPR1473 Abcam 
P53 FITC 5 μl DO-7  Biolegend 
H2A.X PerCP/Cy5.5 5 μl 2F3   Biolegend 
Ki-67 PE/Cy7 5 μl Ki-67   Biolegend 
Notch 3 PE 5 μl MHN3-21   Biolegend 
NK cell ligands  
CD48 Alexa Fluor 700 2.5 μl HM48-1  Biolegend 
CD112 PE/Cy7 5 μl TX31 Biolegend 
CD155 PE 2.5 μl 4.24.1 Biolegend 
E-Cadherin (CD324) APC 2 μl   Biolegend 
HLA A-B-C PerCP/Cy5.5 2.5 μl W6/32  Biolegend 
HLA-E PE/Cy7 2.5 μl 3D12 Biolegend 
ULPB-1 Alexa Fluor 488 5 μl 170818 R&D 
ULPB-2 PE 5 μl 165903 R&D 
ULPB-3 APC 5 μl 166510 R&D 
MICA/B PE 5 μl 6D4 Biolegend 
NK cell markers  
CD3 FITC 2.5 μl HIT3a Biolegend 
CD56 APC 2.5 μl HCD56 Biolegend 
CD16 PerCP 5  μl 3G8 Biolegend 
NKp30 Alexa Fluor 647  5  μl P30-15  Biolegend 
NKG2D PE 5  μl 1D11  Biolegend 
CIC markers     
CD44 APC 5  μl IM7 Biolegend 
CD24 PE 5  μl ML5 Biolegend 
CD326 (EpCam) FITC 5  μl 9C4 Biolegend 
Intracellular cytokines and checkpoint antibodies  
CD107a(LAMP-1) Pacific blue  
 
H4A3 Biolegend 
IFN-gamma PE/Cy7 5  μl 4S.B3 Biolegend 
TNF-alpha Alexa Fluor700 5  μl MAb11 Biolegend 
Peforin  FITC 5  μl dG9 Biolegend 
Granzyme B PE 5  μl QA16A02 Biolegend 
PD1 Alexa Fluor 700 5  μl EH12.2H7 Biolegend 
TIGIT (VSTM3) Brilliant Violet 421™ 5  μl A15153G Biolegend 
CD366 (Tim-3) APC/Cy7 5  μl F38-2E2 Biolegend 
Other     
anti-mouse CD16/32  Purified  / Biolegend 




8.4 Chemical and biological reagents  
 




                                    Product              Source 
Bafilomycin-A1  Sigma Aldrich 
Bovine serum albumin (BSA)  Merck  
Brefeldin A (BFA) solution  Biolegend 
C12FDG Sigma Aldrich 
Collagenase IV  Sigma Aldrich 
DNAse I  Sigma Aldrich 
Doxorubicin  Sigma Aldrich 
Ficoll-Paque density gradient medium GE Healthcare 
Monensin solution Biolegend 
Heparin Sigma Aldrich 
ISOTON™   sheath fluid  Beckman Coulter  
Liquid nitrogen  BOC 
Xenolight RediJect D-Luciferin Perkinelmer 
MatrigelTM        Corning 
ECM Gel from Engelbreth-Holm-Swarm murine sarcoma Sigma Aldrich 
Propidium iodide  Sigma Aldrich 
Ribonuclease A Sigma Aldrich 
Sodium chloride (NaCl)  Calbiochem  
Sodium hydroxide (NaOH)  Fisher Scientific  
Solution 18 AO.DAPI Chemometec 
                                Equipment  Supplier 
Autoclave  Rodwell  
Cell culture incubator 37°C (without CO2)  LEEC  
Cell  culture incubator 37°C, 5% CO2  Sanyo, Binder  
Centrifuges Sanyo, Eppendorf  
Class II safety cabinets  Walker  
Fridges  Lec  
Freezers -20°/-80° Lec/Revco/ Sanyo  
Gallios Flow cytometer  Beckman Coulter  
Haemocytometers  SLS  
Light microscope  Nikon/Olympus  
NucleoCounter®® NC-250™  ChemoMetec  
Microcentrifuge  MSE  
MoFlo™ cell sorter Beckman Coulter  
Nanodrop 8000 Spectrophotometer  Thermo scientific  
Vortex  Scientific industries  
Water baths  Clifton  
IVIS Lumina III Imaging machine  Perkin Elmer 
Gulmay RS225 Ionising Radiation Cabinet (City hospital) Xstrahl 
NanoString nCounter™ FLEX platform  NanoString Technologies 
Softwares  
NucleoView™ software Chemometec 
Kaluza 1.3 version Beckman Coulter  
Nanostring nSolver™ version 3.0/ Advanced Analysis module version2.0 NanoString Technologies  
MetaCore version 19.2  Thomson Reuters 
Living Image Software (IVIS Imaging Systems) Perkin Elmer 
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